Molecular studies on the hypoxanthine phosphoribosyltransferase of Plasmodiun falciparum by Shahabuddin, Mohammed
MOLECULAR STUDIES 
ON THE 




A Thesis Presented For The Degree Of 
Doctor of Philosophy 
Department of Molecular Biology 
University of Edinburgh 
March 1990 
I hereby declare that I alone have composed this 
thesis, and that except where stated, the work 




Hypoxanthine phosphoribosyltransferase (EC 2.7.2.8) of P. falciparum has been 
studied for its biological properties and cellular location. The enzyme plays an 
important role in the parasite's life, and therefore is a putative target for 
chemotherapy against malaria. 
Due to the difficulty in obtaining large amounts of the enzyme from the 
parasite, it was over-expressed in E. coil, first as a fusion protein with E. co/i 
-3-galactosidase. This facilitated the one step purification of the protein, using 
-galactosidase substrate affinity chromatography, for making antibodies 
against the enzyme. 
The antibodies thus made was used to investigate the cellular location, a 
prerequisite for a successful drug design against the parasite enzyme. 
Immunofluorescent microscopy (IFA) and immunogold electron microscopy 
revealed that; 
the enzyme is expressed at all the stages of the parasite's life, 
the enzyme is concentrated in some vesicular bodies of unkown origin, 
in the sporozoite, it may be released into the intrapellicular spaces. 
Subsequently, the enzyme was over-expressed directly in E co/i, as a 
non-fusion protein and retained its enzymatic activity. This opened the way to 
study the enzyme for its biochemical properties and structure-activity 
relationship. 
The active E. co/i-expressed P. fa/ciparum HPRT compensated a S. 
typhimurium hpt mutation. The strain, named S. typhimuriurn SH4 can now be 
used to screen large number of putative antimalarial drugs which might act 
against the parasite HPRT. This will be both simple and inexpensive. 
The cell free extract of induced SH4 was used to study some biochemical 
properties of the enzyme. Such a study confimed the finding that unlike any 
other Plasmodia studied so far, P. fa/ciparum HPRT can use xanthine as its 
substrate in addition to hypoxanthine and guanine. However, competitive 
inhibition studies revealed that hypoxanthine is the most favourable substrate. 
The possible biological significance of such properties is discussed. 
This thesis is dedicated to my mother 
and father. 
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Chapter 1 
Introduction 
Malaria is a parasitic disease of man, caused by the species of genus 
PIasmodIuij primarily characterised by periodic fever and transmitted by the 
bite of infected mosquitoes. 
Clinical symptoms of malaria generally develop within 8 to 30 days 
following the inoculation of the parasite in sporozoite form by the bite of an 
infected Anophe/ine mosquito. The symptoms involve mainly periodic chill, 
fever and sweating, but, in severe cases, accompanied by anemia, enlargement 
of , spleen and pigmentation of tissues. In cerebral malaria, changes of 
behaviour may occur in early stages, excitement, mania, coma and epileptiform 
attack may follow. 
Only four species of the parasite of genus Plasmodium infect humans 
naturally. Among these P. fa/ciparum is the most deadly and causes malignant 
form of malaria. P. v/vax is most widely distributed and common. P. v/vax and 
P. ovale are characterized by the periodic appearance of the symptoms after a 
latent period of up to 5 years. P. ma/ar/ae is also widely distributed but less 
than P. v/vax and P. falc/parum. 
One of the main reasons of continuing research on the disease and its 
worldwide concern is that malaria is still a major health problem of most of the 
modern world, specially in tropical and subtropical countries. At present about 
102 countries remains endemic and this is placing over half of the world 
population in risk (TDR report, WHO 1989). The situation in 	third world 
countries 	more serious, where none or very few antimalarial measures are 
undertaken. It is estimated that there aX at least 100 million cases of malaria 
reported annually and it contribute at about a million deaths per year (TDR 
report, WHO,1989). Despite the intensive efforts made against malaria during 
the last four decades, the original levels of endemicity in Asia, Africa and 
Amazonian region of Latin America haVhardly changed. Malaria can also 
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cause risks to even people living in nonendemic areas through importing by 
travellers and immigrants from endemic areas. 
P. falciparum the most dangerous species of Plasmodia, fcy which Africa is 
hyperendemic, causes death due to the cerebral malaria. cerebral 
malaria has a mortality rate of 20% even with good medical care. In 
nonimmune children, it causes anemia and growth retardation in mild cases. It 
is also responsible for the maternal morbidity, foetal dysmaturity and anemia in 
pregnant mothers. 
Apart from the deadly effect on human health, malaria can also affect the 
economy of a country indirectly. It vqas shown that during an epidemic of 
malaria in Paraguay, agricultural development was markedly reduced (Conly, 
1976) 
1.1 History of malaria. 
Malaria is one of man's oldest diseases. Hippocrates in 5th century first 
described the fever (a symptom of malaria) and noted the observations of the 
relationship between intermittent fever and the marshy land. From early 
times the disease was known in France and in Italy. The Italians used to 
practice the drainage of swamp as a measure of control of malaria duringàrly 
17th century. The belief was that air from these wet areas carriM the disease. 
It was not until A 18th century that the fever took the Italian name mal'aria (bad 
air), which recognize the relationship of the disease with the bad air of the 
marshy land. 
Although there was a lot of description of the disease, the causative 
agent was not known at that time. It was in 1847 when German pathologist 
Meckel first realisedthe relationship between the black pigment he 'saw in the 
blood, spleen and liver of dead bodies of malaria patients on Pace 
About 30 years later the French pathologist Kelsch saw the pigment in the 
blood of malaria patients and noted that the pigments are most noticeable just 
before the onset of fever. Another contemporary French pathologist, Laveran, 
who was working in an Algerian hospital, claimed to see parasites in red blood 
cells. He described the presence of clear bodies which contained pigment and 
noted the oval and crescent shape of the clear bodies. He confirmed his 
observation in 1880, when he saw that the blood of a young soldier was 
enriched with the crescent form. These are now known as the gametocytes 
(the sexual stage) of P. fa/ciparum. Marchiafava and Celli, in 1885, saw the 
multiplicative form of the parasite in red blood cell of patients. At about the 
same time, Golgi saw these parasites and described their synchronous release 
from the red cell just before the onset of fever. This form is now known as 
the merozoite of the P. falciparum. In Russia, Danilewsky discovered avian 
and amphibian malaria parasites.. 
But it was still a big mystery how the parasite infected its hosts. It was 
long suspected, but not proved in parts of India and China that mosquitoes and 
malariawsfa related. In the late 1870s, Patrick Manson working in China showed 
the mosquito was a possible Vector of filariast, In 1893, Smith and 
Kilbourne showed that a tick could transmit a cattle red blood cell parasite, 
Babesia. 
On the basis of these results, Ronald Ross, in 1894, speculated the 
possible role of mosquitoesin the spread of malaria. He started examining 
mosquitoes for the presence of the malaria parasite. But it was,after a long 
search,,he saw black pigment, ox indication of the presence of malaria 
parasites, in the midgut of a particular type of mosquito, Anopheles. To 
investigate the further role of,mosquito, Ross started working on, \avian malarial 
parasite (P. re/ictum). I  He discovered that the infective form of the 
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parasite can be found in the mosquito salivary glands and he successfully 
infected sparrowS us these mosquitoes. Hence the role of mosquito in 
the spread of malaria discovered. The,cycle starts when the mosquito feeds 
on the bird. The parasitized blood sucked in the mosquito midgut, multiplie5 
and becomes a orivt tV to the bird and -. - migrate to the 
mosquito's salivary gland. An uninfected bird becomes infected when it eats 
the infected mosquito or when the infected mosquito takes its meal on thQ. 
bird. Soon after this discovery , the presence ofcsimilar cycle for human 
malarial parasitewas confirmed. In 1897, MacCallum in Canada described the 
maturation of the sexual form and fertilization of HaemoproteuS columbiae 
in mosquito midgut. The exoerythrocytic stage of plasmodium was first 
proposed by Grassi in 1902 and finally demonstrated by Raffaele in 1934. The 
liver stage of the mammalian Plasmodiv¼1 was demonstrated by Short and 
Garnham in 1948. 
1.2 The life cycle and developmental biology of malaria parasite. 
Figure 1.1 shows the detaillife cycle of P. falciparum as described by 
Garnham (1966). The life cycle of the parasite starts, in the mammalian host, 
when an infected female Anopheles mosquito bites a human host. The 
sporozoites from salivary glandalong with saliva are injected into the capillaro 
of the host's peripheral circulatory system. These sporozoites are motile and 
about 11 pm in length and 1 j.im in diameter. porozoites enter into the main 
blood stream though the capillaries in the skin and within 30 to 40 minutes 
they accumulate in liver and disappear from the blood stream. Studies with 
rodent parasites indicated that before invading the hepatocyte the parasite may 
passage through the Kuffer cell in the liver sinusoid (Meis et at, 1983). 
Nothing about the nutrition and metabolic activity of the sporozoite during this 
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brief blood stage is known. 	Since sporozoites do not undergo any 
multiplication, presumably the biosynthetic rate during this period is very low. 
And perhaps most of the energy is spent in the mechanical movement of the 
parasite in transit to the liver cell. Within the hepatocyte the parasite remains 
in a membrane bound structure, called the parasitophorouS vacuole. 
In hepatocytes the parasite undergoes a rapid transformation. It grows 
bigger in size, The nucleus replicates several times and cellular components for 
several thousand new parasite are synthesized. Then within the parasitophorous 
vacuole the parasite divides, the hepatocyte bursts and about 40,000 
merozoites are released into the blood stream. After release from the 
hepatocyte P. falciparum merozoiteS invade red blood cells. The mechanism of 
merozoite release is not clear. This stage is called the preerythrocytiC stage. 
The merozoites of P. fa/ciparum can not reinvade hepatocytes, however there 
is evidence that other human malarial parasites can reinvade hepatocytes 
(Krotoski at a/., 1980; 1982). 
The merozoite is pear shaped and about 1.5 lIm long. The apex consists 
of a polar ring, two rhoptries, which contain electron dense material, 
micronemes and dense granules. The content and the origin of dense granules 
is not clear (Toni et al., 1989). The merozoite is surrounded by outer, inner and 
a plasma membranes. On the surface there are rough bristle like structures. 
Invasion only occurs when the the erythrocyte ot its 
epical end. 
The mechanism of attachment and invasion has been studied extensively 
(Ladda, 1969; Dvorak et al, 1975; Aikawa et al, 1978; Aikawa and Seed, 1980). 
Most of these results are on the basis of electron microscopy, and the 
molecular basis of the mechanism is not clearly known. After proper 
orientation, the merozoite binds possibly to - glycophorin A on the surface of 
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the erythrocyte membrane. After attachment the content of the rhoptries are 
released into the junction. Th, causes a rapid invagination o- the red cell 
membrane, which attorj5 the merozoite to invade. The invasion is a very rapid 
process, taking no more than a minute. 
Once the merozoite is in, it remains in the parasitophorous vacuole, 
surrounded by the parasitophorous vacuole membrane. This membrane was 
believed to be a part of the red cell membrane, but there is evidence that most 
of this vacuolear membrane structure -15 of parasitic origin. During invasion 
the merozoite sheds its surface coat. Inside red cell the merozoite transforms 
intofeeding form, rapidly grows bigger and in a Giemsa stained slide under vL 
light microscope looks like a signet ring. This is called the ring stage. 
The nucleus undergoes a second round of mitotic division about three to 
five times and the vacuole grows bigger. This is the trophozoite stage of the 
parasite. The parasite'ows much bigger in sizeti iroccupies most of the red 
cell. r-o%%o%A%1thi5 rhoptries, micronemes and apical ring form, the cytoplasm 
divides and buds out with one nucleus in each. This is the schizont stage. 
The schizont then bursts and 8 to 24 new merozoites o.i AQ 4,which 
reinvade new red cells. This is called the erythrocytic cycle. 	- takes 4 
hours in case of P. fa/ciparum 	 in the case of other human 
parasites. The erythrocytic cycle is the stage which is responsible foriinical 
symptoms of malaria. 
During parasite maturation inside., massive changes occur on the surface 
of the red blood cell (reviewed by Howard R. J., 1988). Although very little is 
known about the biochemistry and genetics of the development there is 
evidence that novel proteins are expressed during the developmental stages 
(Vermeulen, et al., 1985). Some of these proteins have been studied in detail 
for their apparent medical importance. 
8 
At the later stage of infection some of the maturing parasiteI inside the 
red cell differentiate into sexual form loi an , unknown m"' 
(Bruce-Chwatt, 1980). The process is called the gametocytogenesis. There is 
evidence that the extent of parasitemia may trigger this process but external 
metabolites may also participate (Pietro Alano, personal communication). In the 
course of differentiation the parasite is transformed intocrescent shaped 
male gametocyte, called ,microgametoCyte, or female gametocytes, called a. 
macrogametocytes. This stage of the parasite is infective for the mosquito 
and the mosquito gut. The fate of these gametocytes in tw,nn 
blood is not clear , however it is believed that they are eliminated from the 
blood st4am if not taken into the mosquito gut. 
The mosquito stage of the parasite starts when a mosquito takes its 
blood meal 	infected human. The gametocytes are taken into the midgut 
of the mosquito where rEi, pro of gametogenesis c,cur. The 
microgametocytes lose the red cell membrane and differentiate into a 
flagellated round shape. Within 10 minutes the nucleus divides mitotically into 
8 daughters wl.c"migrate into the flagella. These nucleated flagella extrude and 
detach. They... are the male gametes. Meanwhile, the macrogametocytes after 
loosing the red cell membrane, differentiate into macrogametes ready for 
fertilisation. 
Within a few minutes fertilisation occurs, the two nuclei fuse to form 
zygote. The round zygote transforms into a leaf shaped ookinete within next 
12 to 18 hours. These ookinetes then cross the mid gut wall, usually 
intracellularly, and eventually reach the basal lamina of the mosquito mid gut 
where they differentiate into oocysts. Over the next 10 to 12 days the oocysts 
grow bigger in diameter and a capsular wall is formed. VerV little is known 
about the biochemistry of oocvsts. They do not have any cytostome to feed 
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themselves, presumably, they obtain their food through the wall. 
On the outer surface of the stomach wall, there may be several hundreds 
of oocysts in one stomach. Inside the oocyst the I znotyua-1 undergo5 
several cycles of replication and the parasite divides to form slender 
sporozoites. Leveral thousands of sporozoites are released into the haemocoel, 
from where they enter into the salivary glands ready to be inoculated into a 
new human host at next blood meal (Pringle, 1966). The over)ll duration of 
the cycle in the mosquito depends on the environmental temperature. At 28 °C 
it is about 8 to 10 days, whereas at 20 °C about 16 days. Under 15 °C the cycle 
can not be completed. 
1.3 Methods of controlling malaria. 
To complete the life cycle, it is very important for the malaria parasite to 
passage through the two hosts, mosquito and human. So, for the transmission 
of the disease in a community, successful contact between this two hosts and 
sound development of the parasite within them is very important indeed. 
Hence, control of malaria may involve: i) The reduction of the numbers of the 
vector in the community, ii) Interruption of the transmission cycle and iii) 
Blocking the normal growth of the parasite in either one or both of the hosts. 
In the following sections I will discuss these methods and pinpoint some 
particular steps where molecular biology can play a major role in the control of 
malaria. 
1.3.1 Vector control. 
Reducing the number of mosquitoes in nature could be the easiest and 
preferable choice of malaria control. Because it does not wrY the 	t -ekment 
of human51 - 	 ethically more acceptable for most countries. Hence, 
it may be the perfect tool for a global eradication programme for malaria. 
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Indeed, in,)950sWHO malaria eradication campaign based predominantly on 
the spraying of insecticide. Th was successful t  -. 
Reduction of the number of mosquitoes can be achieved in several ways: 
Preventing the mosquito from feeding on man. 
The transmission cycle can be interrupted by preventing mosquitoes from 
feeding on man. Use of bed nets, Mosquito nets on windows, insect repellent 
and protective clothing are the most common measures,can be used for this 
purpose. However, in developing countries where malaria is hyperendemic, 
these could be very expensive for individual families. 
Number of breeding site reduction. 
Anopheles mosquito lays their eggs on standing fresh water, like wells, 
paddy fields and swampor sometimes even on very slowly running water. The 
eggs hatch, and spend their larval and pupal stages in the same place. So, 
reducing breeding sites could be another way of reducing number of 
mosquitoes. This method of controlling malaria WAs tona hksWy. Ross himself 
suggested this method in India. However, in tropical countries, where monsoon 
rain is heavy, it is very common that rain water collects in foot prints, 
cart-tracks, leaf axils. Besides, in agricultural areas, making irrigation channels 
and water reservoirs is common. 
Use of antilarval agents. 
After hatching, the larvae feeds on the decomposing biomaterials in the 
waters and usually lie parallel to the surface for breathing. Use of larvicide, 
like Purple green ( Copper aceticarsenite) and use of a film of oil onater 
surface which interruptsthe breathing of larvacan be used to reduceumber of 
mosquitoes. Larvivorous fish, such as guppy and minnows have also been 
successfully used to control malaria. 
Use of insecticide. 
Since the introduction of DDT (dichioro diphenyl trichloroethane) and 
dieldrin in the mid forties, direct attack on adult mosquito was the main focus. 
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ThhX 
The rationale was,, after taking blood meal at night 	-- a mosquito is,at rest 
in a dark corner of a house: If the corner was previously sprayed with 
residual insecticides, the mosquito would die before transmitting malaria. 
There are several advantages of this method. Firstly it is easy to organize 
spraying of houses. Also it is easy to train personnel to carry out ii6cJJ-5 
is 
Pore easily effected on a countrywide basis than antilarval measures. Indeed, 
it was the major tool of 1955 WHO malaria eradication programme. During the 
early stages the house spraying was a great success. In 1957, Itt seemed that 
malaria eradication from the worldssible. However, the insecticides and 
other organochlorines which were introduced afterwards have fallen out of 
-favour a r to some degree. The first reason was, these insecticides were found to 
be toxic at high concentrations for plants and animals. Second but more 
serious, resistant mosquito vectors were beginning to emerge rapidly. By 1976, 
3 species were resistant to DOT only, 21 species to both DDT and dieldrin and 
42 species to dieldrin only. 
1.3.2 Vaccination. 
Vaccination of human5 against the malaria parasite is possibly the best 
way to control the disease. Indeed, a cheap, effective and easily administered 
vaccine would be of great value in the eradication of malaria from the world. 
Hence, it is not surprising that a major goal of current malaria research is 
vaccine development. Although 	global eradication was successfully 
achieved with the smallpox immunisation campaign, despite the worldwide 
search, it has not yet been possible to develop a successful vaccine for 
preventing malaria, or for any other human parasitic diseases 
Trypanosomiasis, Leishmaniasis, Filariasis, Leprosy and Schistosomiasis 
However, there are successful vaccines against some veterinary parasitic 
diseases. For example, dog hookworm a (A. caninum), cattle and sheep lung 
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worm (0. viviparus, D. filaria) (Miller, 1971; Urquhart, 1962). These vaccines are 
mostly attenuated parasites and the procedure is not possible for 
application on man, mainly for ethical reasons and also for the danger of 
possible immunopathogenicity. 
One of the major difficulties in developing vaccines against malaria is its 
complexity as aA infectious agent and its unique ability for adaptation and t 
:€ mechanism which the parasite has evolved to its vertebrate hosts 
immune system (Sher 1988). Another great difficulty which concerns this work 
to a certain extent is that until now there is no practical way of obtaining 
sufficiently large quantity of antigen to immunise a large population. The 
introduction of the in vitro culture method for erythrocytic stage of 
P. fa/ciparum (Trager & Jensen, 1976) opened a new era for research in the 
field of vaccine development. However; this method is not economically 
feasible for the production of a vaccine antigen to a commercial level. 
1.4 Immunity against malaria and vaccine design. 
It is important for a good immune response that the parasite and the host 
immune system should come into close contact. An infection can take one of 
three different courses. Firstly, the parasite can multiply very fast, faster 
than the hosts immune response and kill the host. Secondly, the immune 
resistance to the parasite can supersede the parasite multiplication rate and the 
host can recover from the disease. Both of these courses are unfavourable for 
transmission. Finally, the infection can be kept to sub-clinical levels by the 
immune mechanism, but it can never cure it. This gives the parasites enough 
time to go through the several developmental stages and get ready for 
transmission. 
To do this the malaria parasite has evolved several e5lo' mechanisms, 
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which allows h. to adapt -t ,& the host's immune system such as antigen 
variation, sequestration of parasitized red blood cells in capillaries etc. These 
evaL°' mechanisms, common in other pathogenic parasites as well, are some 
of the major obstacles in the way of vaccine development. Hence, the use of 
classical immunology and methods of vaccine development 	not suitable 
for 	- parasite vaccine development. These difficulties actually led to the 
development of the new subjects, like parasite immunology and molecular 
parasitology. 
With regard to the life cycle stages as vaccine targets, designing of 
antimalarial vaccines fall into several classes (Figure 1.2). 
1.4.1 Sporozoite vaccines. 
Immunisation against the sporozoite stage is aimed to destroy the 
parasite immediately after entry into the human body. This will stop subsequent 
development of the parasite to the pathogenic stage i.e. the erythrocyte stage. 
Within a few minutes after introduction into the human body the sporozoites 
disappear from the blood stream. In contrast, a period of several days are 
required for immune response to develop in a naive host. Hence the 
immunological selection pressure which would favour the development of 
evasion mechanism against the sporozoite stage is n.Thus, it has been 
proposed that at least theoretically, vaccination against the sporozoite stage is 
the most logical approach (Nussenzweig & Nussenzweig, 1988). 
Although the sporozoite stage in the vertebrate host is very short, 
protective immunity has been achieved in rodent, monkeys and humans with 
y-irradiated mosquitoes ( Cochrane et al., 1980; Nussenzweig and Nussenzweig, 
1986). The immunity was fully stage and species specific. The animal was 
fully protected against the sporozoite stage and susceptible to infection by 




Figure 1.2 	Stage specificity of antimalarial vaccine. 	Malaria vaccines are 
directed against: a) Sporozoites in vertebrate host; b) asexual or erythrocytic stage; c) 
gametocyte of sexual stage; or d) gametes in mosquitoes. Antibodies against 
gametes can be produced in vertebrate host and act on the parasite in the mosquito 
gut when ingested with the blood meal. 
is 
will be needed against the various human malaria parasites. Moreover, the 
immunity was very short lived - about three months, although it could be 
boosted ( Clyde et al., 1973, 1975; Rieckmann et al., 1974). 
Search for the protective antigen revealed that the immune response 
against sporozoite5is essentially directed against a single protein molecule, the 
circumsporozoite protein (CSP). The protein constitutes the surface coat of the 
sporozoite. The gene for the protein has been cloned from different species of 
Plasmodia including P. fa/ciparum and deduced primary structure has shown 
that the protein has an unusually long repeat of ,tetrapeptide, which in 
P. falciparum is NANP (Dame et a/., 1984; Enea et al., 1984). These repeat 
regions of the protein have been shown to be the most immunodominant part 
of the protein (Ballou et é!., 1985; Zavala et al., 1985). These and other studies 
put the repetitive epitope of the CSP in the focus of antisporozoite vaccine 
development. 
The results of immunisation with two different vaccines both based on 
these repeats were not conclusive (Ballou et al., 1987; Herrington et a/., 1987). 
The immune response was poor and the subsequent challenge with 
P. falciparum showed very insignificant protection. However, one person in 
each case was fully protected and some acquired a certain degree of 
protection. Moreover, the immune response was found to vary with age and 
also higher immune response did not necessarily correlate with the higher 
degree of protection (Hoffman et al., 1986). Furthermore, the mechanism of the 
immune response against the sporozoite seems very complex. Recent studies 
have shown that response may be T-cell mediated, which may act against t.. 
hepatocytic stage of the parasite by releasing y-interferon (Schofield et al., 
1987). These results indicate that vaccine development against A  sporozoite 
stage needs further study of e CSP immunology and the mechanism of the 
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immune response. 
1.4.2 Asexual erythrocytic stage vaccines. 
The second and most important stage of parasite development to which 
the vaccine development is aimed, is the asexual blood stage. Compared to 
the sporozoite stage, antibody responses to the asexual blood stages of 
P. falciparum and other malaria parasites are very polyspecific. This and other 
o. 
advantages %icintroduction of cj in vitro cultivation of P. fa/ciparum which 
facilitated the preparation of large amount of antigen has made this stage most 
popular to the vaccine developers. 
A number of different approaches have been used to identify the asexual 
blood stage antigens and a wealth of data has been accumulated in this field 
(Brown et al., 1982; Freeman et al., 1980; Hall et al., 1983). Although not all of 
these antigens have proven to be good candidates for vaccines, some of them 
by their location on either the merozoite surface or in some secretory 
organelles oJ merozoites are strong candidates for malaria vaccine. Table 1.1 
shows some of these important candidate antigens. Merozoite surface antigens 
are interesting because these antigens are easily accessible to immune 
attack. Moreover, there is evidence that the host protective immune response 
can be directed against these antigens (Miller et a/., 1975). Preclinical testing 
on Aotus and Saimiri monkey has been done with purified asexual stage 
antigens (Hope et al., 1981, Ridley et al., personal communication). Although 
the result5of these tests were not conclusive, however encouraging. 
One of the major problems of immunisation of a large human population 
with such vaccines is to prepare,in large amounts, free from the contamination 
of the erythrocyte membrane material. Contaminants could induce complex 
immunopathogenicity and cause fatal haemolytic disease in the recipient. 
Development of synthetic vaccine5 or preparation of the vaccine antigen in 
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Table 1.1 Cloned genes of Plasmodium falciparum (TDR/WHO toCp.awt 	o'ri1 tt) 
Estimated relative 	Year 
molecular mass, 	gene 
M, 'KOOO 	cloned 





Acidic basic repeal antigen (ABRA. Pt p 101) 102 K 1986 V E SChizonts 
Actin (Pt actin-l. II) 1988 V 
Aldolase 41 K 1988 V E V 
Asparagine-rich protein (ARP) 160-220 K 1986 E all stages 
Clustered asparagne-rich protein (CARP) 15-36 K 1986 E 
Circumsporozoute protein (CSP) 40-60 K 1984 V E. V. V. P sporozoite surface V. U 
Circumsporozoite.proteinre)aled antigen 
)CRA. 5.1. exp-1) 23K 1985 V E 
trophozoite/schizont 
vacuoles 
Dihydrololate reductase (DHFR)/thymidylate 
synthase (IS) 1987 V T 
Falciparum interspersed repeat antigen (FIRA) >300 K 1985 E infected erythrocytes 0 
Clycophorin-binding protein (GBP 130) 96-130 K 1985 V E 
secreted: cytoplasm and 
merozoite surface V 
Neat-shock-related proteins (Pt hsp 70) 71-75 K 1986 V E all stages v 
Pt HAP-I (knob-associated hiscidine-rich protein, 
KAHRP) 85-108 K 1986 ' V E 
knobs: 
infected cell cytoskeleton 
Pt HAP-11 60-72 K 1986 V secreted; cytoplasm 
Pt HAP-lit (small histidirie-alanine-rich protein. 
SHARP) 28-33 K 1985 V E schizonts 
Hypoxanthirie.guanine phosphoribosyl transfer-
ase(HGPRT) 1987 V I 
Lactate dehydrogenase (LOH) 36 K 1985 
Liver-stage-specific antigen (LSA-1) 1987 E esoerythrocytic schizonts V 
Mature erythrocyte surface antigens (MESA. 
Pf EMP2) >250 K 1986 E 
cytoskeleton of mature 
infected cell 
Meroattite surface antigen-2 (MSA-2) 45-51 K 1988 V E, P merozoite surface V 
Precursor to major merozojie surface antigens 
(PMMSA. P190, Pf 195, PSA. gp195) 185-210 K 1985 V E. Y. V. P schizonl/merozoite surface V 
Rhoptry proteins 55 K 1987 E V 
105K 1988 E 
rtioptries/host membrane 
Ring-infected erythrocyte surface antigen 
(RESA/Pf 155) 155 1985 V 
m
K E. V. 
micronees of merOzoiles; 
ring cytoskeleton V 
S-antigen 140-230 K 1985 s,f E. V. P parasitophorous vacuole 
Thrombospondin . relatedanonymous protein 
(TRAP) 1988 V 
Np 126 113-140K 1987 V E 
schizonts; 
parasitophorous vacuole 
Pt 11-1 260-350K 1984 E 
mature infected 
cell membrane 
Pfs 25 	• 25 K 1988 V E ookinete Surface 
= Eschenctria coli; V Yeast: V = Vaccine virus: P Synthetic peptides. 
0 - Diagnostics V Vaccines; I = Drug therapy. (N 
de=elopmment.) 	 ote that aS proteins defined as antigens by the human immune response may have potential in riacci 
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genetically engineered bacteria may be a solution. The latter is possibly 
economically more feasible. 
1.4.3 Sexual stage vaccines. 
As it was mentioned in the life cycle, some of the infected red cells 
transform into macro and microgametocytes, thus initiating the sexual stages 
of the cycle. During this and the following steps upuntil the invasion iy  the 
ookinete?the mosquito midgut wall parasites spend more than 24 hours in 
contact with the vertebrate blood. During this time the sexual stage parasites 
are vulnerable to the vertebrate immune attack, both in the vertebrate body and 
mosquito midgut. This is, therefore, the third point of attack parasite 
development. In comparison to the sporozoite and asexual blood stage, very 
little work has A clone to assess the potential of the sexual stage antigens as 
candidates for vaccines. The main reason for this is that the sexual stages are 
nonpathogenic and do not directly contribute to the disease. But from an 
epidemiological point of view, the prevalence of malarial infection depends on 
the availability of the gametocyte to the mosquito and 	successful zygote 
formation in the mosquito midgut. Therefore the relevance of 	immunity to 
these stages can not be ignored. 
Mendis and her colleagues (1987) have recently shown that human 
populations in endemic areas possess high titres of antibody to sexual stages. 
They suggested that these may play an important role in the control of malaria 
epidemics. Immunity against sexual stages is commonly called "malaria 
transmission blocking immunity". Induction of such immunity has been 
demonstrated in birds, rodents and monkeys. In most of these cases the 
immunogens were the sexual stages of the parasite. Immunity against all the 
sexual stages has been shown; against intracellular gametocytes in the 
circulation (Harte et al., 1985), extracellular gametes in the mosquito midgut 
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(Mendis at a!, 1979), fertilized zygote in the mosquito midgut (Kaushal at al., 
1983) and ookinetes in the mosquito midgut (Vermeulen at al., 1985). 
Searching for the target antigen for such immune response resulted in the 
identification of three sets of proteins in P. gaiinaceum and P. fa/ciparum. 
These are 230 kD (Grotendorst at al., 1984; Rener at al., 1983), 48/45 kD and 
31/25 kO (Grotendorst at al., 1984; Vermeulen at al., 1985) proteins. The 230 
kD and the 48/45 kD proteins are the surface proteiri5of the gametes andAalso 
found on the surface of the gametocytes. Antibodies against these proteins 
were found in the individuals exposed to P. fa/ciparum. The 31/25 kD protein is 
the ookinete surface protein. Neither the immunology nor the biochemical 
properties of these proteins have been elucidated to date. Further study may 
reveal the importance of these antigens. 
1.5 Chemotherapy. 
Despite the tremendous efforts towards designing a vaccine against 
malaria, it seems that we still have to go a long way to fulfill the dream. What 
remains for the immediate cure of malaria is to use chemoprophylaCtiC agents. 
Successful chemotherapy of malaria was carried out long before the cause of 
the disease was known. About 300 years ago powder of the barks of Acinchona 
tree was used to treat malaria fever in Peru. This treatment was then 
transported to Spain and then spread to other parts of Europe. Later the active 
ingredient quinine was isolated and used against malaria. Since then a large 
number of other antimalarial drugs have been introduced for malaria treatment. 
The rationale of selecting a drug against the parasite is to find a 
chemotherapeutic agent which is toxic against malaria parasites at a certain 
concentration but would be completely harmless to humans at the same 
concentration. 
0*1 
The choice of drug 	depends on whether it will be used for preventive 
purposeS or for curative purposeS and also depends on the species of the 
parasite being treated. The dose determination,, also important. A high dose 
may cure the disease by rapidly eliminating the parasite from the blood stream 
but this would reduce the extent to which the parasite is exposed to the host 
immune system and subsequentlyvery low immune response will ru-W which 
will not be good for a... long lasting immune response. On the other hand an 
exact dose would reduce the clinical malaria but allow a longer exposure of the 
parasite to the immune system. 
Structures of some of the important antimalarial drugs are shown in 
Figure 1.3. Not all antimalarials are active against all the stages of the parasite. 
According to the stage against which they are active, the antimalarial drugs are 
classified into four catagories. None of the antimalarials are active against the 
sporozoite stage, but some are taken up by the mosquito in a blood meal and 
inhibit development of the oocyst, thus preventing the production of 
sporozoites. These drugs are called the sporontocides. Members of such 
class are primaquine and pamaquine (chemically both are 8-aminoquinolifleS) 
and also proguanil and pyrimethamine (chemically diaminopyrimidine). Drugs 
like proguanil and pyrimethamine which also destroy the exoerythrocytic stages 
are called the tissue- schizontocides. The drugs acting on the asexual blood 
stages are called the blood-schizontocideS. These include quinine. mepacrine, 
chloroquine, pyrimethamine and dapsone. Some antimalarials affect 
gametocytes. These are the gametocytocides and includes chloroquine, 
amodiaquine and quinine etc. 
Now, if there are drugs against all the stages of malaria parasites, why do 
we need any more drugs or vaccines? The main reason is the horrific 
emergence of . resistant parasite strains against existing antimalarials. 
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The molecular structure of some antimalarial drugs. 
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Resistance to causal prophylactics, like pyrimethamine and proguanil has been 
known for about 30 years, especially in south-east Asia and Africa. Such 
resistant strains are found in all four species of human malaria. These types of 
resistant stains are not too dangerous, because the drugs to which they are 
resistant are not used for the treatment of the acute malaria. In contrast, 
resistance against the drug of choice for acute malaria, i.e. chloroquine, has 
been described for the most dangerous species P. fa/ciparum. Such resistant 
strains were first described in Columbia, subsequently found in Brazil and in 
many parts of south-eastern Asia, and recent studies shows that chloroquine 
resistant strains of P. falciparum are present in eastern Africa. The alarming 
emergence of chloroquine resistance is doubled by the fact that chioroquine 
resistant strains are sometimes also resistant to - amodiaquine and 
mepacrine and that some have a lower sensitivity to quinine. Quinine is 
normally used to treat resistant P. fa/ciparum malaria. If such multidrug 
resistant strains of P. fa/ciparum become widespread, particularly in the malaria 
endemic countries, the disease may become completely uncontrollable. 
1.6 Mechanism of action of some antimalarial drugs. 
A large amount of work has been done on the mechanisms of drug action 
during the last half century. This has been reviewed by Peters and Howells 
(1978) and Elslager (1974). Recent knowledge about the action of some drugs 
has been described here. 
Sulfonamides, sulfones and drugs of this group show their selective 
toxicity by competing with paraaminobenzoiC acid (PABA) for the active site of 
the enzyme dihydropteroate synthase, in the pathway of folic acid metabolism 
(Figure 1.4). The enzyme catalyses the condensation of PABA with 
























Figure 1.4 	Folate metabolism in Plasmodia 
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dihydrofolate, a cofactor in purine and pyrimidine precursor biosynthesis. 
Humans utilise preformed folic acid for their requirement of dihydrofolates. 
- -. The above mechanism was accepted for long time but, recent study 
shows that folic acids interfere with the sulfonamide drug activity, indicating 
that the action of these drugs may be on other pathways as well (McCormick et 
al., 1972). 
Little is known about the mechanism of the resistance against the 
sulfonamide group of drugs. Resistant strains can be obtained by slow 
increase of the drug concentration in the culture medium. It appeared that the 
resistant parasites survive by bypassing the PABA utilisation steps. Instead 
they use the host cell folates. The resistance against sulfonamides is usually 
associated with less sensitivity to dihydrofolate reductase inhibitors. This type 
of resistance is stable and is carried through all stages and subsequent 
generations (Peters., 1971) 
The selective action of 2,4-diaminopyrimidifles, like pyrimethamine and 
trimethoprim and triazines like. cycloguanil resides in their greater affinity to 
the parasite enzyme dihydrofolate reductase (DHFR) than to the host enzyme. 
DHFR is a key enzyme in folate metabolism since it converts the pteridine ring 
to the tetrahydro reduction state required forthe reaction in which the folate 
cofactors are synthesized. it has been shown that this drug binds 100 to 1000 
times more tightly to the Plasmodial enzyme than to that of the host 
(McCormick et al., 1971). 
Perhaps the mechanism of resistance of DHFR inhibitors is most 
thoroughly studied. Recent comparison of amino acid sequence of sensitive 
and resistant PfDHFR, showed that one amino acid change in the active site 
due to a point mutation in the gene conferred the change in substrate binding 
of the enzyme (s I) But there may be other mechanisms involved as 
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well, such as; alteration of the transport of drug across the cell membrane, 
gene amplification which may result in larger amount of the enzyme production 
in resistant cells (Schimke., 1980), and involvement of a deletion in 5' flanking 
region of the gene on the drug resistance has also been hypothesized (Shiu 
wan Chan and John Scaife, personal comm.). 
The mechanism of action of blood schizontocides such as chloroquine, 
quinine, mefloquine and amdiaquine is not clearly understood. These drugs 
can be divided into two groups on the basis of their structure and effect on the 
morphology of the parasite. In the first group, exemplified by chloroquine, 
there are two easily protonable highly electronegative nitrogen atoms present 
in the molecule and the most noticeable morphological effect is swelling and 
fusion of adjacent digestive vacuoles, followed by their sequestration in 
autophagic vacuoles, i.e. pigment clumping (Warhurst and Hockley, 1967). 
The second group, exemplified byuinine do not cause clumping of the 
pigment but the digestive vacuole may swell and the pigment in them may 
become less electron dense (Peters et a/.,1977). This group of drugs has only 
one electronegative nitrogen atom. The exact effect on the biochemistry of the 
parasite by these drugs is not clear. However, it has been suggested that 
these drugs may complex with the ferriprotoporphyrin IX, the degradation 
product of haemoglobin, and interact with the subcellular membrane resulting 
in swelling of the vesicles and subsequent lysis (Chou and Fitch, 1981). 
Resistance to this group of drugs does not emerge as often as to others, and 
the primary mechanism of this resistance may be due to the change in the 
transport system of the drugs. 
Naphthoquinones and hydronaphthoquiflOnes are found to be active 
against both primary tissue and blood forms of the parasites. It has been 
suggested that these compounds exert their antimalarial effect by blocking 
electron transfer at a cytochrome mediated step in the energy producing 
respiratory chain (Roberts et al., 1978). Later it was found that these 
compounds act on dihydroorotate dehydrogenase, an enzyme involved in 
pyrimidine biosynthesis which also coupled the pyrimidine synthesis with 
oxygen utilisation (Gutteridge et al., 1979). 
1.7 Parasite biochemistry as the target for chemotherapy. 
The above discussion on mechanism of degradation and drug resistance 
emphasized the fact that antiparasitic drugs exert their effect by inhibiting or 
disturbing major biochemical pathways which may be unique to the parasite. 
So, it may be imagined that the complete and exhaustive knowledge of 
biochemical pathways is the prime requirement for success in antimalarial 
chemotherapy. To date, knowledge of the malaria parasite's biochemistry is 
far from complete, but the above discussion indicated that there exist in the 
parasite unique biochemical determinants andAthese could provide a basis for 
the successful development of chemotherapeutic agents. 
Attempts hao, been made to rationalise drug design. Although folate 
metabolism ha5 been a fruitful target for drug development success has been 
very limited in other areas. This is due to several technical reasons. One 
major factor has been the lack of appropriate test systems. For example, the 
target of naphthoquinones was first believed to be ubiquinone 8, a counterpart 
of mammalian ubiquinone 10 when the early inhibition assays were carried out 
with beef heart mitochondria, although correlation of the inhibition with the 
activity data was very poor (Sweeney et al., 1983). As stated in section 1.6 the 
target is now known to be dehvdroorotate dehydrogenase. 
The development of techniques of in vitro culture of P. falciparum and of 
isolation and fractionation of parasite material have removed this constraint in 
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part. But obtaining enough material for structural study of enzymes is still not 
possible by these techniques. Moreover, maintaining cultures and screening 
drugs is expensive and needs trained personnel. 
Recent development of genetic engineering and monoclonal antibody 
techniques for manipulating parasite DNA and protein could play an important 
role in understanding the parasite biochemistry and in the identification of 
potential chemotherapeutic targets. The difficulties of the production of 
sufficient quantities of the enzyme from cultured parasites could be overcome 
by cloning in a suitable vector, the Plasmodial genes which code for the 
particular enzyme. Simmons et a! (1985), showed the feasibility of such an 
approach. They identified the antibody to P. fa/ciparum lactate dehydrogenase 
(LDH)(EC 1.1.1.27) and subsequently cloned the gene for this enzyme in E. coil. 
These studies indicated that the parasite-specific LDH was structurally distinct 
from the host cell enzyme. 
In the following sections I will be discussing some possible areas of 
metabolic pathways 	P. falciparum as potential chemotherapeutic targets. 
1.7.1 Energy metabolism. 
The glucose metabolism route is fundamentally similar in all organisms. 
So, it seems unlikely that these pathway could be a target for malaria 
chemotherapy. However, there is evidence that Plasmodial enzymes involved in 
this pathways can be quite distinct from those of the host. Sherman (1966) 
reported the heterogeneity of lactate dehydrogenase in P. /ophurae. He also 
showed that the active site of the parasite enzyme is distinct from that of the 
host. This knowledge was later extended to P. falciparum by Simmons et al 
(1985). To date, there has been no report on the biochemical investigation of 
any other purified glvcolytic enzymes. This is mainly because of the problems 
of growing the parasite in large quantities for conventional biochemical 
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analyses and also due to the excessive lability of Plasmodial enzymes. Detailed 
characterisation may provide some parasite-specific receptors and this may 
now be possible using molecular biological approach. 
1.7.2 Protein synthesis. 
It is now generally agreed that erythrocytic stage Plasmodia get amino 
acids for protein synthesis from three different routes ; CO2 fixation, free amino 
acid pools of plasma and red cells, and red cell haemoglobin (Sherman 1979). 
CO2 fixation is a minor source for parasite amino acid requirement, as has 
been shown by the fact that the parasite mostly depends on the exogenous 
sources. Despite this there is no detailed description of the mechanism by 
which the parasite performs nitrogen fixation. For examples one of the 
important CO2 fixation enzyme, phosphoenolpyruvate carboxylase has reported 
only in P. berghei (Siu 1967). Likewise, the mechanism of uptake of CO2 and 
free amino acids have not been described either. However, if this involved 
some parasite-specific carrier, it may be possible to inhibit protein synthesis by 
blocking such transport proteins. Kutner et al (1983) have described a new 
pathway for anion transport in human red cells infected with P. falciparum. 
It is believed that haemoglobin is the major source of parasite amino 
acids. Parasite-specific proteases have been identified in different malaria 
parasites (Gyang et al., 1982; Sherman and Tonigoshi 1983). These 
aminopeptidases therefore could be specific targets for the design of 
antimalarial drugs. Although the mechanism of protein synthesis in the malaria 
parasite appears to be typically eukaryotic, nothing is known about the specific 
details for this synthesis. 
1.7.3 Lipid biosynthesis. 
It has been shown that the malaria parasite obtains most of its 
phospholipids, IysophospholipidS, cholesterols and fatty acids and phospholipids 
by exchanging the components with plasma during the turnover of erythrocytic 
lipids (Sherman 1979). Moreover, both membrane lipids of the host cell as well 
as the parasite become available for Plasmodial lipid biosynthesis by 
endocytosis. It seems therefore unlikely that lipid biosynthetic pathways could 
be targets for antimalarial drug design. However, parasite specific enzymes of 
lipid biosynthesis such as phosphatidylserin decarboxylase (EC 4.1.1.65) and 
phosphatidylethanolamine methyltransf erase (EC 2.1.1.17) (Vial et a/., 1982; 
1985), have been identified and so this approach cannot be disregarded. 
1.7.4 Folate metabolism. 
Malaria parasites can synthesize folic acid by the de novo pathway. 
Sulfonamide, & sulfone, interfereçwith the biosynthesis of dihydrofolate and 
pyrimethamine, an inhibitor of dihydrofolate reductase block the formation of 
tetrahydrofolate. It is known that the malaria parasite, in contrast to host can 
use PABA and not folic acid for synthesis of folates. But more recent studies 
have revealed that in P. fa/ciparum both folic acid and PABA interact with 
salfadoxin (McCormick et al., 1972). This may indicate the existence of another 
metabolic pathway by which the parasite is capable of utilising red blood cell 
folic acid, in'bsence of plasma folate or PABA. Further investigation of this 
pathway may reveal some parasite-specific receptor which could be a target 
for an antimalarial drug. 
1.7.5 Nucleic acid metabolism. 
	
During 	intraerythrocytiC schizogony, malaria parasites multiply rapidly 
to produce merozoites. Sinden (1978) suggested that during intraerythrocytic 
development from an invading merozoite to a fully mature schizont the amount 
of DNA increases 10 to 20 fold. The parasite doubling time is approximately 6 h 
(Sherman 1979), and so this needs large amount of nucleic acid synthesis in 
certain stages of parasite's life. Studies have shown that the DNA of 
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P. falciparum has a unique base composition of approximately 17-19% G+C 
(Goman at al., 1982). Similarly RNA from malaria parasites is typical of & 
protozoan having a G+C content of 35% in contrast to that of 65% in human 
(Sherman 1979). These features suggest that if such a unique DNA and RNA 
composition is important for the parasite's life, then this could be a suitable 
target for drug design. 
Malaria parasites can synthesize pyrimidine by the de novo pathway. The 
pathway is shown in Figure 1.5. The enzymes for thymidylate synthesis have 
been identified in several plasmodia species. Inhibition of one of these, 
dihydrofolate reductase (DHFR) has been shown to be the basis of the action of 
pyrimethamines. DHFR and thymidylate synthase (TS) in Plasmodium exist as a 
bifunctional enzyme complex whereas the mammalian enzymes exist separately 
(Ferone and RoIc1 1980). It is not known yet if this is an exploitable difference. 
Some of the enzymes of pyrimidine biosynthesis have been identified in 
P. fa/ciparum (Gero at al., 1981; Rathod and Reyes 1983). The same enzymes 
have also been detected in P. berghei (Hill at al., 1981). Their studies showed 
that the first three enzymes in the pathway, carbamoylphosphate synthase, 
aspartate transcarbamylase and dihydroorotase seem to exist in a complex 
similar to eukaryotes. The fourth enzyme, dihydroorotate dehydrogenase is of 
considerable interest, since it is inhibited by cyanide and antimycin A. It has 
been suggested that during oxidation of dihydroorotate, electrons are fed into 
the cytochrome chain at the ubiquinone level. The prime purpose of this 
electron transport chain is its involvement in the orotate biosynthesis. The 
cytochrome is the only cytochrome known in Plasmodia and the inhibition of 
the cytochrome oxidase could therefore, be one of the chemotherapeutic 
targets (see Fig. 1.5). 
In contrast to the de novo biosynthesis of pyrimidines Plasmodia, like 
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other parasites cannot synthesize purine rings de novo, and these are obtained 
preformed, preferably as hypoxanthine (Konigk 1977), by the purine salvage 
pathway. All the major enzymes of purine salvage pathway have been 
identified in P. fa/ciparum (Sherman 1979). These include adenosine deaminase, 
purine nucleoside phosphorviase, hypoxanthine-guanine phosphoribosyl 
transferase (HGPRT) and adenosine kinase. Based on the kinetic parameters, 
Reyes et al (1982) suggested that HGPRT and adenosine deaminase are 
structurally distinct from the host enzymes. Another enzyme of interest in 
purine salvage pathway is adenylosuccinate synthase. This enzyme catalyses 
the synthesis of adenylosuccinate, an intermediate in conversion of inosine 
monophosphate to adenosine monophosphate. One inhibitor of this enzyme, 
halacin has been studied for its ability to inhibit synthesis of adenylate. 
Webster et a! (1984) showed that halacin blocks synthesis of adenylates from 
hypoxanthine. 
1.8 Rationale of chemotherapy. 
In the above discussion it has been demonstrated that parasite-specific 
enzymes exist which could be potential targets for drug design against malaria. 
As discussed above, the major problem of studying these enzymes is difficulty 
in getting enough purified enzyme from in vitro cultured parasites. Further 
problems arise due to the excessive lability of plasmodial enzymes for some 
unknown reason. Development of genetic engineering technologies could 
contribute considerably in overcoming at least some of these problems. For 
instance, if the genes specifying these enzymes can be cloned and sequenced, 
structural information can be readily obtained. Expression of these genes in 
well-studied prokaryotes could give enough protein for crystallography. 
Structural data could then be compared with that of the host protein and key 
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differences could then be pin pointed and putative drugs Ccu& be designby 
computer aided designing (CAD) (Silverton 1984). Such drugs may only act on 
the parasite enzyme but not onost's enzyme. ft 
Another advantage of such a structural study is that, it could give 
information about any functional change in the protein which causes - 
resistance against a drug. One excellent example of this is pyrimethamine 
resistance. Pyrimethamine is a specific inhibitor of DHFR. Resistance to 
pyrimethamine has been shown to be due to a point mutation in the active site 
Qk 
of the enzyme ('t 	198). This has been identified by cloning the gene 
from both sensitive and resistant strains. 
Direct and functional expression of enzyme-encoding genes in a 
bacterium may present an extra advantage. Expressing such a gene in a 
bacterium with a mutation in the homologous gene could result in 
complementation of the bacterial mutation. Such a system could be excellent 
for screening putative drugs against the parasite enzyme. This would be both 
inexpensive and simple to perform. 
As mentioned before, P. fa/ciparum, cannot synthesize purine nucleus de 
novo and exclusively relies on the activity of the salvage pathway for its 
purine requirements. This could be a potential target for drug action. The main 
rationale of applying such an approach for understanding the salvage pathway 
is that the key enzyme HPRT has been studied extensively in several 
organisms. The cDNA of the P. fa/ciparum HPRT has been cloned and 
sequenced (King and Melton 1987). Comparison of the predicted amino acid 
sequence with that of the host revealed several dissimilariVes between them. 
In the present work described in this thesis, hypoxanthine guanine 
phosphoribosyl transferase of P. falciparum, denoted PfHPRT has been chosen 
for study at the molecular level. To place the PfHPRT in context, I will review 
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the essential features of the nucleic acid metabolism in Plasmodia in detail, 
concentrating on P. falciparum. This will in turn lead to a brief review of 
purine metabolism in plasmodia and then PfHPRT. I will also discuss 	purine 
metabolism in both 	man and mosquito, hosts of human malaria parasites. 
1.9 Nucleic acid metabolism in Plasmodia. 
DNA 
Each intraerythrocytic merozoite in a schizont is haploid, 	- contains 
about 0.1 pg DNA and has a chromosome number of 14 (Wellems, 1988). 
Kinetic study of P. falciparum DNA synthesis, where the erythrocytic cycle is 48 
hours, suggested that in the asexual intraerythrocytic stage DNA synthesis 
starts at 29.5 hours, at a time when the parasite is in early trophozoite stage. 
DNA synthesis increases logarithmically until 44 to 48 hours, the end of the 
schizogony (lnselberg & Banyal 1984). Waki et al (1985) also suggested similar 
timing. Similar stage specificity for DNA synthesis was reported by Newbold et 
a! (1982) for P. chabaudi, where the cycle is only 24 hours. These authors 
Th 
observed DNA synthesis at,early trophozoite stage and very little synthesis was 
noted during the first half of the cycle with the maximum rate of synthesis at 
late trophozoite and schizont stages. In P. fa/ciparum it is reported that during 
this period the DNA content increases about 10 to 20 times (Sinden 1978). 
This tremendous amount of DNA synthesis at certain time points in the 
parasite's life suggest that a huge amount of DNA precursor molecules are 
needed and raises the question about the source of such precursors. 
The genome size of P. falciparum has been estimated to be 3.8 x 108  base 
pairs and 10% of the genome to contain repetitive sequences (Hough-evans 
and Howard 1982). Dore et a! (1980), reported the P. berg/wi genome size of 2 
X 10 bp with a variable repetitive frequency between 3 to 18%. By comparison, 
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the human genome consists of 3 x 10 9  base pairs with 25% repetitive sequence 
(Gaubatz et al., 1976) and that of E. coil is 4 x 106  base pairs. 
One unique character of the Plasmodia genome is its very high A+T 
content. The G+C content of P. falciparum genome as estimated by Goman et 
a! (1982) is 18-20%. Similar numbers have also been reported for P. Iophurae 
(Walsh and Sherman, 19686), The G+C content varies somewhat between 
different species of Plasmodia: for instance, in simian malaria parasites, the the 
G+C content is found to be 37% (Sherman, 1979), whereas in rodent malaria it 
is 24%. 
RNA 	 114, 
In comparison with DNA content ofintraerythrocytic malaria parasite, the 
total RNA content is 	 5 times 	Most of this t5-' ribosomal 
RNA present in the metabolically highly active cytoplasm (Gutteridge and Trigg 
1970). The sedimentation value of plasmodial rRNA was found to be about 25S 
and about 17S, typical for prokaryotes (Sherman et al., 1975; Tokuyasu1969). 
For comparison the values for other eukarvotes are 28S and 18S (Sherman and 
Jones 1977). Nucleotide composition of rRNA also supported this result. The 
G+C content of Plasmodial rRNA is about 35% (Sherman 1979) whereas that of 
eukaryotes is about 65%. - 
The organisation and copy number of plasmodial ribosomal genes are also 
novel among eukaryotes. Plasmodial rRNA genes are small in number and 
dispersed in the genome. In contrast the genes in most other eukaryotes are 
high in number (100 or more) and tandemly repeated in the genome. Langsley 
et a! (1984) cloned most of the genes of both subunits and showed that two 
genomic clones both contained all three ribosomal genes, but from two 
different transcriptional units. The ribosomal RNA genes are organised in a 
typical eukaryotic pattern of 18S-5.8S-28S. Copy number analysis of 
P. falciparum rRNA genes revealed that each of the 2 ribosomal transcriptional 
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units is present four times in the genome i.e. there are only 8 rRNA genin the 
genome (Langsley 1984). They also suggested that the large rRNA subunit gene 
contained one intron. The pattern of introns in ribosomal genes are another 
interesting feature of the malaria parasite ribosomal DNA structure. The 25S 
ribosomal gene has twqntrons and the 17S gene has one (Unnasch and Wirth 
1983). Presence ofthe intron in the 17S gene is unique to Plasmodia, no other 
eukaryote or prokaryote is known to contain an intron in its 17S rRNA gene. 
P. fa/ciparum mRNA has been extracted from blood stage in vitro cultured 
parasites and translated (Hyde et a! 1984, Wallach et al., 1982a and 1982b). 
The translation efficiency of P. fa/ciparum mRNA in in vitro with commercial 
reticulocyte lysate has been assessed. Wallach et a! (1982a) observed that the 
efficiency is markedly increased if supplemented with homologous tRNA. They 
were able to translate proteins up to Mr 200000 Da. However other workers 
have successfully translated P. falciparum mRNA without the above 
modification (Hyde et al., 1984; Coppel 1984). Franco da Silvera and 
Mercereau-Puijalon (1983) isolated mRNA from different stages of erythrocytic 
parasite. By in vitro translation of thh mRNA they demonstrated a 
stage-specific pattern of proteib expression as also seen in vivo. Hyde et al 
(1984) also produced similar results and found proteins ranging from 16 to 230 
kDa proteins which were synthesized consistently, whereas some high 
molecular mass proteins were only expressed in the schizont stages. These 
authors also measured the amount of mRNA present in different stages of 
intraerythrocytic development of P. fa/ciparum. They reported about 4-6% of 
total RNA is mRNA, and 82%rRNA and about 14% is tRNA. The average size of 
poly A RNA was 1.2 kb with a modal value of about 3.5 kb. The average size 
of the poly A tail was estimated at approximately 120 to 200 bp. 
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1.10 Nucleic acid precursor metabolism. 
As mentioned above, the intraerythrocytiC stages of Plasmodia possess 
a., 
high rates of DNA and RNA synthesis. For these purposes they requirevast 
amount of precursor molecules. The host erythrocytes are capable of providing 
enough essential precursor molecules to allow the successful growth and 
multiplication of the parasite within the cell. Mammalian erythrocytes can 
synthesize nucleotides, although they do not synthesize any nucleic acids. 
However, the synthesis of purine rings does not take place in erythrocytes, 
rather they are obtained in the plasma from the liver or other organs and 
subsequentlyutilised via the salvage pathway. 
It was first shown in 1967 that P. berghe/-infected erythrocytes do not 
incorporate tritiated uridine and thymidine into parasite nucleic acid (Sherman 
1979). Similar attempts to incorporate uridine into plasmodial RNA also failed 
(Conklin et al., 1973). Later, it was discovered that the parasite can incorporate 
radioactive bicarbonate and furthermore that they contain several enzymes of 
pyrimidine biosynthesis (Walsh & Sherman 1968b). Since the discovery of de 
nova pyrimidine biosynthesis, all six enzymes of the de nova pathway have 
been detected in several Plasmodia species, which catalyse the conversion of 
carbamyl phosphate to thymidylate (Hill et al., 1981; O'Sullivan & Ketley 1980). 
Figure 1.5 shows the de nova pyrimidine biosynthesis pathway in Plasmodia. 
1.10.1 Metabolism of purine nucleotides. 
Biosynthesis. 
All living organisms which can synthesise purine nucleotides de nova 
follow the same basic pathway (Lehninger, 1982). The detail of the pathway is 
shown in Figure 1.6. The synthesis begins with the donation of an amino 
group by glutamine to position one of ribose 5'-phosphate and the purine is 
then built on it, step by step. The ring closure occurs to yield the 
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Figure 1.6 	The de novo purine biosynthesis pathway. (1) displacement of PPI by 
the side chain amino group of glutamine, (2) addition of glycine, (3) formylation by 
N 10-formyl tetrahydrofolate, (4) transfer of a nitrogen atom from glutamine, (5) 
dehydration and ring closure, (6) carboxylation, (7) addition of aspartate, (8) elimination 
Of fumarate, (9) formylation byN 10-formyltetrahydrofolate,(10) dehydration and ring 
closure, (A) Adenytosuccinate synthase, (B) Adenylosuccinate lyase, (C) IMP 
dehydrogenase and (D) GMP synthase. 
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five-membered imidazole ring. Aspartate donates its amino group to the 
imidazole ring and a second ring closure causes the fusion of the two rings of 
the purine nucleus. Thus the first intermediate of the purine nucleotide, IMP is 
formed. AMP and GMP are synthesised from IMP via separate branches of the 
pathway, which in turn convert to ATP and GTP by phosphorylation. AMP is 
formed by two step addition of an amino group, donated by aspartate, 
catalysed by adenylosuccinate synthase and adenylosuccinate lyase. In E. coil 
these two enzymes are coded by purA and purB genes. Similarly formation of 
GMP from IMP is catalysed by IMP dehydrogenase and GMP synthase which are 
coded by guaA and guaB respectively in E. coil. 
Catabolism. 
Similar to the biosynthesis, the degradative pathway of purine is also 
basicallysame in all living organisms. The pathway is shown in Figure 1.7. 
Degradation starts by the action of 5'-nucleotidase on the nulceotides. AMP 
yields adenosine, which is then deaminated to inosine by adenosine deaminase. 
Inosine is then hydrolysed into hypoxanthine by nucleosidase and then xanthine 
and uric acid by one enzyme, xanthine oxidase. GMP is first converted into 
guanosine by nucleosidase and then to xanthine by guanosine deaminase, 
which in turn produces uric acid. In primates uric acid is the excretory end 
product of purine catabolism. But in some animals they further degrade into 
allantoin, allantoic acid and urea. 
Purine salvage pathway. 
In all living systems free purine bases are constantly formed in cells 
during the metabolic degradation of nucleotides by the pathway described 
above. However, most of these free purine bases are salvaged and used over 
again to remake nucleotides and only a small fraction are catabolised and 
excreted. For instance, the human body excretes only 0.6 g uric acid per day 
(Lehninger 1982). 
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Figure 1.7 	Purine degradation pathway. Those organisms excreting each of the 
various catabolites as end products are indicated. 
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Compared to the complex biosynthesis of purine by the de nova pathway, 
the salvage pathway is simple. Basically, only one reaction is involved. AMP is 
produced from adenine by enzyme adenine phosphoribosyl transferase and 
GMP from guanine by guanine phosphoribosyltranSferase (GPRT). In several 
organisms, including human, GPRT also catalyses the conversion of 
hypoxanthine to inosine, hence called hypoxanthine-guanine phosphoribOSyl 
transferase (HGPRT). Besides this, most living cells can also catalyse the 
interconversion of purine bases via IMP, as the common nucleotide. Figure 1.8 
shows the details of purine salvage and the interconversion of the free bases 
and nucleosides and nucleotides. 
1.11 Purine metabolism in Plasmodia. 
1.11.1 2e novo synthesis. 
Unlike the thymidine and uridine, when tritiated hypoxanthine or adenosine 
were injected into the P. berghe/-infected mice or rats they were readily 
incorporated into the parasite nucleic acids (Sherman 1979). Similar results 
were obtained with P. know/es/infected erythrocytes (Gutteridge and Trigg 
1970). Tracy and Sherman (1972) showed with P. /ophurae that the uptake and 
accumulation of adenosine, inosine and hypoxanthine is directly related to the 
growth stage of the parasite . The explanation for these results became clear 
when Walsh & Sherman (1968) showed that the parasite can not incorporate 
labeled glycine and formate into DNA or RNA, suggesting that Plasmodia are 
incapable of synthesizing the purine ring de nova. It was therefore, concluded 
that Plasmodia obtain purine nucleotides necessary for their nucleic acid 
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Figure 1.8 	Purine salvage pathway. (1) Adenine phosphoribosyl transferase 
(APRT), (2) hypoxanthine phosphoribosyl transferase (HPRT), (3) guanine phosphoribosyl 
transferase (GPRT), (4) purine nucleoside phosphorylase (PNP), (5) adenosine 
deaminase (ADA), (6) inosine kinase, (7) guanosine kinase, (8) IMP dehydrogenase 
(IMPD), (9) GMP synthetase, (10) adenylosuccinate synthase (ASS) and (11) 
adenylosuccinate lyase. 
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1.11.2 Salvage pathway. 
Now, if Plasmodia completely rely on the salvage of preformed purines, 
what is the favoured purine which is utilised in viva by the parasite ? 
Approximately 80% of the erythrocytic purine is in the form of ATP, and 
probably this ATP serves as the source of purines for the parasite. Trager 
(1950) reported that addition of ATP enhances the survival of extracellular 
P. /ophurae. Later, it was shown that purines from radioactive ATP or AMP are 
incorporated into saponin freed P. berghei (Van Dykes et al., 1969). These 
authors concluded adenosine was the substrate of choice for Plasmodial purine 
requirement. 
These studies were further elaborated by Manandhar et a/., (1975), who 
suggested that adenosine itself does not enter into the salvage pathway. he 
proposed that adenosine is first converted to hypoxanthine in the intracellular 
medium and this hypoxanthine serves as the initial entry compound to the 
salvage pathway. This suggestion was supported by the fact that Patterson's 
compound 555, an adenosine transport blocker did not have any effect on the 
utilisation of adenosine. On the other hand, both uptake and 
phosphoribosylation of hypoxanthine was completely blocked by purine 
6-sulfonic acid-3N-oxide. Tracy and Sherman (1972) also speculated that the 
added adenosine is probably deaminated to inosine during uptake. 
A similar prime role of hypoxanthine in Plasmodium purine salvage was 
confirmed not only for P. berghei, but also for P. chabaudi and P. !ophurae 
(Sherman 1979; Hansen et al., 1980) and for Leishmania donovani and 
Leis/imania brazil/ens/s (Marr et al., 1978) and Crithidia fasciculata (Kidder et al., 
1979) 
The present knowledge of purine metabolism in Plasmodia is primarily 
based on the enzymatic data as described for the cell free extracts of different 
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species of this parasite (Konigk, 1977). Reyes et a/., (1982) described the 
presence of purine salvage enzymes in P. fa/ciparum. In the following sections, 
the basic characteristics of the purine salvage pathway in this parasite is 
discussed in detail. 
Adenine, adenosine and AMP reutilisation. 
Studies with P. chabaudi revealed that the adenine and adenosine can be 
used by three different routes as shown in Figure 1.9 (Walter & Konigk, 1974). 
Conversion of adenine to AMP is catalysed by the adenine phosphoriboSyl 
transferase (APRT)(Fig. 1.8). This enzyme has a very low specific activity in 
P. falciparum (Reyes et al., 1982). Such a low level of APRT activity is also 
reported in P. chabaudi (Walter and Konigk 1974). Similarly the specific activity 
of the enzyme adenosine kinase which converts adenosine to AMP was also 
found to be remarkably low in P. fa/ciparum (Reyes et al., 1982). The authors 
concluded that these two pathways of adenine nucleotide utilisation are of 
minor importance in the parasite's life. 
In contrast, the activity of adenosine deaminase (ADA), which catalyses 
the conversion of adenosine to inosine was found to be very high. The 
specific activity of ADA in P. falciparum cell free extract was about 4000 times 
higher than that of adenosine kinase and about 1000 times higher than APRT 
(Reyes et al., 1982). So, it was suggested that the enzyme ADA may play an 
important role in plasmodial purine metabolism. 
The 	i\ effect of Patterson's compound 555, an inhibitor of adenosine 
transport blocker, on incorporation of adenine nucleotides into the parasite 
nucleic acid, indicated that most of the adenosine mayconvertIntO inosune 
before entry into the parasites, perhaps by the host cell enzyme (Sherman 
1979). Human red blood cells have been shown to contain comparatively high 
amounts of ADA (Reyes et al., 1982). This made the enzyme less suitable as a 
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Figure 1.9 	The purine salvage pathway in the intraerythrocytic asexual stage 
parasite. For enzyme abbreviations see Figure 1.8. 
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substrate specificities and sensitivities to different inhibitors of purified adenine 
deaminase from different plasrnodial and human sources have suggested that 
the enzymes from the parasite and human are indistinguishable for all the 
purine analogues surveyed. For example, Schimandle & Sherman (1983), 
studied purified enzyme from P. Iophurae and showed that most of its physical 
properties are similar to the red cell enzyme. However, they reported that the 
parasite enzyme is unique in its lack of sensitivity to the inhibitor, EHNA 
(Erythro-9-2-hydroxy-3--nonyl adenine). A similar pattern of insensitivity to 
EHNA was also reported for P. fa/ciparum ADA (Daddona et al., 1984). 
AMP can be converted into inosine via two routes. Firstly, by AMP 
-ac 	
i phosphorylase, AMP can transform-unto adenosine, which n turn forms inosine, 
catalysed by ADA. On the other hand, AMP can directly form lMPcatalysed by 
AMP-deaminase, whichthen dephosphorylated to inosine. Enzymes for both 
routes are present in Plasmodia (Scheibel & Sherman 1988). 
Utilisation of inosine and guanosine. 
Both P. fe/c/part/rn and human red blood cells contain purine nucleoside 
ek &) 
phosphorylase (PNP) for inosine and guanosine utilisation (Reyes,,1982). The 
enzyme catalyses the conversion of nucleosides into corresponding 
nucleotides; for example, inosine into hypoxanthine. The enzyme is also 
described in P. chabaudi (Konigk 1977). High activities of both ADA and PNP in 
host red cells and in the parasite suggested that adenosine is readily converted 
into inosine (both in red cell and parasite cytoplasm). This inosine is in turn 
converted into hypoxanthine, which is the primary substrate of the purine 
salvage pathway. 
Similarly guanosine is converted into guanine. Since guanosine is not 
readily taken up by the parasite (Tracy & Sherman, 1972), this route of purine 
utilisation may be of less importance. That no activity for adenosine and 
xanthine phosphorylase were detected in P. fa/ciparum led to the suggestion 
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that these steps may not play any important role in the parasite's purine 
metabolism (Reyes at al., 1982). 
PNP from P. /ophurae has been purified by Schimandle at al., (1985). Their 
studies in comparing the human enzyme with that of the parasite, revealed that 
the parasite enzyme is unique in several aspects. 
Utilisation of Hypoxanthine and guanine. 
Purine nucleotide uptake studies with 'saponin-freed' P. Iophurae showed 
"P 
that only hypoxanthine, adenosine, inosine and guanine are readily 	taken, by 
the parasite. In contrast guanosine, xanthine, adenine, AMP, ATP and IMP 
uptake was very low (Tracy and Sherman, 1972). Since the guanine 
concentration in red cell and plasma was found to be very low and adenine and 
inosine readily converts into hvpoxanthine, it has been suggested that 
hypoxanthine is the most favourable purine for use by Plasmodia. Indeed, the 
hypoxanthine utilising enzyme hypoxanthine phosphorybosyl transferase (HPRT) 
is shown to be present in P. falciparum in high activity. HPRT catalyses the 
phosphoribosyl group transfer between hypoxanthine and phosphoribosvl 
pyrophosphate (PRPP), producing inosine monophosphate (IMP) from 
hypoxanthine. 
HPRT activity in P. fa/ciparum extract was some 160 times more than that 
of the APRT (Reyes at al., 1982). HPRT has been purified from P. Iophurae 
(Schimandle at al., 1987), P. chabaudi (Walter and Konigk 1974) and 
P. falciparum (Queen at al., 1988) and shown to be unique in several aspect 
from the host enzyme (see below). Through these differences, the enzyme 
could be a potential target for drug design against malaria. Since the 
enzyme plays a key role inthe parasite's life and the primary aim of this thesis 
is to study the P. fa/ciparum HPRT (denoted PfHPRT) at the molecular level, I 
will discuss the properties of this enzyme in detail, later. 
IMP is converted to both AMP and GMP by the de novo pathway. By one 
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route, IMP is first converted into adenylosuccinate by adenylosuccinate 
synthetase which cvc- .to AMP by adenylosuccinate lyase. Similarly, the 
otherproduces GMP from IMP via XMP in an enzyme catalysed-reaction. The 
enzyme IMP dehydrogenase, catalysing XMP synthesis has been identified in 
P. Iophurae. It is predicted that both adenylosuccinate lyase and GMP 
sythetase may be also present in the parasite (Sc.heibel and Sherman, 1988). 
Both the routes are shown in figure 1.6. 
1.12 Purine metabolism in the parasite's host. 
Since the malaria parasite depends entirely on bothertebrate and insect 
host5, for preformed purine nucleotides the story will remain incomplete without 
discussing the purine metabolism in the hosts. Any alteration of purine 
metabolism in these hosts may interfere with the parasite metabolism. For 
example, addition of allopurinol, an inhibitor of xanthine oxidase in the drinking 
water of rat mice enhanced the severity of the malarial infection (Sherman, 
1979). It was suggested that maybe the inhibition of xanthine oxidase 
increased the concentration of - hvpoxanthine, the most favoured purine of 
the parasite. 
Mammals including - :man can satisfy their requirement for purine 
nucleotides by both de novo biosynthesis and salvage pathway as described 
above. 
However, in addition to its usual role purine metabolism serves quite an 
unusual purpose in terrestrial insects, including mosquito. The work of 
McEnroe and Forgash (1958), revealed that insects can synthesize purines by de 
novo biosynthesis. They showed that labelled formate is readily incorporated 
into purines. These purines are formed by a long series of reactions which 
involve the addition of ammonia, glycine, formate and aspartate to a 
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phosphorylated derivative of ribose. The pathway is possibly the same as in 
other animals as shown above. 
The absence of functional HGPRT in insects (reviewed in Swerdel & Fallon 
1987), suggested that the salvage pathway is not the primary pathway by which 
these organisms obtain their purines. However, the enzymes XPRT and APRT 
(Backer, 1974) were detected in insect cells. 
The main function of purine metabolism in insects appears to be nitrogen 
excretion. Excretion of nitrogen in the form of uric acid is characteristic in 
most terestrial insects and purine biosynthesis in these organisms is 
high (Gilmour 1965). In most animals however,the end product of nitrogen 
excretion is urea. It is suggested that since the solubility of uric acid is low, It 
can be excreted in solid form, thus, reducing the loss of water from the insect 
body. Several enzymes which catalyse the interconversion of purines have been 
detected in insects. These include deaminases, which convert adenine to 
hypoxanthine and guanine to xanthine (Figure 1.10) and also the enzyme 
xanthine oxidase, which oxidises hypoxanthine to xanthine and xanthine to uric 
acids. )t appears therefore, that the purines formed are readily converted into 
uric acid. Xanthine oxidase is probably the crucial enzyme in the formation of 
uric acids. 
1.13 Hypoxanthine phosphoribosyltranfe rase (HPRT, EC 
2.7.2.8) 
There is wealth of information on the study of HPRT from a wide range of 
organisms. However, most studies focus on the human enzyme. The reason is 
that deficiency in this enzyme causes varying degrees of clinical manifestation 
in humans. A partial deficiency in HPRT activity causes excessive accumulation 
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responsible for severe gout. Complete loss of activity causes,severe central 
nervous system disorder, named Lesch-Nyhan syndrome. Moreover, extensive 
study made this enzyme a widely used marker for gene transfer in the 
mammalian system and in the study of somatic cell genetics (Melton 1987). 
The reaction catalysed by HPRT is as follows: 
HN 
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kiN 	 (PRPP) 	 Inosinate 
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The primary substrate of the enzyme is hypoxanthine. However, the enzyme 
can use other purines with different specificities as its substrates. Table 1.2 
shows the Km values of HPRTs from different sources for different purine 
substrates. Krenitskv et a/., (1969) showed that the human HPRT can use both 
hypoxanthine and guanine with similar specificities, whereas the affinity 
towards adenine and xanthine is about 2500 to 2000 times less, suggesting that 
these are not the substrate for the enzyme. This is emphasized by -the fact 
that human cells contain a separate enzyme for adenine, named APRT. Human 
HPRT can also use 6-mercaptopurine with a similar efficiency to hypoxanthine 
and guanine. HPRTs from parasitic protozoa like P. /ophurae (Schimandle et al., 
1987), P. chabaudi (Walter and Konigk, 1974) and Leishmanla donovani (Tuttle 
and krenitsky, 1980) also show similar substrate specificity. However, some 
parasitic HPRTs can use xanthine with higher affinities. For example 
P. fa/ciparum (Queen et al., 1988), Elmer/a tenella (Wang and Simashkevich, 
1981) and Glardla Iamb/ia (Aldritt and Wang, 1986). P. fa/clparum HPRT is 
unique in Plasmodium species investigated so far in that it can use xanthine. 
On the other hand Crith/dia fasciculata, a kinetoplastid flagellate, does not have 
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Source Purine Km Reference 
Hx 0.46 Queen et al. 
P. 	falciparum G 0.30 
1988 
X 29.0 
Hx 2-25 Queen et a. 
Human G 2-4 
1988 
erythrocyte 
P. 	chabaudi Hx 2.5 
Walter & 
G Konigk, 2.0 1974 
- x 
Hx 3.8 Schimandle 
P.lophurae G 2.4 et 	al., 
1987 
Hx 2.0 Allen et a: 
i. donovani G 1.0 1989 
x 
Hx 0.25 Wang et al 
E. 	tenella G 0.37 
1981 
x 15.0  
Hx 514.0 Aldritt et 
G. 	larnblia 30.0 al.,1986 
543.0  
Table 1.2 	Km values of different purines to HPRT of different organisms. Hx = 
hypoxanthine, G = guanine and X = xanthine. 
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any xanthine-utilising activity and has two separate enzymes for hypoxanthine 
4. (JotO 
and guanine (Kidder A 1979). Leishmania donovani has a separate enzyme for 
xanthine utilisation (Tuttle & Krenitsky, 1980). In contrast to the eukarvotic 
HPRTs, most prokaryote enzymes can only use hypoxanthine. E. coil has 
separate enzymes: GXPRT which can use guanine and xanthine and HPRT which 
predominantly use hypoxanthine as substrate (krenitsky et al., 1970). However, 
gram positive bacterium Lactobacillus casel HPRT can use hypoxanthine and 
guanine, as observed in eukaryotes and has separate phosphoribosyl 
tranferases for xanthine and adenine (Krenitsky et al., 1970). 
HPRT requires Phosphoribosyl pyrophosphate (PRPP) as its second 
substrate. The phosphoribosyl moiety of the PRPP is transferred into the 9 
position of hypoxanthine. The affinity of HPRT towards PRPP also varies 
according to its source and also slightly with the purine used (Krenitsky et al., 
1970; Queen et al., 1988). The Km for P. fa/ciparum HPRT in presence of 
hypoxanttiine is reported to be about 20.7 i.IM (Queen et al., 1988). 
The enzyme also needs magnesium ions for its activity. Krenitsky et al., 
(1969) studied the effect of the metal ion on the activity of purified human 
enzyme. From kinetic studies they found that the dimagnesium salt of PRPP is 
a better substrate for the enzyme than the monomagnesium salt or the free 
acid. They suggested that magnesium may effect the initial rate of the reaction 
by forming a complex with the substrate. Addition of extra salt was found to 
be stimulatory up to a certain extent. However beyond, the optimum 
concentration the magnesium ion inhibited the reaction drastically. The 
Optimum MgSO4 concentration they reported was in the range of 5 to 20 mM, 
when the M9 2PRPP concentrations were between 1mM and 5 mM. 
HPRT has been purified from several organisms. The protein in human 
erythrocytes naturally exists as tetramer with a relative molecular mass (Mr), as 
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estimated by sedimentation equilibrium centrifugation, of 81-83 kD (Olsen & 
Milman 1977), and a predicted subunit size of 24.5 kD (Kiyj 4 MeAPo . 1987). 
Strausget al., (1978) showed the enzyme can also exist as dimer or trimer 
depending on the buffer and PRPP concentration. In contrast P. falciparum 
enzyme is independent of the PRPP concentration and present as a dimer, with 
an apparent Mr of 56 kD (Queen et al., 1988). The predicted Mr of the 
P. falciparum enzyme is 26.4 kD (King & Melton 1987). The estimated size of 
HPRT in different organisms appears to be different. For example, the HPRT 
proteins in P. chabaudi and P. Iophurae are 71 and 79 kD respectively ( Walter 
& Konigk, 1974; Schimandle et al., 1987) and that of the Giardia labila is 63 kD 
(Aldritt and Wang 1986). The protein in E. coil and L. casei is reported to be 75 
kD and 44kD respectively, as estimated by gel exclusion chromatography 
(Krenitsky et al., 1970). 
The HPRTs of different sources also differ in p1 values which are indicative 
of the total charge content of the protein. Whereas human red blood cell HPRT 
shows three different peaks at p1 values of at 5.6, 5.7 and 5.9 (Olsen & Milman 
1977), P. fa/ciparum HPRT showed only one peak at about 6.2. The p1 value of 
P. Iophurae (Schimandle et al., 1987), P. chabaudi (Walter & Konigk 1974) and 
Giardia Iamb/ia (Aldritt & Wang 1986) are 5.3, 7.6 and 6.8 respectively. 
P. falciparum HPRT is most sensitive to heat at 50 °C. At this temparature 
about 60% of the initial activity was lost within 30 seconds. However, the 
activity could be stabilised if preincubated with PRPP (Queen et al., 1988). 
Under these conditions more than 90% of the initial activity remained after 30 
minutes incubation. A similar stabilisation of activity was also observed with 
human (Olsen & Milman 1974) and rat liver (Natsumeda et al., 1977) HPRTs. 
Krenitsky et al., (1970) reported that HPRT from Lactobacillus casei is much less 
sensitive to heat inactivation. They showed that the enzyme retained about 
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70% activity when heated at 60 °C for 10 minutes. In contrast, the same 
authors reported that the E. coil enzyme is comparatively more sensitive; it 
retains only 20% of the initial activity at the same condition. 
A study of the effect of chemical modification of human HPRT in order to 
identify essential amino acid(s) present in the active site, was reported by 
Krenitsky - C.) ...,. (1969). The authors showed that the activity was not 
affected by the serine modifier chemical, diisopropyl fluorophosphate, but was 
efficiently inhibited by the sulfhydryl reactants p-chloromercuribenzOate and 
N-ethylmaleimide. This inhibition does not occur when the enzyme is 
preincubated with PRPP. Moreover, when the enzyme was incubated with 
sulfhydryl reagents like 2-mercaptoethanOl and dithiothreitol the activity was 
found to be increased. Queen et al., (1988) reported the result of similar 
experiments with the P. fa/ciparum enzyme. They reported a similar efficient 
inhibition of the P. fa/ciparum HPRT with p-chloromercuribenzOate. Wilson et al 
., (1982) sequenced the human HPRT and showed that the N-terminal 
methionine is removed by processing and the existing N-terminal alanine is 
acylated. No such information is known about Plasmodial HPRT. 
Finally, HPRT is a cytosolic soluble enzyme. The enzyme from human red 
blood cells is found in the cytoplasm as a soluble protein (Melton, 1987). 
Reyes et al., (1982) reported that the P. fa/ciparum enzyme is present in the 
soluble fraction of the sonicated supernatant. In contrast, recent studies 
revealed that the enzyme in Trypanosoma brucei and Trypanosoma cruzi is 
present in some membrane bound vesicles, termed glycosomes (Opperdoes, 
1987). Glycosomes are specialised vesicles, related to eukaryotic peroxysomes 
and glyoxysomes and contain most of the glycolytic enzymes (Opperdoes, 
1987). A similar location has also been reported for the HPRT of Leishmania 
mexicana (Hassan et al., 1985). 
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1. 14 The project proposal. 
The above discussions and literature survey have reflected P. fa/ciparum 
as one of the most dangerous killer parasitic disease in the world. The failure 
to develop a successful vaccine against the disease and the rapid emergence 
of resistant parasite strains against the existing chemoprophylactic drugs. 
emphasized the importance of the continuing work on new drug development. 
Study on the mechanisms of action of existing drugs and the mechanism 
of resistance have revealed particular biochemical pathways as the possible 
targets for effective drug design. One such pathway is purine metabolism in 
the parasite because the parasite cannot synthesise purine rings by the de 
novo pathway and solely depends on the host's supply of preformed purines. 
These preformed purines are utilised by the so-called purine salvage pathway. 
The enzyme HPRT is one of the key enzymes in the pathway, and so plays an 
important role in the parasite's life. Comparison of HPRT of P. fa/ciparum with 
other organisms, particularly with that of the human host, showed that the 
parasite enzyme is different in several biochemical aspects. This makes the 
enzyme a putative target for antimalarial drugs. 
However, the problem of isolating large amounts of the native parasite 
protein from the cultured parasite by conventional methods, and the unusual 
instability of the parasite enzyme made it difficult to study the parasite enzyme 
at the molecular level, which is the prime requirement for drug designing. 
Recent development; in genetic engineering and molecular biology have 
made it possible to study eukaryotic genes and manipulate them to 
overexpresS in well-characterised expression systems. This facilitates the 
obtaining of large amounts of the protein of interest for structural studies. 
Thus far, no full-length P. falciparum enzyme has been expressed in bacteria in 
a functionally active form. 
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This thesis is thus proposing the overexpression of P. fa/ciparUm HPRT in 
E. coil. Such overexpression may provide the following information: 
Whether E. coil can express P. falciparum HPRT in an active form. 
Direct and functional expression of the full-length PfHPRT in E. coil will 
provide enough parasite enzyme for detailed molecular studies. 
If such a functional recombinant parasite enzyme can complement a 
mutation in a bacterial homologous gene, the strain may provide an easy way 
to screen putative anti-PfHPRT drugs. 
Antibodies against the recombinant PfHPRT could be a probe for 
PfHPRT in vivo, to study the native enzyme processing and location in the 
parasite cytoplasm. 
1.15 Gene expression in f..!cll. 
As described in the project proposal, it has been mention-that to obtain a 
usable quantity of PfHPRT protein, the gene will be overexpressed in E. coil. 
This depends on the development of a suitable host-vector system capable of 
expressing P. falciparum protein in large amounts. Expression of biologically 
active eukarvotic protein in bacteria has already proven useful in biotechnology 
(Harris 1983). To place the subject in context, I will first discuss E. coil gene 
expression briely and then review eukaryotic gene expression in the bacterial 
system. 
One of the main reasons for using E. coil as the host for a eukaryotic 
gene is that the control of gene expression in this organism is Very wt 
understood. In E. coil structural genes fcm operons with a control region 
located at begining of the gene. These control elements are the operator and 
promoter (Miller & Reznikoff, 1980). Upon transcription the operon produces 
mRNA, which in turn translates into protein. The extent of the expression of 
any gene in a cell depends on the type of the promoter and operator of the 
operon. Usually these control elements are used to express cloned genes in 
bacteria (Harris, 1983). 
In E. coil, the transcription of a gene starts when RNA polymerase binds 
to the promoter of the operon. Study of several operons revealed that E. coil 
promoters have two consensus sequencej the -35 and -10 regions (Rosenberg 
and Court, 1979). It has been suggested that this region binds closely to the 
sigma factor of RNA polymerase and ensures the orientation of the enzyme so 
that transcription will only proceed in the correct direction. The transcription 
has been stopped by a GC rich palindromic sequence present in the 
downstream of the gene. Several other factors may also be involved in the 
regukJn of transcriptional termination (Greenblatt, 1981). 
The extent at which mRNA is translated into protein depends on the 
efficiency of the binding of the ribosome to the translation initiation region. 
This ribosome binding site (rbs) or trans initiation region (TIR) 
consist of an AUG codon and a small nucleotide sequence 3-9 bases long 
(Shine-Delgarno (SD) sequence) lying within 3-12 bases upstream of the 
initiation codon (Shine and Delgarno, 1975). There is no consensus sequence 
described for this region. Thus, it is possible that the sequence variation in 
this region may regulate the extent of translation of mRNA at least in part. 
Other possible regulation may be exerted through the secondary structure of 
the 5' region of the mRNA. Iserentant and Fiers (1980) showed that translation 
efficiency is increased if the SD sequence and AUG codon is freely accessible 
to the ribosome. Translation stops when one of the three stop codons is 
encountered by the ribosome. 
59 
1. 16 Expression of eukaryotic genes in E . 
 are several potential problems involved in the expression of 
eukaryotic genes in E. coil. The majority of eukaryotic genes contain 
intervening sequences in the coding region, which are spliced out from 
trancribed mRNA before translation. In contrast, no bacterial gene is known 
which contains an intron, and so it is likely that bacteria do not contain the 
proper machinery for such splicing. This suggests that eukaryotic genomic 
DNA may not be used as a source of the gene for expression. This problem is 
overcome by using cDNA. Thus far, there are several cases where eukaryotic 
cDNA has been used to express genes in E. coil (Baty et al., 1981; Guarente at 
al., 1980). 
Transcriptional signals in eukaryotic genes are different from those of 
prokaryotes (Corden et al., 1980). Moreover, the eukaryotic mRNA structure is 
also different tothe bacterial counteCpart. For instance, eukaryotic mRNA is 
usually polyadenylated at the 3' end and capped at 5' end and does not 
have the equivalent sequence of the bacterial SD region (Kozak, 1981). 
Thus transcription of a eukaryotic gene is usually controlled by inserting 
the DNA adjacent to a strong prokaryotic promoter in an expression vector. 
Several prokaryotic promoters are used for this purpose; the lac promoter, the 
trp promoter, bacteriophage A early promoters, PL  and  PR  (Caulcott and Rhodes, 
1986) and a-lactamase promoter. The expression is increased by using a high 
copy number plasmid, which increases the gene dosage in the cell (Gelfand et 
al., 1978). Efficient termination of transcription may also increase the 
expression of the gene. This is ensured by placing a termination site after the 
cloned gene (Nakamura and Inouye, 1982). Such transcriptional stops are rrnB 
terminator of E. co/i and phage fd terminator. 
To achieve the translation of the cloned eukaryotic gene, it is usually 
fused to a prokaryotic gene in the correct translational reading frame. This 
uses the rbs and initiation codon of the prokaryotic gene. For this purpose 
E. coil -galactosidase is widely used. Translation also start5from the initiation 
codon of the foreign gene if it is placed in front of prokaryotic rbs (Backman et 
al., 1976) 
A second potential problem in heterologous expression is that of codon 
usage. Analysis of coding sequences of highly expressed E. coil mRNA showed 
that there is marked preference for particular codons for some amino acids 
(Grosjean and Fiers, 1982). Ikemura (1981) showed such bias correlates with 
the abundance of particular tRNA species. In accordance with this, AlT rich 
Plasmodium genes show a preference for A/T containing codons whereever 
possible. Scaife, J (1988) showed by comparing the codon frequency of 
sequenced Plasmodium genes with that of the E. coil genes, that several 
codons preferred by P. falciparum, like TTA, ATA and AGA, are rarely used in 
E. coil (see also Hyde et al., 1989). Table 1.3 shows comparison of codon 
usage for some amino acids, which highlights the difference between the two 
organisms. It was suggested that such differential codon bias may reduce the 
efficiency with which a Plasmodium protein is made in E. coil, due to the 
reduced availability of the certain tRNA5. 
Moreover, several eukaryotic proteins undergo different types of post-
translational modifications, which may be important for the activity of the 
protein. Many of these modifications do not occur in E. coil. Finally, in E. coil, 
protein synthesis is in a state of rapid turnover. To keep the metabolic system 
going, new proteins are synthesised and old protein5 degrade . Such a system is 
highly selective, It has been showr that abnormal proteins are preferentially 
recognised and degrade more efficiently (Goldberg and S. John, 1976). The 
machinary for protein degradation in E. coil is not clearly understood. Bukhari 
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Codons Amino acid P.f. E.c. 
TTA Leu 67 3 
TCA Ser 33 2 
ATA lie 48 1 
ACA Thr 56 5 
AAT Asn 78 8 
AGT Ser 34 4 
AGA Arg 58 1 
GGA Gly 50 1 
Table 1.3 	Codon preference of P. fa/ciparwn The table shows codons for some 
amino acids which are rarely used in E. coil (Grosjean and Fiers, 1982). The numbers 
are percentage of the codon usage for the particular amino acid (From Scaife, 1988). 
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and Zipser (1973) showed that mutation in the Ion gene, which codes for an 
ATP-dependent protease, reduces the rate of degradation of nonsense 
polypeptides. Itakura et a/., (1977) and Goeddel et al., (1979) showed that short 
foreign peptides are unstable in E. coil. A higher expression was achieved by 
linking the eukaryotic gene with a large prokaryotic gene, i.e. -gaIactosidase 
Sa trfused protein was synthesised. 
Fusion of a eukaryotic gene with a bacterial protein also facilitates the 
purification of the recombinant protein. 	-galactosidase fusion proteins can be 
purified by affinity column chromatography either by using an 
anti-galactosidase antibody column or a substrate affinity column (Marston, 
1987). Efficient purification of the target protein may also be obtained by 
fusing with maltose binding protein (Mama et al., 1988). 
However, in general the eukaryotic polypeptide alone is required for 
further studies, and therefore a strategy is needed for correct cleavage of the 
fusion protein. The strategy used in this project to allow this was to construct 
the fusion protein with a cleavage site placed between the bacterial sequence 
and the foreign protein. A number of cleavage sequences have - been 
reported thus far, which can be broadly divided into two types, chemical and 
enzymatic. Although chemical cleavage was successfully used for small foreign 
proteins (Goeddel et al., 1979; Szoka et al., 19Z() it is quite unsuitable for large 
proteins. In contrast enzymatic cleavage is far more specific and widely used. 
For instance Endoproteinase IVs C (Allen et al. 1985) Enterokinase (Belagaje et a! 
1984) and Blood factor Xa (Nagai et al. 1985) have been successfully used. 
Another problem with producing eukaryotic proteins in E. coil is that the 
product frequently accumulates as insoluble aggregates (inclusion bodies) 
within the producing bacterium when overexpressed (Wittrup et al., 1988). 
These inclusion bodies are usually resistant to mild detergents and the proteins 
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can only be released by using strong denaturing agents, such as 6-8 M urea or 
6 M guanidine hydrochloride. Such harsh treatment often denatures the protein 
n'eversibly and recovery of active protein by refolding is often difficult or 
impossible for a large protein ( Schein, 1989). The mechanism of 
inclusion body formation is not clearly understood. However, it has been 
shown that expression at a lower temperature reduces the degree of inclusion 
body formation. For example, increased solubility was achieved for Diptheria 
toxin (Bishai et al., 1987) and basic fibroblast growth factor (Squires et al., 
1988) at 30 °C as compared to 37 °C. For details about the production of soluble 
eukaryotic protein. 5ee the review by Schein (1989). 
Direct expression of a eukaryotic gene in E. co/i has several advantages 
over expression as fusion protein. Native protein can be obtained in sufficient 
amount for biochemical studies and the expressed protein is often functionally 
active (Persico et al., 1989). Such protein can be used to study structure 
activity relations of the protein by in vitro mutagenesis and X-ray 
crytallography. 
1.17 Working Plan. 
To achieve the goal described in the 'project proposal' the following 
strategy is planned. 
Firstly, to avoid degradation and facilitate the subsequent purification of 
the bacterially synthesised PfHPRT, the protein will be expressed as an E. coil 
-gaIactosidase fusion protein. This can be done by fusing the hprt gene with 
the /acZ gene in a suitable expression vector. 
The fusion protein will then be purified from the induced bacterial lysate. 
To achieve this, classical protein purification methods, like gel chromatography 
and affinity chromatography will be employed. To check whether the expressed 
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protein retains the enzymatic activity, the fusion protein will be assayed for 
both -galactosidase and HPRT activity. An attempt will then be made to 
release the PfHPRT domain of the fusion protein. The purified protein will be 
used to make antibody against the PfHPRT protein which will be an important 
tool to probe the protein in vivo and in vitro. 
In the second stage, PfHPRT will be expressed directly in E. co/i. A 
non-fusion expression vector will be used for this purpose. The expressed 
protein will be assayed for activity. This information will be very important 
since the active protein can then be used to complement a bacterial hpt 
mutation. Moreover, the protein will be a source for obtaining large amounts 
of the parasite protein for structural studies by X-ray crystallography etc. 
Successful complementation will result in a bacterial strain which can be 
used to screen potential antimalarial drugs for activity against PfHPRT. This 
bacterium will also allow us to study the biochemical parameters of the 
parasite enzyme. 
Finally the antibodies will be checked for specificity and then will be used 
to probe the native protein in western blot analysis and used in vivo to study 
possible-stage specific expressionof the enzyme in the parasite and to study 
the location of the protein in vivo. This will be done by indirect 
immunofluorescent microscopy and immunogold microscopy. Such information 
will help in designing an effective drug against parasite HPRT. 
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Chapter 2 
Materials and methods. 
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2.1 Microbiological methods. 
2.1.1 Strains and plasmids. 
The bacterial strains and plasmid vectors used in this study are listed in 
Table 2.1. The S. typhimurium strain KP1684 was a gift from Kaz Jensen. 
Vector pMS1S was obtained as a member of the series of 3 expression vectors 
containing, pMS1S, pMS2S and pMS3S and was a generous gift from Michael 
Schrieber, Germany. Expression vector pJLA503 was bought from MODEM, 
U.S.A. Other bacterial strains and plasmid vectors are being used in our lab for 
several years. 
2.1.2 Media. 
L-broth: 	 Tryptone (Difco Bacto) 10 gms, Yeast extract (Difco 
Bacto) 5 gm, NaCl 10 gm dissolved in 800 ml of 
distilled water and pH adjusted to 7.2 with 1M 
NaOH and finally the volume was top up to 1 litre. 
Sterilized by 	autoclaving 	at 	121 °C and 15 psi 
pressure. 
L-agar: 	 Same as L-broth but supplemented with agar 
(Difco) 15 gIL. 
Minimal medium A 1 : 	This medium contains 1 x M9 salt, 2% glucose, 10 
MM MgSO4, 0.1 mM CaCl2, 1 Vg/ml vitamin Bi. For 
solid minimal medium, the above is supplemented 
with 1.5% agar (Bacto). 
M9 salt: 	 Na2HPO4 60 gm, KH 2PO4 30 gms, NaCI 5 gm and 
NH4CI 10 gm dissolved in 1 litre of distilled water. 
for E. co/i 
TABLE 2.1 
Bacterial strain Reference 
Escherichja coli NM 522 Cough & Murray, 	1983 
Escherichja coli FIB 101 Boyer et al., 	1969 
Escherichja coli NM 654 Noreen Murray Unpublished 
Salmonella typhimurium 
KP 1684 Houlberg & Jensen, 	1983 
Salmonella typhimurium 
LB 5000 Bullas & Ryo, 	1983 
Parasite strain 
Plasmodium falciparum 	Xl Thaithong and Beale, 	1981 
Plasmjd vectors 
pMS Schreiber M,. unpublished 
pJLA503 Schauder et al., 	1987 
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Made as 4 x stock solution and sterilized by 
Minimal medium B 2 
Antibiotic: 
autoclaving. 
Tris 12 gm, KCI 2 gm, NH 4CI 2 gm, MgCl2.6H20, 0.5 
g, NaSO4 50 mg, Na 2HPO4 50 mg dissolved in 800 
ml distilled water. The pH is adjusted to 7.6 with 
dilute HCI and the volume to 1 litre with distilled 
water. After autoclaving ZnCl2 (0.001 mM), glucose 
(1 %) and vitamin Bi, 1 jig/ml are added (Houlberg 
et al., 1983). 
Liquid or molten agar medium was supplemented 
with 50 pg/mI ampicillin when appropriate. 
2.2 DNA methods. 
2.2.1 Preparation of plasmid DNA. 
Small scale preparation. 
This method was routinely used for checking transformant strains and 
initially adapted from that of Birnboim & Doly (1979). Cells from 1.5 ml 
overnight culture were spun down for 1 min and resuspended in 80 p1 GTE 
solution (25 mM Tris-HCL pH 8.0, 10 mM EDTA, 50 mM glucose) by vortexing. 
Lysogen solution (stock 10 mg/ml in GTE), 20 p1, was added to the tube, mixed 
and left on ice for 30 mm. After addition of 200 p1 of alkaline SOS solution (0.2 
M NaOH, 1% SDS), the solution was kept on ice for further 5 mm. This was 
followed by addition of 150 p1 of 3M Na-acetate, pH 5.0 and one more hour on 
ice. The precipitate thus formed was removed by a 10 min centrifugation in an 
Eppendorf microfuge. To the clear supernatant, 1 ml cold absolute ethanol was 
2for S. typhi 
added, mixed and kept in -20 °C for 30 mm. DNA was pelleted by a 10 mm 
centrifugation and resuspended in 100 p1 of 0.3 M Na-acetate pH 5.0 and 
reprecipitated with 200 p1 of cold absolute ethanol by incubating at -20 °C for 
15 mm. After pelleting the DNA again, These were dried under vacuum and 
finally, resuspended in 50 p1 of 1 x TE buffer (0.1 M Tris-HCI pH 8.2, 0.01 M 
EDTA). 
Large scale plasmid preparation. 
An 500 ml L-broth, containing 50 pg/mI ampicillin, was inoculated with 1 
ml of overnight culture and incubated for 12 to 14 hours with shaking. The 
cells were then separated by spinning at 5000 rpm in Sorval RC513 centrifuge 
with GSA rotor for 20 min and resuspended in 6 ml SET solution (25% sucrose, 
50 mM Tris-HCI pH 8.1, 40 mM EDTA). To this 1 ml lysozyme (stock 10 mg/ml 
in SET) and 1 ml 0.5 M EDTA were added. The mixture was kept on ice for 5 
min with occasional swirling. Thirteen ml of Triton mix (2 ml 10% Triton 
X-100, 25 ml 0.5 M EDTA, 10 ml 1M Tris-HCI pH 8.1, water to 200 ml) was 
added. The solution was kept on ice for 10 min and mixed by swirling. The 
lysate was centrifuged for 30 min at 15000 rpm on Sorval RC513 centrifuge, with 
SS-34 rotor. Clear amber-coloured supernatant was decanted and CsCl (0.95 
g/ml) and ethidium bromide (0.5 ml of 5 mg/ml) were added. The mixture was 
centrifuged to equilibrium at 38k rpm for 72 hours at 18 °C. Plasmid band can 
be visualized by long wave UV light, and removed by side puncture (Maniatis et 
al., 1982). The ethidium bromide was removed by extracting with TE saturated 
butan-2-ol and then dialysed against TE buffer to remove CsCI. the DNA was 
then precipitated with ethanol (see below ). 
2.2.2 Ethanol precipitation of DNA. 
Ethanol precipitation of DNA was performed routinely. For this 1/10 
volume 3 M Na-acetate was added followed by 2.5 volume cold 100% ethanol. 
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The mixture was kept at -20 °C for 30 min and the DNA pelleted by centrifuging 
for 10 min in an Eppendorf microfuge. The supernatant s were discarded and 
the pellets washed with 70% ethanol in water and centrifuged again. Finally 
the pellets were dried under vacuum for 5 mm. The DNA was resuspended in 1 
x TE and stored in -20 °C. 
2.2.3 Transformation of plasmid. 
A 20 ml L-broth was inoculated with 200 p1 of overnight culture of the 
bacterium to be transformed with plasmid, and grown at 37 °C with shaking for 
1.5 h to early log phase and chilled on ice for 10 mm. The cells were then 
spun down at 4000xg at 4 °C and resuspended in 10 ml ice-cold 50 mM CaCl2 
and left on ice for 45 min before spinning down. The pelleted cells were then 
again resuspended in 2 ml on ice-cold 50 mM CaCl2 and called the competent 
cell. DNA to be transformed, is mixed with 200 p1 portions of the competent 
cell and left on ice for 45 mm. This was then heat shocked in a 42 °C water 
bath for 3 mm. To this mixture, 0.5 ml of prewarmed L-broth was added and 
incubated at 37°C unless otherwise stated. Finally the cells were plated on 
L-agar plates, supplemented with ampicillin and incubated overnight at 37 °C, 
unless any other temperature stated. 
2.2.4 Digestion of DNA with restriction enzymes. 
DNA was digested routinely to completion, according to the condition 
suggested by the suppliers (Boehringer-Mannheim, New England Biolabs. 
U.S.A.). Double digestions were carried out simultaneously in one of the 5 
buffers (A, B, L, M and H) as described by Boehringer-Mannheim. Digestion s 
were terminated by heating at 65 °C for 10 minutes and subsequent 
precipitation with ethanol where appropriate. 
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2.2.5 Klenow filling of 5' protruding ends of DNA. 
To fill 5' protruding ends of restriction enzyme digested DNA, Klenow 
fragment of E. coil DNA polymerase I (Boehringer-Manheim) was used as 
described by Maniatis et al., (1982). In brief, 2 units of the enzyme was mixed 
with 1 p1 DNA with 5' protruding ends ( 1 pg ) and 2.5 p1 lOx Klenow buffer. 
To this 1 p1 dNTP mix (2mM) and water to final volume 25 p1 were added and 
mixed. The mixtures were incubated for 30 minutes at room temperature. The 
reaction mixtures were then extracted once with phenol:chlorofOrm and ethanol 
precipitated. lOx Klenow buffer contained 0.5 M Tris-HCI pH 7.2, 0.1 M MgSO4, 
1 mM dithiothreitol (DTT) and 0.5 mg/ml BSA. 
2.2.6 Ligation of DNA. 
Both steaky and blunt ended ligations were performed using the same 
buffer condition, only in case of blunt ended ligation 2 to 3 times more ATP 
were added. In detail, the DNA5 to be ligated were mixed and suspended in 
ligation buffer (66 mM Tris-HCI pH 7.2, 1 mM EDTA, 10 MM MgCl 2, 10 MM 
dithiothreitol (DTT), 0.1 mM ATP). To this mixture 5 units of T4 DNA ligase 
were added and incubated overnight (16-18 h). Reaction was stopped by 
freezing the reaction mixture at -20 °C. 
2.2.7 Cloning of DNA. 
Cloning of DNA fragments in plasmid vectors were performed as 
described by Maniatis et a! (1982) . The plasmid vector and the insert DNA 
were digested with appropriate restriction enzyme and mixed in a ratio of 
vector:insert = 3:1 and ligated (see section 2.2.6). The ligated DNA were then 
transformed into the suitable bacterial host. The transformants were initially 
selected on L-agar plates containing 50 jig/ml ampicillin and confirmed by 
isolating plasmid by mini plasmid preparation. 
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2.2.8 Colony hybridisation. 
For colony hybridisation ampicillin resistant colonies were transferred 
onto a nitrocellulose membrane ( H'ibond N, Amersham) placed on a fresh 
L-agar ampicillin plate. The plates were incubated overnight either at 37 °C or 
30°C. The filters were then peeled off and placed colony side up, on whatman 
3MM paper presoaked with denaturing solution (0.5 M NaOH, 1.5 M NaCl) and 
left for 10 mm. Filters were then neutralized with 1 M Tris-HCI pH 7.4 for 10 
min with 2 changes and finally, washed once with 2 x SSC and put in a sealed 
bag for hybridisation. 
2.2.9 DNA gels: 
Large agarose gels. 
DNA was fractionated by electrophoresis through 0.7%, 1.0%, or 1.5% 
agarose gels as described bellow. Horizontal slab gels ( 28 x 14 x 0.5 cm), 
connected by wicks at each end of 500 ml buffer tanks were routinely used. 
The electrophoresis buffer contains 50 mM Tris-HCI, 20 mM trisodium acetate, 
1 mM EDTA, pH adjusted to 8.2, with glacial acetic acid and 0.5 Jig/ml ethidium 
bromide (TAE buffer). Agarose type II (Sigma) was melted in the same buffer, 
used at concentrations appropriate for resolution of particular fragments 
(Maniatis et al., 1982). 
DNA samples for electrophoresis were prepared by addition of 1/10th 
volume loading buffer (Ficoll 10% and bromophenol blue 0.025%). 
Electrophoresis was carried out at 6 volts/cm for 30 mm. and then overnight at 
3 volts/cm. Marker DNA was Hindill digested Xcl875 DNA. 
Mini agarose gels. 
For rapid checking, small amounts of DNA (0.05 to 0.5 pg) were 
fractionated using gels ( 10 x 5 x 0.5 cm) . Gels contained 0.8% agarose in 89 
mM Tris-HCI pH 8.2, 89 mM Boric acid, 2 mM EDTA (TBE buffer) and 0.5 pg/mI 
ethidium bromide. Gels were electrophoresed under the same buffer for 60 
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min at 150 volts and immediately photographed. 
2.2.10 Gel photography. 
Gels were photographed under short wave UV light using Ilford HP5 
professional 5" x 4" sheet film, and a red filter. Exposures were for 30 sec to 1 
mm. films were develop for 5 min in Ilford Microphen developer and fix for 5 
mm. All size measurements were performed directly from the negative. 
2.2.11 Southern blotting. 
The DNA was first fractionated on large agarose gel and transferred on 
Hybond N nitrocellulose (Hybond N is the trademark of Amersham) sheets as 
described by Southern (1975) as follows. The gel was immediately 
photographed and cut into size (if needed), denatured in 0.5 M NaOH, 1.5 M 
NaCl (2 x 500 ml; 15 min each) then neutralized in 1 M ammonium acetate and 
0.02 M NaOH (2 x 500 ml; 30 min each). The gel is then assembled in a 
'sandwitch' structure as follows. Nitrocellulose, cut into the size of the gel and 
soaked in neutralization buffer was placed on the gel with 6 sheets of 3 MM 
Whatman filter paper and 2 to 3 inches of paper towels with a heavy weight on 
top. Transfer was completed in 1 to 2 hours as monitored under UV after 
restaining with .5 pg/mI ethidium bromide. Filters were washed in 2 x SSC 
(0.3 M NaCl, 30 mM Na-citrate pH 7.0) for 2 min stored wet in a polyethylene 
bag at 4 °C until used. 
2.2.12 Extraction of DNA from agarose gels by electroelution. 
To isolate a DNA fragment from an agarose gel, the DNA was separated 
on a large gel. A trough of 3 mm wide was cut immediately in front of the 
relevant band. The rear of the trough was lined with a strip of dialysis tubing 
and the trough was filled and replenished as necessary, with TAE buffer. 
Electrophoresis was continued at 250 V for 30 min until the band had entered 
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the trough. The current was reversed for 30 seconds and the buffer trough 
containing the DNA fragment was removed. The trough was washed out once 
with the buffer to recover as much of the DNA fragment as possible. The 
preparation was extracted sequentially with an equal volume of butanol, phenol, 
phenol:chloroform (1:1 vlv), chloroform and ether (2x), preequilibrated with TE. 
The DNA was then ethanol precipitated. 
2.2.13 Labelling of DNA by nick translation. 
DNA used for probing a southern blot was labelled with ct[ 32P]-CTP (NEN) 
of specific activity 410 Ci/mM (0.8 mCi/mI). The labelling reaction was 
performed using the nick translation kit (BRL) according to the protocol 
supplied with the kit. Usually 500 ng of DNA were labelled and the activity 
incorporated was 1-10 x 10+6 cpm/pg DNA. The incorporated counts were 
separated from the unincorporated label by passing the reaction mixture over a 
sephadex G-50 (fine) 'spun column' (Maniatis et al., 1982). Probes were 
denatured by boiling for 10 min and diluted into 20 ml of hybridisation solution 
(below). 
2.2.14 Hybridisation. 
The filters were preincubated for two hours at 37 °C in hybridisation 
solution (HS): 4 x SSC (0.15 M NaCl, 0.015 M Na 2citrate, pH 7.0), 50% 
formamide, 0.1% SOS, 1 x Denhardt solution (0.02% BSA, 0.02% polyvinyl 
pyrolidone, 0.02% ficoll), containing 50 jig/ml sonicated salmon sperm DNA 
(Sigma). Blots were then hybridized overnight in HS containing the freshly 
boiled labelled probe at 37 °C with constant shaking. 
After hybridisation the filters were washed at 37 °C with shaking in 0.1% 
SOS and 0.1X SSC, 4 x 15 min washes. This was followed by 4 x 15 mm 
washes in aix SSC only. The wet filters were then put in a sealed 




Autoradiography was routinely performed using CRONEX 4 X-ray film 
(Dupont), cassettes and lightning plus intensifying screens. The films were 
exposed overnight or longer at -70 °C and develped with Photosol xray film 
developer (Photosol, England.). 
2.2.16 Polymerase Chain Reaction (PCR). 
PCR was performed by adapting the method as described by (Saiki et al., 
1988). In the reaction mixture: 2 p1 dNTP solution (10 mM dATP, 10 mM dCTP, 
10 mM dTTP, 10 mM dGTP), 10 p1 Taq pol buffer (10 mM Tris-HCI pH 8.3, 50 
mM KCI, 1.5 mM MgCl2, 0.01% gelatin), 10 p1 oligo-primer 1(1i.iM), 10 p1 oligo-
primer 2 (1pM), 10 j.il target DNA (50 ng and bOng) and 58 p1 sterile distilled 
water were added sequentially. To these 2 units of Taq DNA polymerase 
(Cetus corporation, U.S.A.) were added and mixed and pulse spin. The reaction 
mixtures were then overlay with 100 p1 of sterile mineral oil. The reaction was 
carried out in a Techne Dri Block PHC-1. using the protocol shown in figure 
2.1. At the end of the reaction 10 p1 of the reaction mixtures were checked for 
amplified DNA by a mini agarose gel. Reaction mixtures were left overnight at 
4°C before ethanol precipitation and resuspended in 1 x TE buffer. 
2.3 Protein methods. 
2.3.1 Estimation of protein. 





1st 	Seg. 2n,g 	Seq. 3rd Seq 
92°C 55 C 70 C 
1st 5 min 2 min 5 mm 
2nd 5 min 2 min 5 mm 
3rd 3 mm .2 min 5 mm 
4th to 25th 1.5 min 1.5 min 5 mm 
26th 1.5 min 1.5 min 10 mm 
Figure 2.1 	Temperature cycle programme for the PCR reaction. 
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preparation of reagent 
Coomassie Brilliant Blue G-250, 100mg was dissolve in 50 ml 95% 
ethanol. To this solution 100 ml 85% (w/v) phosphoric acid was added. The 
solution was diluted to a final volume of 1 liter. The solution was filtered 
before used. 
Protein assay. 
Protein solutions in 0.1 ml were mixed with 5 ml of the protein reagent 
and mixed by inversion. The absorbance of the solution is measured at 595 nm 
after 2 min against a reagent blank prepared from 0.1 ml of the appropriate 
buffer and 5 mIs of protein reagent. The amount of protein was estimated by 
comparing the absorbance with an standard curve, which was prepared 
simultanuously using bovine serum albumin (BSA) as the standard protein. 
2.3.2 SDS-PAGE. 
Proteins were routinely fractionated according to their size using the 
Sodium dodesyl sulphate polvacrylamide gel electrophoresis (SDS-PAGE) as 
described by Laemmli (1970). In this case 4.75% stacking gel pH 6.8 and 7.5%, 
8%, 10% or 12.5% separating gel pH 8.8 were used. Samples were prepared by 
mixing equal amount of Laemmli sample buffer (0.125 M Tris-HCI pH 6.8, 4% 
SDS, 10% 2-mercaptoethaf101, 20% glycerole and 0.04% bromophenol blue) with 
the protein solution, mixed and left in room temperature for 5 min and heating 
in boiling bath for 5 mm. Samples were centrifuged for 5 min before loading 
on gel. Ten to 50 uI of sample were used for electrophoresis. Electrophoresis 
were carried out with 20 mA constant current for 3 to 4 hours. 
The molecular marker used was, prestained high molecular weight 
standard (Sigma) and contained: y2-Macroglobulin (180 kD), -galactosidase 
(116 kO), Fructose-6-phosphate kinase (84 kD), Pyruvate kinase (58 kD), 
Fumerase (48 kD), Lactic dehydrogenase (36.5 kD) and Triosephosphate 
isomerase (26.6 kD). 
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2.3.3 Analysis of SOS-PAGE for protein profile. 
After electrophoresis gels were removed from the apparatus and 
transferred into a plastic tray containing staining solution (0.1% coomassie Blue 
R-250, 50% methanol, 10% acetic acid) and stained for 1 h. Gels were then 
destained overnight with several changes of destaining solution (10% methanol, 
10% acetic acid). The protein profiles were then analysed by comparing the 
protein bands for size and intensity. The relative molecular mass were 
estimated by comparing with that of the marker proteins. 
2.3.4 Western blot. 
Western blotting were carried out as described by Tawbin et al (1978) 
using the Bio-Rad Trans-blot apparatus. After SDS-PAGE gels were removed 
from the electrophoresis apparatus and washed with transfer buffer (20% 
methanol, 0.25 M Tris,0.192 M glycine, 0.1% SOS). Hybond N nitrocellulose 
membrane cut into same size of the gel, soaked with blotting buffer and placed 
on the gel. The gel with the membrane were then arranged in the gel cassette 
and place in the transfer chamber. Transfers were performed with 50 volts 
overnight with cooling. 
Filters were blocked with 5% skimmed milk in TS buffer (10 mM Tris-HCI 
pH 8.0, 150 mM NaCl) at room temperature for 1 h with shaking and probed 
with antisera in same buffer at specified dilution overnight. These were 
washed with TS buffer for 30 min with 4 changes. The blots were then 
incubated with alkaline phosphatase conjugated antirabbit or antihuman lgG 
with 5% milk in TS buffer for 4 h. The blots were again washed for 30 minutes 
with TS buffer with 4 changes developed with protoblot kit (Promega) as 
described by the manufacturer. 
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2.3.5 Assay of PRTase activity 
Assay mixtures, in a final volume of 50 .il, contained 225 mM Tris-HCI pH 
7.5, 5 mM MgSO4, 0.1% BSA, 2 mM PRPP and 100 liM of 3H-hypoxanthine 
(Amersham) or 14C-guanine or 14C-xanthine (NEN, Dupont). The reactions were 
started by adding enzyme extract. The control contained no extract. The 
reactions were allowed to continue for 10 minutes at 37 °C and stopped by 
heating at 100 °C for 5 mm. Precipitated proteins were pelleted by 
centrifugation for 10 minutes. Aliquots of 20 1.11 of reaction mixtures were 
applied to Whatman No. 3MM filter paper, previously spotted with a solution 
containing 0.1 i.Lmole of non-radioactive mixture of purine and it's 
corresponding ribonucleotide. Chromatograms were developed in an ascending 
direction at room temperature for 2 h in 5% Na 2HPO4 :isoamyl alcohol, 2:1 v/v. 
The extent of the conversion of the purines to corresponding nucleotides was 
determined by cutting out the UV light absorbing spots containing the 
corresponding ribonucleotide. The radioactivity of each spot was counted 
(Beckmann, LS7000, liquid scintillation system) in 2 ml Scintillation fluid (4 g 
PPO, 0.01 g POPOP, 50 ml Triton X-100 in a total volume of 150 ml of toluene). 
2.3.6 Assay of -galactosidase. 
For B-galactosidase assay o.1 ml of the extract (diluted if required) were 
added in 0.9 ml enzyme assay buffer (O.1M Na-phosphate buffer pH 7.0, 10 mM 
KCI, 1 mM MgSO4, 50 mM 2-mercaptoethanol) and incubated at 28 °C for 5 mm. 
The reaction was started by adding 0.2 ml of ONPG (o-nitrophenyl B- D-
galactopyranoside, 4 mg/ml) and incubated for 2 mm. the reactions were 
stopped by adding 0.5 ml 1 M Na2CO3. The extent of reaction were determined 
by measuring the optical density of the reaction mixture at 420 nm. 
2.3.7 Induction of recombinant cells for protein expression. 
Induction for $-gal:PfHPRT fusion protein. 
For the induction of the fusion gene under the control of the lac 
promoter, the recombinant bacteria were grown overnight in 5 ml L-broth with 
ampicillin (50 Vg/ml) at 37 °C with shaking. The cultures was diluted 1:20 with 
fresh medium and the growth continued for 3 to 4 hours before adding IPTG 
(Isopropyl-thiogalactoside, final conc. 2 mM). The growth were continued for 
further 2 to 3 hours when the cells were collected by spinning at 6000 rpm for 
10 min in Sorval RC513 centrifuge and GSA rotor. 
Induction nonfusion PfHPRT in E. coll. 
To study expression of the recombinant PfHPRT under the control of X 
PL/PR promoters and repressed by c1857 protein, a 5 ml culture of the 
bacterium was grown overnight (30 °C) in L-broth containing 50 pg/mI 
ampicillin in a shaking water bath. To induce expression the temperature was 
shifted to 42 °C for 1 hour. A 1.5 ml aliquot was centrifuged, for one minute 
and the pelleted cells were resuspended in 50 p1 of distilled water and 
processed for SDS-PAGE. 
2.3.8 Purification of the fusion protein. 
Cell lysis. 
For lysis induced cells from 500 ml were suspended in 10 ml lysis buffer 
(50 mM Tris-HCI pH 8.0, 1 mM EDTA, 100 mM NaCI) by vortexing and kept on 
ice. To this, 50 p1 fresh PMSF (phenylmethylsulphonylfluoride, 50 mM in 
methanol) and 0.5 ml lysozyme (stock 10 mg/ml) was added and mixed well. 
The suspension was incubated on ice for 20 min with occasional swirling. 
Thirty mg deoxycholic acid was added to the mixture, mixed with swirling and 
transferred into a 37 °C water bath and stirred with a glass rod. This time the 
suspensions became thick and viscous. A 200 p1 of deoxyribonuclease (DNAse, 
1 mg/ml) was added and incubated at 37 °C for 30 min until the suspension 
[:1] 
.was no longer viscous. 
Isolation of inclusion bodies. 
The dense inclusion bodies were released from the cells by lysis (above) 
and then isolated from the cell lysate by differential centrifugation method 
(Glover, 1987). For this, cell lysates were centrifuged sequentially at speeds of 
500, 1000, 1500, 3000 and 12000 xg for 15 mm. The pellets of each 
centrifugation step were washed once with lysis buffer. Finally the pellets and 
the final supernatant were diluted in SOS-sample buffer and analysed by 
SOS-PAGE. 
Washing inclusion bodies. 
To remove coprecipitating meterials, the inclusion bodies were washed 
with Triton X-100 and urea. Cell lysates were centrifuged at 1000 g for 20 mm 
to remove intact cells and debris. The supernatant was then centrifuged at 
15000 rpm for 20 minutes to collect the inclusion bodies. The pellets were 
first washed once and resuspended in 5 ml lysis buffer. To wash with Triton 
X-100, pellets of the 100 1.11 inclusion bodies were suspended in 0.5% Triton 
X-100 and left in room temperature for 5 minutes and centrifuged for 10 min in 
a Eppendorf microfuge. The supernatant was removed and the pellets were 
resuspended in fresh 0.5% Triton X-100 solution. A portion of 10 111 of the 
pellet was dissolved in SDS sample buffer for analysis. The washing step was 
repeated for 3 times. The pellets from 3 consecutive washings were analysed 
for protein profile by SDS-PAGE. 
For washing with urea, inclusion bodies from 50 j.il suspensions were 
resuspended in 0.5, 1.0, 2.0, 5.0 M urea solutions in 0.1 M Tris-HCI pH 8.5. The 
suspensions were mixed, left in room temperature for 5 min and finally 
centrifuged at 13000 g for 20 minutes. The supernatants and pellets were then 
analysed by SOS-PAGE to check the extent of purity. 
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Gel filtration. 
For gel filtration, appropriate amount Sephacryl-200 (Pharmacia, Sweden) 
was washed thoroughly with distilled water and equilibrated with urea buffer (8 
M urea, 25 mM Tris-acetate pH 5.0, 1 mM EOTA, 1 mM 2-mercaptoethanol). A 
70 x 1.6 cm column (Pharmacia column K16) was prepared with a flow rate of 
30 ml/ti using a peristaltic pump. The column was equilibrated with 200 ml 
buffer. The void volume was estimated by running 0.5 ml blue dextran (10 
mg/ml) through the column. The outlet of the column was connected with an 
automatic fraction collector (LKB 2070 ULTRORAC Ii, LKB, Germany) through a 
UV monitor (with 280 nm filter,). The UV monitor was connected with a 
recorder (LKB type 6520-4, LKB, Germany). The sample was prepared by 
dissolving the inclusion bodies in urea buffer, to a protein concentration of 
about 10 mg/ml. The sample was then centrifuged for 10 min in Eppendorf 
microfuge. Before loading on the column the sample was passed through a 
0.45 pm filter (Whatman). Two ml of the sample was then chromatographed on 
the column with the urea buffer, at an elution rate of 20 ml/h. Fractions of 5 
ml was collected until the major peak was completely eluted out and the 
reading on the UV monitor was zero. Aliquot of each sample from the peak 
was analysed with SOS-PAGE for protein profile. The fractions containing the 
fusion protein was pooled togather and dialysed against IS buffer (50 mM 
Tris-HCI pH 8.0, 100 mM NaCl). 
2.3.9 Purification of the fusion protein from soluble fraction. 
Preparation of affinity column. 
ECH-Sepharose 4B (Pharmacia Fine Chemicals) was thoroughly washed 
according to the supplier's recommendation. To 100 ml gel 1 mmol of APTG 
(p-amino- phenyl - 8-D-thiogalactOside (Sigma) in 10 ml distilled water was 
added. The pH was adjusted to 4.7 and 7.5 mmol of N-acetyl-N'(3-
dimethylaminopropy1carbidiimide (Sigma) in 8 ml water were added drop wise 
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to the mixture. The pH was maintained at 4.7 for 1 h and the reaction was 
allowed to proceed for 24 h at room temperature by gentle stirring. The gel 
was thoroughly washed with distilled water and stored at 4 °C. A column of 4 x 
0.5 cm is prepared with the APTG-coupled gel and equilibrated thoroughly with 
the equilibrium buffer (20 mM Tris-HCI pH 7.4, 10 MM MgCl 2, 1.6 M NaCl, 10 
mM 2-mercaptoethanol). 
Affinity chromatography 
Bacterial lysate prepared in the equilibrium buffer by sonication and 
centrifuged at 15000 rpm for 20 mm. The supernatant diluted to 10 to 15 mg 
of protein/ml with the same buffer. The solution was applied to the 
APTG-ECH-Sepharose affinity column. The extract was passed through the 
column which retained the fusion proteins. The column was washed with 200 
ml of the buffer used for equilibration, no more material absorbing at 280 nm 
appeared in the flow through. The protein was eluted from the column with 
100 mM sodium borate, 10 mM 2-mercaptoethanol, pH 10 and fractions of 1 ml 
was collected. The elution profile was monitored by measuring absorption of 
each fraction at 280 nm. 
2.3.10 Digestion of the fusion. protein with factor Xa. 
Digestion of the protein with activated factor Xa was performed as 
described earlier (Nagai et at., 1984). Two mg of the fusion protein in Factor Xa 
buffer (50 mM Tris-HCI pH 8.0, 100 mM NaCl, 1 MM  CaCl2) was mixed with 50 
jig of activated factor Xa (Sigma) and incubated for 2 h. The extent of 
digestion was estimated by electrophoresis of the sample on SDS-
polyacrylamide gel. 
2.3.11 Production of polyclonal antiserum. 
To produce polyclonal antiserum rabbits against purified -gal:PfHPRT 
fusion protein, 180 jig of the protein in 2 ml PBS was emulsified in 2 ml of 
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Freund's complete adjuvant (Bacto labs.). For primary injection, 0.5 ml of the 
emulsion was given intramuscularly into each of the four limbs of 2 female 
New Zealand white rabbits (12 weeks old). At the 33rd day a further 100 jig 
protein was injected through the same route after emulsified with equal volume 
of Freund's incomplete adjuvant. After 15 days 90 jig protein was injected into 
each rabbit intramuscularly as booster dose. On 8th day after boosting 10 ml 
blood was collected from the marginal ear vein of both the rabbits and the 
serum was tested for immune response by Ouchterlony immunodiffusion test 
using the fusion protein as antigen. The rabbits were bled by cardiac puncture 
and the blood was kept at 4 °C overnight until the clot retracted. The blood 
was spinned at 5000 rpm on a benchtop chillspin centrifuge for 15 mm. The 
clear serum was stored at -70 °C and designated anti--gal:PfHPRT serum. 
2.3.12 Ouchterlorty double immunodiffusion. 
Ouchterlony immunodiffusion test was used to test the presence of 
specific antibody in immunized rabbits and performed on microscope slides. 2% 
agarose in PBS was melted in a boiling water bath and poured on precleaned 
microscope slide placed on a levelled surface. After setting the gel punch 
were made using cork borer as shown in figure 4.10. The agarose plugs were 
removed using a needle. The wells were filled with antiserum or antigens until 
the meniscus just disappears. The slides were then placed in a humid chamber 
and incubated overnight at room temperature. Precipitin bands were appeared 
within 12 hours. The slides were then washed thoroughly with PBS over a 
period of 8 hours and finally with distilled water to remove unreacted proteins. 
The gels were dried on the slides in room temperature. The slides were then 
stained with coomassie blue R250 in 10% acetic acid and washed thoroughly  
with 50% methanol and 10% acetic acid and finally air dried and photographed. 
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2.3.13 Preabsorption of antiserum with E. co/i extract. 
Antibodies against E. co/i proteins and 	-galactosidase in the rabbit 
antiserum were removed by incubating 0.5 ml of the serum with 1 ml sonicate 
of induced E. coil strain NM522/pMS1S. Cells from 200 ml overnight culture 
were collected and resuspended in fresh 500 L-amp medium after one hour 
incubation at 37°C IPTG was added to a final concentration of 1 mM and the 
growth was continued 	for 	further 	6 	hours. The cells were collected and 
resuspended in 5 ml PBS and sonicated with full power for 2 minutes. The 
lysate was stored in -20 °C as aliqouts of 0.5 ml. For preabsorption 0.5 ml 
serum was mixed with 0.5 ml sonicated lysate and incubated for 15 minutes at 
37°C with shaking. The mixture was centrifuged for 10 min in microfuge 
centrifuge. The preabsorption step was repeated once more with fresh lysate. 
Finally, the preabsorbed serum can be stored at 4 °C with 0.05 % Na-azide for 
atleast 1 month. The antiserum was diluted with 5% skimmed milk in PBS to 
desired concentration. 
2.3.14 Preabsorption of antiserum with red cell membrane. 
For IFA the serum was also preabsorbed with RBC membrane. Packed 
red blood cells (2 ml) were resuspended in 15 ml distilled water and left on 
room temperature for 10 minutes. The RBC ghosts were then collected by 
spinning at 5000 g and resuspended in 2 ml PBS, and stored at -20 °C in 
aliquots of 200 p1. For absorption, 500 p1 of the antiserum preabsorbed with 
E. coIl lysate, mixed with 200 41 of the red cell membrane and left overnight at 
4°C. The membranes were spun down and the clear supernatant use for IFA 
with suitable dilution. 
2.3.15 Indirect immunofluoresCenCe assay (IFA). 
The experiment was actually an adaptation of that as described by Voller 
et al (1980). in detail, for blood stage parasite, smear was done with infected 
cells from in vitro cultures with parasitemia about 5% (slides were prepared by 
Anne McGowen and stores at -70 0C). This slides were fixed either with chilled 
methanol or acetone and quickly dried. The acetone fixed slides of sexual 
stage parasites were obtained from Dr. David read, protozoan genetics and 
acetone fixed slides of infected mosquito salivary glands were the source of 
the sporozoites and obtained from Professor David Walliker, protozoan genetics, 
University of Edinburgh. These slides were stored at -20 until required. The 
IFA was carried out at room temperature in a moist chamber. Before adding 
antibodies the slides were washed with PBS (0.15 M NaCl, M sodium phosphate 
buffer pH 7.4) for 1 min and air dried. Each slide was then separated into small 
squires using 'nail polish' paint. Each square was then treated with 20 jil of 
the antiserum of different dilutions for 30 mm. The antiserum was diluted with 
5% dried skimmed milk in PBS. The slides were washed with PBS for 3 times 
and incubated with Fluorescein isothiocyanate (FITC) conjugated antirabbit or 
antihuman lgG antibodies (Sigma) (final dilution 1 in 1000) for further 30 
minutes. Slides were counter stained with DAPI, washed air dried and mounted 
with Citifluor (Citifuor Ltd. UK) and examined at 1000 times magnification by 
fluorescence microscopy. Photographs were taken on Kodak gold 400 ASA film 




Expression of Plasmodium falciparum HPRT 
in Escherichia coIl 
as a B-galactosidase fusion protein 
A potential problem in the expression of a foreign protein in a bacterial 
system is proteolytic degradation of the expressed recombinant gene product 
(Itakura et a/., 1977). To avoid this at least in part and to facilitate the 
subsequent purification of the recombinant protein, the immediate objective of 
this project was to express the P. fa/ciparum HPRT enzyme in E. coil as a 
-galactosidase fusion protein. There is evidence to suggest that although 
certain foreign proteins are unstable in E. co/i, fusing them with a larger E. coil 
protein may impart stability (Goeddel et al., 1979). To date numerous 
eukaryotic gene products have been successfully expressed as -galactosidase 
fusion proteins (Harris, 1983). Furthermore, several techniques are available for 
the purification of -galactosidase fusion proteins from total cell extract 
(Marston, 1986). 
The Pfhprt gene like many other eukaryotic genes, contains a noncoding 
intervening sequence (intron) in the structural region (Sullivan et al., 1987; Khan 
and Scaife, personal communication). It was therefore decided to use the 
PfHPRT cDNA clone previously isolated and characterised (King and Melton, 
1987), for expression studies, since intronic sequences in the structural gene 
would prevent its expression in E. co/i (see introduction). 
A second problem in the expression of eukaryotic genes in E. coil is that 
the transcriptional signals in eukaryotes are different from those of prokaryotes 
and are not usually recognised by prokaryotic RNA polymerase (Corden et al., 
1980). Moreover, the structure of eukaryotic mRNA is different to bacterial 
mRNA. For example, eukaryotic mRNA is polyadenylated at the 3' end and 
normally capped at the 5' end. Such structures may be important for ribosome 
binding or mRNA stability in eukaryotes (Breathnach and Chambon, 1981). On 
the other hand, eukaryotic mRNA does not seem to have an equivalent of the 
SD sequence present in prokaryotic mRNA (Kozak, 1981). These features in 
UE 
eukaryotic mRNA mean that cDNA of eukaryotic origin may need to be 
manipulated to allow its expression in bacteria. 
3.1 Structure of the cDNA of PThprt. 
Figure 3.1 shows the nucleotide sequence of the cDNA clone isolated by 
King and Melton (1987). The sequence can be broadly divided into three 
distinct regions; a 5' noncoding sequence, an open reading frame ( encoding a 
protein of predicted molecular mass of 26.392 kD) and a 3' noncoding 
sequence. The 5' region is 125 bp long and contains 4 translational stop 
codons in the same phase as the translational reading frame, two of which 
immediately precede the initiation codon. The expression of this cONA clone, 
containing the 5' noncoding sequence, was therefore considered unlikely and 
may explain the failure of previous attempts to express the gene (King and 
Melton, 1987). Furthermore, this region is extremely A/T rich (88%), typical of 
the P. fa/ciparum genome. The 3' flanking region of the cDNA clone which is 
239 bp long, is also over 87% AlT rich, containing 2 long stretches of A's ( 27 
and 28 bases in length) and a long AT ladder ( 36 bases long). Such AT rich 
segments may form stable secondary structure which could interfere with the 
translation of the recombinant mRNA. Secondary structure may also be 
responsible for the random deletions and rearrangements of P. fa/ciparum 
insert DNA commonly seen in bacteria. Thus, for expression studies, it was 
considered necessary to remove from the cDNA clone, both the 5' sequence up 
to the initiation codon, and the 3' sequence, following the translational stop 
codon. 
As mentioned in the general introduction, the AlT codon bias, observed in 
all P. fa/ciparum genes thus far characterised, is also present in the PfHPPT 


























*** 	 • 
CTTTGTGGAATGGTTTTAAAGCTGATTTCGTTGGATTCTCAATTCCTGATCACTTTGTTG 
roLeuTrpAsnGlyPheLysAlaAspPheValGlyPheSerlleProAspHi sPheValV 
*** 	•*** 	• 	 • 	 • 	 * 
TTGGTTATAGTTTAGACTATAATGAAATTTTCAGAGATCTTGACCATTGTTGTTTGGTTA 
alGlyTyrSerLeuAspTyrAsnGlullePheArgAspLeuAspHisCysCysLeuValA 







Figure 3.1. 	Plasmodium fa/ciparum cDNA (King and Melton, 
1987) The E. co/i rare codons are shown in esteriscs at above and the 
stop codons in 5' end are underlined. 
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HPRT protein in bacteria, the cDNA clone contains certain A/T biased codons, 
e.g.. ATA (Isoleucine), GGA (Glycine) and TTA (Leucine) codons, are rarely, if 
ever, used in E. co/i (Scaife, 1988). 
The absence of any restriction enzyme sites in suitable positions,(Figure 
3.2) in the noncoding regions of the cDNA prevented the removal of the 
flanking regions, without sacrificing portions coding sequence. To overcome 
similar problems other workers have digested with Ba131 (Silhavy et al., 1984). 
However, this technique has drawback. The digestion of DNA can not be 
properly controlled and therefore generates products of different sizes. 
Selection of an optimal fragment from this mixture is time consuming. 
Moreover, the DNA products of such treatment are blunt ended and therefore 
difficult to clone in the correct frame and orientation. To avoid these 
problems, it was decided to use the Polymerase Chain Reaction (PCR) to 
remove the flanking sequences of the open reading frame of the PfHPRT cDNA 
and in addition, to help position this in the desired place and frame in 
expression vector. PCR is used to amplify a particular region from a large 
piece of DNA (Saiki et al., 1988). In the following sections the strategy, used 
for the expression of PfHPRT I as a -galactosidase fusion protein will be 
explained in detail. 
3.2 The expression vector and selection of host. 
The vector used for the expression of PfHPRT as a -gaIactosidase fusion 
protein in E. coil was pMS1S. The vector is one of a series of three, pMS1S, 
pMS2S and pMS3S, which differ only at the unique EcoRl site, positioned at the 
3' end of the -gaIactosidase gene, at which the reading frame is shifted. 
The main features of the vector are shown in Figure 3.3. The vector 
contains the complete -galactosidase gene up to amino acid 1023 which is 
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Figure 3.2 	Restriction map of PfhprtcDNA. A = Alul, B = BgIll, D = Dral, H = Hinfl, 
M = Mnll, S = Sau3Al. Bold line shows Pfhprt open reading frame. 
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BamHI pMSIS AGA GAA_TIC 
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Xhoi 
EcoE 
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AGT MT TM TAG ATA ATA GCC CGG GCT TCC iW. TCG AGI -3 
Polylinker sequence of pMS1S, pMS2S, pMS3S. 
Figure 3.3 	Structure of the pMS vector. 
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regulated under the control of the lac promoter. Immediately downstream of 
the 1023rd codon of the -galactosidase, is an Xhol restriction site, followed 
by 2 Kpnl sites which located a small polynucleotide sequence. On translation 
this sequence produces a tetrapeptide, Ile-Glu-Gly-Arg which is the recognition 
site for activated blood clotting factor X (factor Xa, Fuzikawa et al., 1972). 
Following the second Kpnl site is a short polylinker region, containing single 
Hindlll, Bglll, Pstl and EcoRl sites. Translational stops are present in each of the 
three reading frames downstream of the polylinker region. A fragment of DNA 
can therefore, inserted into one of the three vectors as same frame with the - 
galactosidase gene. When induced the foreign DNA will be translated as a 
fusion protein linked to the s-gal domain by the tetrapeptide. If this hybrid 
protein is treated with activated blood factor X, the foreign protein domain will 
be released (Nagai and Thogersen, 1984). The pMS vectors also contain the 
B-lactamase gene which confers ampicillin resistance. 
The first step of using this vector would be to select a suitable host for it. 
Expression of the /acZ gene is repressed by maintaining the pMS1S plasmid in 
a host that overproduces lac repressor, i.e. due to the l a
Cl q  allele. Two strains 
of E. coil carrying the 1q mutation, NM522, and TG1 were tested for suitability 
and efficiency. A strain without la
Cl q  allele, E. coil HB101 was included as a 
control. The three strains were transformed with the pMS1S plasmid and 
transformants were selected by ampicillin resistant phenotype and confirmed 
by isolating the vector from the selected transformants. The transformed 
strains were grown, induced and subsequently processed. Treated cell lysates, 
from a 300 1.Ll culture were electrophoresed on a 7.5% SDS-polyacrylamide gel 
for protein profiles (method). 
Figure 3.4 shows a typical coomassie stained gel. 	The result 
demonstrated that the -galactosidase is expressed in induced TG1/pMS1S 
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Figure 3.4 	Expression of -gaIactosidase in different pMS1S transformed 
E. co//strain. (1) uninduced TG1/pMS1S, (2) induced TG1/pMS1S, (3) uninduced 
NM522/pMS1S, (4) induced NM522/pMS1S, (5) uninduced HB101/pMS1S and (6) 
induced HB101/pMS1S. The arrow shows b-galactosidase protein. 
Mr(kD)1 	2 3 4 56 
iii- 
180- 







(lane 2) and NM522/pMS1S (lane 4). The protein is not present in the 
uninduced transformants (lanes 1 and 3), suggesting that the gene is well 
regulated in these strains. Visual comparison of the protein levels show that 
the induction of -galactosidase is at least 4 to 5 times higher in NM522 (lane 
4) than that in TG1 (lane 2). Strain NM522 was therefore selected as the host 
for pMS1S in expression studies. The strain did show some leakage in the 
regulation of s-gal when uninduced (lane 3), but this was ignored because the 
high level of expression of the protein, which was considered important for 
subsequent purification of the fusion protein. The protein is not induced in 
strain HB101/pMS1S (lane 6) to a high level, rather a low level expression was 
observed in both induced and uninduced transformants, suggesting the vector 
gene is not well regulated in this strain as expected from a non lac? mutant 
strain. 
3.3 The origin and efficient induction, of the B-galactosidase was 
confirmed. 
To confirm the origin of the -galactosidase in induced NM522/pMS1S 
and to demonstrate the regulation of the vector gene more clearly, the profiles 
of uninduced and induced NM522 cells only and uninduced and induced 
NM522/pMS1S were compared in a 7.5% SDS-polyacrylamide gel. The 
coomassie stained gel shown in Figure 3.5, indicates that neither uninduced nor 
induced NM522 cells (lane A and B respectively) contain any visible level of 8-
galactosidase. Similarly no protein is observed in uninduced NM522/pMS1S 
(lane D). -galactosidase protein is seen in the induced transformant 
NM522/pMS1S confirming that it is of vector origin. Comparison of the protein 
level in induced and uninduced (lanes C and D) NM522/pMS1S also confirms 
the efficient induction of the vector /acZ gene in this strain. 
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Figure 3.5 	Origin of Induced -gaIactosidase in E. co/i NM522/pMS1S. (A) 
uninduced E. co/i NM522, (B) induced NM522, (C) induced NM522/pMS1S and (D) 
uninduced NM522/pMS1S. 
Mr(kD) A B C 	D 
180 
116 	 -- 





3.4 Removal of 5' and 3' flanking regions of Pfhprt cDNA. 
As mentioned before, it was considered important to remove the flanking 
sequences of the open reading frame (ORF) from the PfHPRT cDNA before 
inserting the coding region into the expression vector. The Polymerase Chain 
Reaction (PCR) was used in this study to achieve this. It was decided to insert 
the ORF of the PfHPRT amplified by PCR into the Hindlil - EcoRl site of the 
vector polyliriker to force the orientation. The sequences of the 2 
oligonucleotide primers synthesized for the amplification of the Pfhprt ORF and 
their relative positions with respect to the cDNA sequence is shown in the 
Figure 3.6. Primer 1 (26 bases) was designed to incorporate the first 18 bases 
of the ORF starting from the ATG. Eight nucleotides, containing a sequence 
AAAGCTTA (HindlIl linker) was included at the 5' end of the primer to facilitate 
the subsequent cloning of the PCR product. The 'A' introduced between the 
ATG and the Hindlil linker placed the ORF of the PfHPRT in frame with the 
vector IacZ gene. 
Primer 2 (22 bases) was designed from the antisense strand, spanned 
from position 818 to 839 in the cDNA (see Fig 3.1). This included the stop 
codon TAA. Two bases at position 836 and 838 was changed to create an 
EcoRl site at the 3' end of the amplified product. The DNA used as the 
template in the PCR reaction was the recombinant plasmid containing PfHPRT 
cDNA inserted into the EcoRl site of pUC8 plasmid (King and Melton, 1987). 
The plasmid was first linearised with Hindlll and the PCR reaction was carried 
out according to the protocol described section. 
After 20 cycles, 10 lii of the reaction mixtures were analysed by 0.8% 
agarose gel. The gel shown in Figure 3.7 indicates that a DNA fragment of 
about 700 bp (lanes B and C ) was amplified from the 3.8 kb plasmid (lane A 
), which is of the expected size for the amplified ORF (720 bp). The 
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Oligo - 2 TATTTATGTAAATAACTTAAGT 
IIIIIIHIIMIH1I 	II 
P f HPRT c DNA-TAAATACATTTAT T GAAG T G ATC AAAAA 
818 
Figure 3.6 	Oligonucleotide primers for PCR reaction and its relative position in 
PfhprtcDNA (fig. 3.1). 
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Figure 3.7 	PCR amplification of Pfhprt open reading frame from 
pUC8-Pfhprt cDNA clone. (A) Hindlil cut plasmid, (B) 10 41 PCR reaction mix 
with 50 ng target DNA and (C) same as (B) except with 100 ng of target DNA. 
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concentration of the product was higher where twice the amount of target 
plasmid was used, indicating that the amplification was proceeded at an 
proportionate rate. To confirm that the amplified product of the PCR reaction 
contained the predicted fragment, the gel was southern blotted and probed 
with labelled PfHPRT cDNA insert of the pUC8 clone (above). The result in 
Figure 3.8, shows that the amplified fragment was recognised by the cDNA 
probe. The PCR reaction mix was subsequently extracted with 
phenol:chloroform and ethanol precipitated. 
3.5 Construction of the IacZ:Pfhprt fusion plasmid. 
Detail of the construction strategy of the recombinant plasmid are shown 
in Figure 3.9. The amplified DNA product of the PCR reaction is predicted to be 
blunt ended and contain a complete ORF from ATG to TAA with a Hindlll site 
preceding the ATG and an EcoRl site following the TAA. To insert into the 
HindlIl-EcoRl site of the expression vector pMS1S, the PCR product was 
digested with both Hindill and EcoRl and ethanol precipitated. The vector DNA 
was also digested with HindlIl and EcoRl and subsequently purified from 0.8% 
agarose gel. Gel purification of the linear vector removed the small 
polynucleotide linker (19 bases), thus preventing selfligation of the vector in the 
subsequent reaction. The vector was ligated with the digested PCR product in 
a vector:insert ratio of 1:5 
3.6 Transformation of the recombinant plasmid into E. 
NM522. 
The ligated mixture was transformed into the selected host E. coli NM522 
and the transformation mixture were spread on minimal-agar plates with 
ampicillin and incubated overnight at 37 C. Ampicillin resistant bacteria were 
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Figure 3.8 	Hybridization of the PCR product with labelled Pfhprt cDNA. 
(A) and (B) PCR products from two different reactions. 
AB 	Mr(Kb) 
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Figure 3.9 	Construction of the recombinant piasmid, pPfPRT1.(see Text) 
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screened for the presence of Pfhprt gene by colony hybridisation using labelled 
purified PfHPRT cDNA. The blot is shown in Figure 3.10. The frequency of 
positive clones identified was approximately one in 15 ampicillin resistant 
colonies. One of the positive clones were selected for further study, and called 
strain SH1. 
3.7 Confirmation of the structure of the recombinant plasmid. 
To confirm the structure, the recombinant plasmid was isolated from 
strain SH1 by mini plasmid preparation and digested with Hindlll and EcoRl or 
EcoRl only and analysed on a 0.8% agarose gel. Figure 3.11 shows the results. 
Upon digestion with Hindill and EcoRl a DNA fragment is released of the 
predicted size, about 700 bp (Lane A). Lane B shows the recombinant plasmid 
digested with EcoRl only. The recombinant plasmid was named pPfPRT1. 
3.8 Expression of the fusion protein in SH1. 
The strain SH1 was then studied for the expression of the recombinant 
protein. The bacterium was grown, induced and cells from 1.5 ml culture were 
processed for SDS-PAGE [method]. 
Protein profiles of the induced SH1, uninduced SH1 and pMS1S 
transformed NM522 were analysed on 7.5% SDS-polyacrylamide gel. Figure 
3.12 shows a typical coomassie stained gel. The result shows that as expected 
B-  galactosidase was induced from the pMS1S transformed NM522 cells (lane 
C). In contrast, a protein of approximately 140 kD was expressed in induced 
SH1 cells (lane B). This is a predicted size of the $-galactosidase:PfHPRT 
fusion protein (26.4 kD plus 116 kD). This protein was neither present in 
uninduced SH1 (lane A) nor in the induced pMS1S transformed NM522 (lane C). 
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Figure 3.11 	Release of insert from pPfPRT1. (A) EcoRl and Hindlil 
digested and (B) only EcoRl digested pPfPRT1. 
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Figure 3.12 	Expression of 	-gaIactosidase:PfHPRT fusion protein. (A) 
Uninduced SH1 (E. co/i NM522/pPfPRT1), (B) induced SH1 and (C) induced 
NM522/pMS is. 
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3.9 Enzymatic activity of the fusion protein. 
One of the ways of proving the authenticity of the expressed fusion 
protein, is to show that it possesses both -galactosidase and HPRT activity. 
This depends on the correct folding of the protein in E. coil and the effect of 
the -gaiactosidase domain on the folding process of the HPRT domain and 
vice versa. There is evidence that -galactosidase fusion proteins retain the 
activity of the foreign protein. To study this possibility cell free extracts of 
uninduced SH1, induced SH1 and induced NM522 were assayed for the HPRT 
activity. Activity of induced SH1 extracts was found to be more than 15 times 
greater than that present in extracts of uninduced SH1 (Figure 3.13 bar 3/4). 
Induced SH1 extract showed 20 times more HPRT activity than the extracts of 
induced NM522 (bar 2/3). 
Similar result was obtained when the extracts were assayed for B-
galactosidase activity. Results shows that the induced NM522 did not have any 
activity for this enzyme ( bar 1 ) whereas, induced SH1 showed at least 50 
times more activity than the uninduced SH1 (data not shown). This results 
indicate that the fusion protein is active for both B-galactosidase and HPRT 
activity. 
3.10 Discussion and conclusion. 
This chapter has described successful expression of P. fa/ciparum HPRT in 
E. co/i as B-galactosidase fusion protein. 
The selection of an E. co/i host for the expression vector pMS1S, led us to 
choose Strain NM522. This strain expressed the vector encoded B-
galactosidase more efficiently than strain TG1, which also contains lad 1 allele. 









Figure 3.13 	HPRT activities in recombinant and parent E. co/i 
Activities in 
bacterial extracts were measured by following incorporation of 3H-hypoxanthine into 
IMP (methods). Data are expressed as percentages of the induced recombinant, SH1, 
(bar 3). (bar 1) induced NM522 and (bar 2) uninduced SH1. 
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higher copy number of the plasmid in NM522 than in TG1. Effect of high copy 
number the accumulation of a recombinant protein is described by O'Farrel et al 
(1978). These authors demonstrated increased expression of the plasmid 
encoded 8-galactosidase by increasing the copy number of the plasmid in the 
cell. 
A second possible reason of the high protein level in NM522 is less 
degradation of the expressed protein compared to that in TG1. Proteolytic 
degradation of expressed protein in E. coil is a normal metabolic process. 
However, the rate of degradation is different for different proteins. Such 
degradation is also depends on the genotype of the strain. For example, 
mutation in the Ion gene (codes for a protease) reduce the degradation of 
nonsense polypeptides (Bukhari and Zipser, 1975). 
The expression of the plasmid gene in NM522 was found to be well 
regulated as shown in figure 3.5, lane D. The result showed that no visible level 
of -galactosidase was present in the uninduced cell. This property is 
essential for a good expression vector, because, overexpression of a 
recombinant protein is a metabolic burden to the cells and results in slow 
growth rate (Carrier et al., 1983). In such cases, cells which lose their plasmid 
soon outgrow plasmid-containing cells during cultivation. Tight control of 
expression allows the cells to be grown first to high biomass before induction 
of recombinant gene expression. 
The analysis of the PfHPRT cDNA revealed that the structure is typical of a 
eukaryotic cDNA and more precisely that of the plasmodium DNA. For example, 
the stop codons preceding the translation initiation codon, the poly A stretches 
and extremely AlT biased codons in the coding region. These led me to 
modify the cDNA for cloning in the expression vector pMS1S; in particular I 
wished to remove the flanking sequences of the open reading frame. . The 
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polymerase chain reaction (PCR) was considered to be the best for this 
purpose. PCR is a powerful tool for amplifying a specific region, from a large 
fragment of DNA. By using thermostable Thermophi/us aquaticus DNA 
polymerase (Taq DNA polymerase) and two oligonucleotide primers which can 
bind to the DNA in two positions of the opposite strands separated by the 
desired sequence, it is possible to amplify the intervening sequences. This 
strategy was exploited in this study to remove the flanking sequences from the 
PfHPRT cDNA. 
To force the orientation of the insertion into the vector two different 
enzyme sites (HindlIl and EcoRl) were created at the ends of the PfHPRT cDNA 
ORF. The Hindill site in the vector was chosen for two reasons. Firstly, to 
force the orientation of the insertion and secondly, to minimize the presence of 
extra amino acids in N-terminal of the released PfHPRT domain from the fusion 
protein, after factor Xa digestion. 
In the PCR reactions a high concentration of the target DNA were used, 
compared to the suggested low amount. The rationale was, although the 
technique is highly sensitive and can use picogram level of target DNA, but this 
needs large number of cycle to amplify the: desired sequence in a usable 
amount and because it is known that Taq polymerase can incorporate wrong 
bases during synthesis and these mistakes could amplify during the subsequent 
amplification steps. It is therefore suggested that use of higher amount DNA 
may reduce the chance of amplification of such mistakes, because usable 
amount of target sequence can be produced using minimum number of cycles 
(3.23). 
The desired sequence was successfully amplified, indicated by the size of 
the fragment and confirmed by the fact that the PCR product was hybridized 
with the purified and labelled PfHPRT cDNA (Figure 3.8). In the blot there are 
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two extra DNA bands recognised by the probe. These may be the denatured 
PCR product as this was not seen when fresh PCR product was separated and 
probed. This is a phenomenon previously noted with an other small piece of P. 
fa/ciparum DNA (Md. Shahabuddin, unpublished), and probably due to the A/T 
rich sequences which confer weak hybridization of two strands of DNA 
compared to G/C rich sequences. 
The identification of the recombinant plasmid as selected by the labelled 
PfHPRT cDNA and the subsequent release of the insert from the plasmid with 
HindlIl and EcoRl double digestion, suggested that the construction procedure 
had gone according to plan. For instance, the PCR reaction produced DNA 
fragments containing PfHPRT ORF with Hindlll and EcoRl site at the ends, the 
PCR products were then successfully digested and produced sticky ends which 
were ligated with the double digested vector and produced the recombinant 
/acZPfhprt fusion plasmid, pPfPRT1. the E. co/i cells harbouring this plasmid is 
called strain SH1. 
Induction of the SH1, with IPTG showed that a protein of 140 kD, similar 
to the size predicted for the fusion protein (142.3 kD) was expressed only in the 
induced bacterium. The absence of this protein in induced pMS1S transformed 
NM522 suggested that the protein is of the recombinant plasmid origin. So, it 
was concluded that P. fa/ciparum HPRT is expressed in The E. coil strain SH1 as 
a -galactosidase fusion protein. 
The expression study also showed an extra protein of about 115 kD is 
expressed in the induced protein. Although it is difficult to suggest any 
explanation for this protein at this instance, but later studies using western blot 
with anti B-galactosidase and and antiPfHPRT antibodies showed that the 
protein is a degradation product of the fusion protein. This point will be 
discussed in detail in the next chapter. 
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To confirm the authenticity of the expressed fusion protein, the cell free 
extract of the induced SH1 was assayed for both HPRT and -galactosidase 
activity. The result conclusively suggested that the strain SH1 upon induction 
expressed the fusion protein which is active for both the enzymatic activity. 
One may argue that the hpt host, NM522 contributed in the higher HPRT 
activity. However, this possibility was excluded since induced SH1 extract 
showed 20 times more activity than the extracts of induced pMS1S transformed 
NM522. The induced recombinant protein also showed high activity of the 
-galactosidase whereas the induced host did not show any activity for this 
enzyme. It may be worth mentioning that the lac operon in NM522 is deleted 
and a AM15 mutant of the IacZ gene is present in the F episome present in the 
cell. The protein from this episome encoded enzyme has no enzymatic activity. 
The expression of the P. fa/ciparum HPRT in E. coil suggested that the AlT 
biased codons, which are comparatively rare in E. co/i did not stop the 
bacterium to express the gene as was suggested earlier (king and Melton, 
1987). However, It is possible that such codons reduced the rate of expression 
of the gene in the bacterium. Changing the so called rare codons to abundant 
codons and comparing the extent of expression, the effect of these codons in 
the expression of the gene could be revealed. 
E. coil is the most studied organism, widely used in the field of 
biotechnology. Several important proteins of medical importance have been 
overexpressed in this organism (Harris, 1983). These also include portions of 
Plasmodium antigens (Gentz et al., 1988) and enzymes (Simmb45,1985). 
However, thus far no Plasmodium protein has been successfully expressed in 
full length in E. co/i. In most of the cases, expression of only part of the 
protein is reported. This chapter thus demonstrating for the first time the 
expression of a full length plasmodial protein as a fusion protein, furthermore, 
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the activity of the recombinant PfHPRT suggest that the expressed protein also 
fold into the native form in and retain its biological activity. Such successful 
expression thus suggest that E. coil could be a successful system for the 










Once the recombinant PfHPRT is made, the next step is to study the 
property of the protein in detail and to purify this for making antibodies against 
PfHPRT. Purification of a recombinant protein may depend on its location in 
the host bacterium. An increasing number of reports of eukaryotic protein 
synthesis in E. coil suggest that, in general, recombinant proteins accumulate 
to higher levels than total cell protein in the cytoplasm, when expressed 
intracellutarly. However, many of these proteins aggregate and form insoluble 
inclusion bodies in the cytoplasm (Wittrup et al., 1988). Purification of the 
recombinant protein from them does not just involve the application of 
chromatographic techniques; the primary objective is to recover active and 
soluble protein. This sometime may need strong denaturing agents, like urea 
or guanidine hydrochloride. 
Such harsh treatments often unfold the polypeptide to inactive form. So, 
the next step is the adjustment of conditions to refold the protein back to 
active form. Finally chemical or enzymatic cleavage of the fusion protein is 
performed to recover the recombinant foreign protein domain. Once the 
polvpeptides are solubilised, conventional chromatographic techniques can be 
applied to purify the protein. 
Some recombinant proteins however, remain predominantly in soluble 
form, examples include -galactosidase fusions with HBV preS2 region 
(Offensperger, et al., 1985) and Cholera toxin CTP3 (Jacobs, et al., 1985). 
Occasionally, this depends on the host and the temperature at which the 
recombinant bacterium is grown (Schein, 1989). In some cases only a fraction 
of the expressed protein is soluble, the remainder being located in inclusion 
bodies. Usually, the purification of such soluble fusion proteins is quite 
straightforward employing an affinity chromatography step; either 
immunopurification or substrate affinity chromatography (Ullmann, 1984). 
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Moreover, degradation of the a recombinant protein can occur in vivo, 
leading to the major product that is not full length. Similar result can also be 
observed if the translation of the recombinant mRNA starts at an internal 
initiation codon (Hope I 1984). To reduce the chances of misleading 
results, western blot analysis of the s-gal fusion protein lysate is employed 
with anti--galactosidase antibody to detect any minor products present. In 
this chapter, the fusion protein will be studied for its degradation pattern and 
location in the host bacterium, then varius methods will be employed to purify 
this from the cell extract. After that, attempt will be taken to release the 
PfHPRT domain from the fusion protein. Finally, purified protein will be used to 
make antibodies against PfHPRT. 
4.1 Anti--gal antibody recognised the fusion protein. 
To study the degradation pattern of the fusion protein in the cell, anti 
-galactosidase antibody was used to probe the separated protein profile in an 
western blot analyse. 
Lysates of whole induced cells from 300 hI culture were separated on a 
10% SDS-polyacrylamide gel [method]. The separated proteins were then 
western blotted and probed with a polyclonal anti-galactosidase antibody. 
The result (Figure 4.1) suggests that the fusion protein is recognised by the 
fusion protein as expected. In addition to this, the result also shows several 
other proteins of size ranging from 20 - 115 kD are recognised by the 




Figure 	4.1 	Recognition 	of 	-gal:PfHPRT 	fusion 	protein 	by 
anti-galactosidase antibody. Proteins from induced SH1 were separated on a 
10% SDS-polyacrylamide gel, western blotted (method) and probed with 
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4.2 The fusion protein forms insoluble inclusion bodies in the 
cell. 
As mentioned at the begining of this chapter that s-gal fusion proteins 
often aggregate and form insoluble inclusion bodies inside cells. Such 
aggregated forms are sometime useful for the purpose of purification of the 
fusion protein. The inclusion bodies are dense and sediment readily with low 
speed centrifugation (Schoner et a/., 1985). Speeds as low as 500xg can pellet 
such aggregates but for some up to 12000xg is used (Marston 1987). 
Fusion proteins may be purified from isolated inclusion bodies and used 
without any further treatment (Cabradilla et al., 1986). Kleid et al (1981) used 
intact fusion proteins in the development of vaccines for FMDV(VP1). 
To check whether the -gal:PfHPRT fusion protein forms such inclusion 
bodies, following experiment was designed. Lysates of induced SH1 cells from 
a 500 ml culture were prepared and subjected to differential centrifugation 
[method]. Briefly, the lysate was centrifuged at 1000 rpm for 20 minutes in a 
bench top Chillspin centrifuge, to remove the unlysed cells and the cell wall 
debris. The supernatant was then centrifuged sequentially at 1500, 2000, 3000 
and finally 12000 rpm for 15 minutes each. Pellets from each centrifugation 
steps were washed with the lysis buffer once and stored at -20 °C. Aliquots 
from the pellet samples and final supernatant were analysed on a 8% 
SOS-PAGE for their protein profile and compared with that of the whole cell 
lysate. The result, shown in Figure 4.2, demonstrated that at each 
centrifugation speed the fusion protein is pelleted and the amount of the 
pelleted fusion protein was found to be similar in each pellet. 
The major outcome of this experiment is that the pellets of 2000 rpm, 
3000 rpm and 12000 rpm seems to contain more than 80 to 90% pure fusion 
protein. This suggests that the inclusion bodies can be isolated with a 
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Figure 4.2 	differential centrifugation of sonicated induced SH1 lysate. 
Proteins from the pellets of different centrifugal forces, whole cell lysate and 
the final supernatant were separated with by SDS-PAGE (method) and stained 
with coomassie blue. 
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considerable extent of purity simply by centrifugation. Nevertheless, much of 
the fusion protein was present in the soluble portion of the cells and could be 
recovered in the supernatant fraction of the lysate. 
4.3 Purification of the recombinant fusion protein. 
Several methods has been described in the literature to purify fusion 
proteins (Marston, 1986). The isolation of the inclusion bodies is quite simple. 
However, these are often resistant to mild detergents like, Triton X-100, and 
recovery of native fusion protein from them need stringent chemical treatment. 
On the other hand, purification from the soluble fraction of the cell lysate is 
lengthy and time consuming. The overall strategy used to purify -gal:PfHPRT 
fusion proteins is described in the following sections and shown in Figure 4.3. 
4.3.1 Purification of the fusion protein from the inclusion bodies. 
To purify the protein from the inclusion bodies cell lysate from the cells 
from 500 ml culture of induced SH1 were prepared as described in method 
section. The lysate was then centrifuges at 1500 rpm for 15 minutes in an 
SS34 rotor at 4 °C. The pellets were discarded and the cloudy supernatant were 
subjected to high speed centrifugation at 10000 rpm for 15 minutes to collect 
the inclusion bodies. The pellet thus obtained was washed twice with and 
resuspended in 1 ml lysis buffer. Such inclusion bodies are presumably free 
from soluble protein and looked like a creamy-white amorphous powder. On 
SDS-PAGE the preparation appeared to contain mainly the fusion protein (data 
not shown). 
Contaminating materials do co-precipitate with the inclusion bodies. They 
may be other proteins of cell or other cellular materials, which could affect the 
efficiency of the solubilisation, cleavage and refolding. Washing of inclusion 
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Figure 4,3 	Overall scheme used for the purification of 	-gal:PfHPRT fusion 
protein from induced SH1 cell. 
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(Marston, 1984). 
The inclusion bodies thus obtained were washed three times with 0.5% 
Triton X-100 [Methods]. Fractions of the pellets were then analysed on 8% 
SDS-polyacrvlamide gel. Figure 4.4 shows the coomassie stained gel. The 
result showed that washing with Triton X-100 did not improve the purity of the 
inclusion bodies significantly as there was no change in the protein profile. 
The major degradation product (115 kO protein) of the fusion protein was 
associated with the fusion protein with the same proportion. 
In the second step of the purification, attempt was taken to solubilise the 
inclusion body. The idea was to separate the fusion protein by gel 
chromatography. Solubilisation of the insoluble inclusion bodies was necessary 
to release the protein from the aggregates, because treatment with mild 
detergent like, Triton X-100 did not release the protein. As mentioned before, 
inclusion bodies often need high concentration of detergents to be solubilised. 
The most widely used detergents are urea and guanidine hydrochloride in a 
wide range of concentrations. 
Accordingly, inclusion bodies were spundown and resuspended in 3 ml of 
0.5M, 1M, 2M or 5M urea solutions in lysis buffer sequentially by vortexing. In 
each step, resuspended inclusion bodies were stand on room temperature for 5 
minutes before centrifugation for 10 minutes [method]. A portion of the pellets 
obtained in each step of the urea treatment were analysed by 8% 
SDS-polyacrylamide gel. The result, shown in Figure 4.5, indicated that the 
inclusion bodies are quite insoluble in 0.5M and 1M urea and very sparingly 
soluble in 2M and 5M urea concentrations. So, this concentrations were 
thought to be unsuitable for obtaining soluble protein. A higher concentration 
of urea was used to solubilise the inclusion bodies. 
This time the pelleted inclusion bodies were resuspended in 5 mIs of 8M 
133 
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Figure 4.4 	Protein profile of the Triton X-100 washed inclusion bodies 
from induced SH1 cells. Lanes (A), (B) and (C) are the inclusion bodies after 
first, second and third wash respectively. The arrow shows the fusion protein. 
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Figure 4.5 	Urea solubilisation of the inclusion bodies. Figure shows the 
protein profiles of supernatant and pellets after treatment of the inclusion 
bodies with different concentrations of urea. (1) and (2) Supernatant and 
pellets of 0.5 M, (3) and (4) those of 1 M, (5) and (6) those of 2 M and (7) and 











urea, mixed and stand on room temperature. Within 2 to 3 minutes the 
inclusion bodies were dissolved and produced an amber coloured solution. 
This was then centrifuges at 19000 rpm for 60 minutes at 4 °C to remove the 
insoluble meterials and the supernatant was then immediately subjected to the 
gel filtration as described in the method section. 
For gel filtration, a sephacryl S-200 (Pharmacia) column of dimension 1.6 
cm X 70 cm was prepared. The bed volume and the void volume of the column 
were 140 ml and 56 ml respectively. Before loading the column was 
equilibrated with 10 bed volumes of 8M urea in the equilibrium buffer. Seventy 
mg protein in 5 ml solution of 8M urea was loaded on the gel and eluted with 
a flow rate of 30 ml/hr. Fractions of 5 ml volume were collected from 
immediately after loading the column. The elution profile of the protein is 
shown in the Figure 4.6a. A major peak of the protein was eluted at the 
volume of 72 ml. Aliquots of 50 p1 from each fractions of the major peak were 
then analysed by SDS-PAGE. Figure 4.6b shows the protein profile of the 
eluted major peak. The result suggested that the fusion protein was not 
separated from the major degradation product of the protein by this 
chromatographic condition. However, other contaminating proteins were 
removed by this method. 
4.3.2 Refolding and factor Xa digestion of the eluted protein. 
Two different methods are commonly used to refold a denatured protein. 
In one method the denatured protein solution is diluted with buffer of high pH 
and incubated. This allows the partial folding of the protein and then the pH is 
adjusted to near neutrality to complete the folding (Marston et al., 1984)). In 
the other method the protein solution is slowly dialysed against the buffer with 
decreasing concentration of the urea. This allows slow refolding of the protein. 
Thus from the pooled fractions of the major peak (20 ml) of the gel 
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Figure 4.6 	Sephacryl S-200 gel filtration of the solubilized inclusion 
bodies (method). (a) shows the major peak of the elution profile and (b) shows 
the protein profiles of the fractions of the major peak. The lane numbers 
correspond with the eluted fraction number of the gel chromatography. 
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chromatography, urea was removed slowly by dialysis and concentrated to 5 ml 
[method]. The extent of refolding was then measured by assaying the protein 
for B-gal and HPRT activity. The protein did not show any activity for either 
enzyme (data not shown). This may indicate that the urea denaturation was 
irreversible or the refolding to the native state was not possible in the 
condition used. 
Although the refolding was not complete, the junction of the fusion 
protein may still be digestible with factor Xa. A 200 p1 aliquot of the 
concentrated protein was digested [method] and the digested protein was then 
analysed by 8% SDS-PAGE. The result is shown in Figure 4.7. No cleavage of 
the fusion protein was observed. 
4.3.3 Purification of the fusion protein from soluble fraction. 
As it has been shown that the purified fusion protein is still contaminated 
with the major degradation product, the denaturation by urea were irreversible 
and the PfHPRT domain of the fusion could not be released by digestion with 
factor Xa, it was decided to purify the protein from the soluble fraction of the 
cell extract. It has been shown in section 4.2 that, a large amount of fusion 
protein were still present in the soluble form (Figure 4.2), and that the soluble 
fusion protein possesses some degree of activity for both HPRT and 
-galactosidase activity (section 3.9). The main reasoning behind the 
purification of the fusion protein from soluble fraction was that, may be the 
two domains of the fusion protein fold separately and the junction point (target 
peptide for factor Xa) is accessible to the enzyme, in the native fusion protein. 
There are several methods for the purification of -galactosidase fusion 
proteins. In this study because the fusion protein was active for B-
galactosidase activity, the substrate analogue affinity chromatography was 
chosen to purify it. An p-aminophenyl thiogalatopyranoside-sepharose (APTG- 
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Figure 4.7 	Factor Xa digestion of the refolded fusion protein eluted from 
the gel chromatography column. (A) Protein profile of the digestion mix 
without activated factor X and (B) that with activated factor X. 
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ECH-sepharose) column of bed volume 4 ml were prepared [method] and 
equilibrated by the method described in the method section. The column was 
equilibrated with 200 ml equilibrium buffer before loading with protein. Protein 
sample was prepared sonication and centrifugation of cell lysate from 500 ml 
induced culture [method]. The clear supernatant was then subjected to affinity 
chromatography [method]. The elution profile of the protein is shown in Figure 
4.8. 
Each fraction in the protein peak were then assayed for s-gal activity and 
alternate fractions for HPRT activity. The activity profile of both the enzymes 
are also shown in the Figure 4.8. The profiles show that the fusion protein was 
efficiently bound and eluted from the column. Some activity of both the 
enzymes were eluted during laoding the sample on the column. 
Comparison of the elution and enzyme activity profiles confirms that the 
fusion protein is active for HPRT activity. This is because the HPRT of the 
bacterium can not bound to the column proved that the activity must has come 
from the fusion protein. 
4.3.4 Purity of the fusion protein. 
To check the purity of the fusion protein, eluted from the APTG column, 
20 1.11 from each fractions (nos. 3 to 8) of the eluted peak were checked by 
SDS-PAGE on a 8% gel (Figure 4.9). The eluted fractions (lane 1-6) contain the 
fusion protein free from most of the soluble proteins of the cells ( see lane 7 ). 
However, two other proteins are also co-purified. These peptides may be 
integral part of the enzymatically active fusion protein. 
4.3.5 Cleavage of the native fusion protein with factor Xa. 
To check whether the cleavage site in the fusion protein is accessible to 
the activated blood factor X, in other words, to release the HPRT domain of the 
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figure 4.8 	APTG-affinity chromatography for the purification of the fusion protein 
from the soluble fraction of the induced SH1 sonicate. Figure shows the elution 
profile of protein (o—O), HPRT activity (e-..-) and 	-galactosidase activity 
Arrow shows the point, at which the elution of the column bound protein start. 
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Figure 4.9 	protein profiles of the eluted fractions from the APTG column. 
The numbers represents the numbers of the eluted fractions (fig. 4.8) and (U) 
shows the profile of the unbound proteins to the APTG column. 
(kd) 	






digested with factor Xa and the digested mixture was analysed with SIDS -PAGE 
(data not shown). The result demonstrated that even the native protein is not 
digestible by the enzyme, suggesting that may be the two domains of the 
fusion protein are very close to each other and the junction tetrapeptide is 
hidden inside the fusion protein and not accessible by the cleaving enzyme. 
4.4 The antibody against the fusion protein has been made. 
Because the HPRT domain was found to be impossible to cleave from the 
fusion protein, I decided to use the whole affinity column purified native fusion 
protein for making antibody. Two rabbits of weight 1.5 kg were immunized 
each with 90 ig of the fusion protein [method]. At the eighth day of boosting 
the sera of both the rabbits were tested for the presence of anti-fusion protein 
antibodies by Ouchterlony immunodiffusion technique [method]. The result is 
shown in Figure 4.10. 
The centre of the rosette contained 20 Ill antiserum. It is seen from the 
figure that the Whole cell extract of induced SH1( a )and the soluble protein 
fraction of the cell ( d ) gave a strong precipitin band with the immune serum. 
Similar band also seen with the pure fusion protein ( b) and with whole cell 
extract of induced pMS1S containing host NM522 (c) , which contained 
-galactosidase instead of the fusion protein. No such precipitin band was 
seen between preimmune sera (f) and the whole cell extract (a) of the induced 
SH1 or between the immune sera (centre) and the whole cell extract of the 
uninduced host NM522 (e). The result suggests that the immune serum indeed 
contained antibody against the fusion protein which also contained anti I3-gal 
antibody. this also suggest that such antibodies were not present in the 
preimmune rabbits. And also that the immune sera may contain antibody 
against other E. co/i proteins as indicated by the faint bands with a,c,d and e. 
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Figure 4.10 	Ouchterlony test for the presence of the antibody against the 
fusion protein. Centre well contained the rabbit serum to be tested. (a) whole 
cell lysate of induced SH1, (b) purified fusion protein from APTG column, (c) 
lysate of induced NM522/pMS1S, (d) supernatant of the induced SH1 lysate, (e) 




The titer of such antibodies may be very low. 
4.5 The antiserum recognised the fusion protein. 
To check the quality and specificity the antiserum was used in western 
blot analysis. Proteins from induced NM522, induced pMS1S transformed 
NM522 and both uninduced and induced SH1 were separated on a 8% 
SDS-polyacrylamide gel and western blotted and probed with the serum 
(method). The result is shown in Figure 4.11, suggested that the antiserum 
does recognize the - gal in a control extract of a pMS1S transformed strain 
(NM522) (Lane B) and the fusion protein (lane D) in the induced SH1. The 
antisera also contained antibodies against other E. coil proteins as seen in the 
induced NM522 (lane A). It is also noticeable that the uninduced SH1 also 
contained small amount of the fusion protein. This may be due to leaky 
expression of the high copy number of the plasmid. 
4.6 E. cQll specific antibodies were removed by preabsorption. 
Western blot with whole antiserum showed that, it contains antibodies 
against E. coil proteins other than the -galactosidase or the fusion protein. 
Thus it was necessary to remove the antibodies against both -galactosidase 
and other E. coil proteins from the serum. One very common technique used 
for this purpose is to preabsorb the serum with whole E. coil cell extract. 
Thus to remove the E. coil and $-galactosidase specific antibodies from 
the serum, it was preincubated with extracts of induced pMS1S transformed 
NM522 [method]. Western blot was performed with the extracts as described 
in the previous section and blot was probed with the preabsorbed serum. The 
protein profile recognised by the serum was compared with that with the 
unabsorbed serum. The result shown in Figure 4.12 clearly suggested that the 
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Figure 4.11 	Recognition of the fusion protein by immunized rabbit serum 
in western blot analysis. Figure shows the protein profiles identified by the 
immune rabbit serum in recombinant and parent E. co/i (A) uninduced 
NM522/pMS1S, (B) induced NM522/pMS1S, (C) uninduced SH1 and (0) induced 
SH1. The arrow shows the fusion protein. 
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Figure 4.12 	Recognition of the fusion protein with the immune rabbit 
serum preabsorbed with induced NM522/pMS1S cell lysate (method) in induced 
SH1 (lane D). Lane A, uninduced NM522/pMS1S, lane B, induced NM522/pMS1S 
and lane C shows the uninduced SH1 cell lysate respectively. 









preabsorption step did successfully remove most of the antiE. coil and 
antiB-gal antibodies. The 8-gal in the induced pMS1S transformed NM522 
(lane B) and other E. co/i proteins (lane A and B) were not recognised by the 
preabsorbed serum. However, the serum still contained antibodies against 
fusion protein which are presumably against the PfHPRT domain. The major 
115 kO protein was also recognised by the serum indicating the presence of 
the PfHPRT domain in this polypeptide. It was concluded that the preabsorbed 
serum mostly contains anti-PfHPRT antibodies. 
4.7 The preabsorbed serum recognised native PfHPRT. 
To confirm that preabsorbed sera indeed contain antiPfHPRT antibody, the 
whole cell extract of the P. fa/ciparum strain Ki were probed with the 
preabsorbed anti-fusion serum. Sample for SDS-PAGE was prepared with 50 j.iI 
of whole parasite and separated on a 12.5% gel. The proteins were first 
western blotted and then probed with the preabsorbed serum with an overall 
dilution of the antiserum of 100. The result shown in Figure 4.13, that only one 
protein of size of about 26.5 Kd is recognised in the whole parasite protein. 
This is the predicted size of the P. falc/parum HPRT (King & Melton, 1987). No 
other protein in the parasite protein profile was found to be recognised by the 
serum, suggesting the specificity of the serum to the parasite HPRT. This 
result also indicated that HPRT is an abundant protein in the parasite, at least 
in merozoite stage. 
4.8 Discussion and conclusions. 
The major theme of this chapter was to understand the -gal:PfHPRT 
fusion protein in molecular level and to purify the protein to make antibody 
against the P. fa/ciparum HPRT. 
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Figure 4.13 	Western blot analysis of the whole P. falciparum, strain Ki, 
cell extract with the antiserum against the fusion protein. The serum 
recognized a protein of size 26.5 kD, similar as the predicted size of the PfHPRT 







The degradation of the product by host bacterium proteases is one of the 
major problems associated with the production of heterologouS proteins in 
bacteria (Hellebust et a! 1989). It has been suggested that many eukaryotic 
foreign peptides are recognised as abnormal proteins and consequently are 
degraded (Goldschmidt R., 1970). For example, Talmadge and Gilbert (1982) 
reported that the half life of human proinsulin in E.. coli is only 2 minutes. 
Such degradation may cause lower yield during the purification steps. 
Understanding the degradation pattern of a protein may help in designing 
better purification scheme. For instance, purification of a stable protein may 
need some special reagent in the buffer or arrangement of particular apparatus. 
To understand the B-gal:PfPHRT fusion protein degradation pattern and to 
show that the authenticity of the fusion protein, the whole cell extract of the 
induced recombinant SH1 was probed in an western blot with anti s-gal 
antibodies. The result of this experiment confirmed the authenticity of the 
fusion protein. Moreover, The antibody recognised many other degradation 
product of the fusion protein. The size range of these protein suggested that 
the protein is severely degraded in the cell. In addition, this experiment also 
showed that the second major protein (about 115 kD) in the induced 
recombinant was also recognised by the antibody. This may suggest that the 
protein is a degradation product of the fusion protein as discussed in chapter 
3. 
The capacity of the proteolytic efficiency is limited for a cell. So, when 
the rate of expression becomes more than the rate of degradation the newly 
synthesized proteins aggregate and form inclusion bodies inside the cell. The 
mechanism of such inclusion body formation is not known. 
Like many recombinant proteins, 	-gal:PfHPRT fusion protein also 
aggregates and form inclusion bodies in the cell. When a lysozyme and 
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deoxycholate treated cell lysate was centrifuged with different centrifugal 
forces the protein pellet of the lowest speed showed an almost identical 
pattern to the whole cell lysate, indicating the presence of the membrane 
debris and unlysed cells. In contrast the profile of the pellets of the higher 
speeds, contains mostly the fusion protein with its major degradation product. 
The absence of any other major proteins suggested that the protein possibly 
forms discrete inclusion bodies. By transmission electron micrography Schoner 
et aI(1985) also showed that inclusion bodies are not membrane associated or 
enclosed in a membrane. The presence of the protein in pellets of different 
centrifugal forces may indicate the size variation of the inclusion bodies. One 
may argue that this is due to the insufficient centrifugation at any particular 
speed. However, this possibility can be ruled out by the fact that the amount 
of protein present in each pellet are almost similar, if the size of the inclusion 
bodies would have been identical, a large amount of protein would be obtained 
in a particular speed. 
The analysis of the protein profile by SDS-PAGE, revealed that the 
inclusion bodies are consist of two major proteins, the fusion protein and the 
major degradation product of it. However, although there is some other 
proteins were present in small amount, the purification of the fusion protein 
was greatly achieved by simply isolating the inclusion bodies. 
Washing with dilute Triton X-100 and urea solutions did not help 
significantly to remove minor contaminating proteins or the release of the 
fusion protein from the aggregates. This may indicate that the intramolecular 
interactions between the fusion proteins are quite big. One fact may be 
interesting to remember at this point that both the - galactosidase and HPRT 
are multimeric proteins. So interaction of two domain may give rise to a large 
multimeric network as shown below schematically and it would probably be 
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very difficult to break such network without denaturing the two active domains. 




This may indicate the strong intermolecular binding force in the inclusion 
bodies. Thus strong denaturing agent, 8M urea was needed to release the 
fusion proteins from these aggregated bodies. However, this treatment 
destroyed the special structure of the protein as indicated by the loss of the 
enzymatic activities for both -galactosidase and HPRT. 
The main idea of the solubilisation was to obtain the protein in pure form, 
particularly free from the degradation product associated with the fusion 
protein in the inclusion bodies, by gel filtration. But gel filtration with 
sephacryl S-200 eluted both the protein in the same peak. Moreover, the 
eluted protein failed to refold into enzymatically active form. This may be a 
result of several reasons. Firstly, the denatured fusion protein was not in pure 
form. The contaminating degradation product may interfere with the refolding 
mechanism. Secondly, during the denaturing process some important amino 
acid might have been modified. Occasionally special treatment is needed to 
protect such modification. For example, sulphonation was used to protect the 
essential cystein residues of recombinant insulin chains (Goeddel et a/., 1979). 
Finally, refolding is a complex process. different techniques have been 
employed for different proteins. The step wise dialysis method used in this 
case may not be ideal for this protein. Detail understanding of the structure of 
the fusion protein and experimentation with several techniques may result in 
the correct refolding of the protein. 
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Active fusion protein was purified from the soluble fraction of the cell 
lysate. This procedure exploited the -galactosidase activity of the fusion 
protein. The protein profile of the purified protein showed that apart from the 
fusion protein two other proteins also bound to the column and eluted. Since, 
the column was only able to bind active 8-  galactosidase proteins, it may 
suggest that these two proteins are probably integral part of the multimeric 
enzyme complex. This is possible, because both -galactosidase and HPRT are 
oligomeric enzymes and may be true in the case of the 115 kD protein as it 
also co-aggregates with the fusion protein, in the inclusion bodies. Moreover, 
we know that - galactosidase protein with deletion in the N-terminal can 
make complex with the full length enzyme (c-complementation). The 58 kD 
protein may not be a part of the enzyme complex, rather a degradation product 
of the fusion protein occurs when eluted with the high pH buffer. Otherwise, 
the protein would have been present in the inclusion bodies. 
The affinity column purified native fusion protein was used to make 
antibody. After the first boost the antisera from both the rabbits were found to 
be high enough to get a precipitin band in immuno-doublediffusion test. In 
western blot a 1:100 dilution of the pooled serum gave intense bands, 
indicating the high titre of the antibodies. However, the western blot of 
induced SH1 profile with this antiserum recognised several bands, in addition to 
the fusion protein. This may be in part due to the degradation of the fusion 
protein as we have seen with anti 8-  galactosidase antibodies. However, it may 
be also due to presence of minute amount of the contaminating E. coil protein 
in the affinity purified fusion proteins which was used as the immunogen to 
make antibodies. These proteins might have raised antibodies against them 
and recognized the E. coli proteins in the western blot. 
Most of these unnecessary antibodies including the antiB -gal antibodies 
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Were successfully removed by preabsorbing with E. co/i extracts containing 
overexpressed -gaIactosidase. The preabsorbed antiserum recognised only 
the fusion protein and also the major degradation product. this suggests that 
this degradation product also contains HPRT epitope(s). 
The preabsorbed serum contained antibodies against PfHPRT is shown by 
the result that it exclusively recognised a PfHPRT size protein as predicted from 
the cDNA sequence data (King & Melton, 1987). No other protein in the 
parasite recognised by the antiserum, indicates that no other protein in parasite 
cross-react with PfHPRT antibodies. The intensity of the HPRT band in the 
parasite protein profile may also suggest that the protein is an abundant 
protein in the parasite. Thus chapter described the successful preparation of 
the PfHPRT specific antibodies. This antiserum can now be used to probe the 
protein in vivo or in vitro and be of an important tool to investigate the 
location of the protein in parasite. And can also be used to purify parasite by 




Direct expression of the Plasmodium falciparum 
HPRT 
in E. coli. 
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The results in chapter 3 and 4 showed that PfHPRT can be expressed in 
E. coIl, at least as a fusion protein with -galactosidase, and also that the 
PfHPRT domain is even able to fold into the active form . The next logical step 
was therefore, to seek direct expression of the native parasite protein in E. coil, 
because one of the main objectives of this project was to study the 
biochemistry and molecular biology of the enzyme. A nonfusion full length 
enzyme is obviously the first choice for such studies. 
Production of foreign proteins in bacteria using a direct expression vector 
has several advantages over production by a fusion vector. In E. coil when a 
protein is expressed directly, it folds into active form and mimics most, if not 
all of its biochemical properties. Non-abundant proteins of the parasite, can be 
over-expressed by using direct expression vector and the protein can then be 
purified and studied by conventional methods. 
As discussed in the general introduction, for direct expression, a bacterial 
promoter and terminators are required for the transcription of the foreign gene. 
In addition the gene must follow an initiation codon (usually an ATG or 
sometimes a GTG) for translation. 
To facilitate direct expression of PfHPRT, the insert in pPfPRT1 (see 
chapter 3) was recloned. It contains the complete PfHPRT ORF and can be 
easily recovered by digestion with Hindill and EcoRl. Moreover the ORF can be 
manipulated for forced orientation in an expression vector, due to the presence 
of two different restriction enzyme sites in 5' and 3' ends. 
5.1 Vector pJLA503 was chosen for the expression. 
The vector used for the direct expression of P. fa/ciparum hypoxanthine 
phosphoribosyl transferase was pJLA503 (Schauder et al., 1987). The detail of 





Figure 5.1 	Structure of the vector pJLA503 (Schauder et al., 1987). 
10 
bacteriophage X promoters PR, P 1  in tandem. The promoters are regulated by 
the product of the temperature sensitive mutant of ci repressor, c1ts857 present 
in the vector. The promoters are followed by a polylinker region. A 51 bases 
long synthetic polynucleotide sequence from -50 to +1 bases of the atpE gene, 
called the atpETIR (atpE translation initiation region) is placed in between the 
promoters and the polylinker region. The atpE gene is a highly expressing 
gene encoding the C subunit of the muitisubunit enzyme ATP synthase. The 
strong transcriptional terminator from phage fd is present in the vector 
following the polylinker region, to stop the readthrough transcription from the 
vector, which may interfere with the mRNA stability and also with expression of 
other genes in the vector (see introduction). The drug resistant marker used in 
this vector is the ampicillin resistant gene. This vector was used to express 
several other eukaryotic and prokaryotic genes (Schauder et al., 1987). The 
E. coil strain NM654 was used as a host for the pJLA503 and its recombinant 
vectors in the expression studies. 
5.2 Construction of the nonfusion recombinant vector. 
The overall construction strategy of the recombinant vector is shown in 
Figure 5.2. In brief, the Hindill-EcoRl fragment of the pPfPRT1 containing the 
ORF, from initiation codon to stop codon was inserted into the Ndel-EcoRl site 
of the pJLA503. The Ndel site contains the ATG, the initiation codon of the 
atpE gene. Placing the ATG of PfHPRT near or at this position wil put the ORF 
at the correct context of the bacterial control elements. The EcoRl site was 
chosen for forced orientation of the gene in the vector. 
For subcloning, the fusion expression vector, pPfPRT1 was digested at the 
unique Hindlil site preceding the ATG of the gene, and the ends were made 






NdeI fd terminator 	
EcoRI 
1. NdeI digestion. 















Kienow to make 
ends blunt. 
EcoRl digestion. 
Gel purification of 
Pf hprt insert. 






Figure 5.2 	Construction of the recombinant plasmid pPfPRT2 (for detail of 
pPfPRT1 see text of chapter 3). 
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linear vector were then digested with EcoRl and the released fragment were 
purified from 8% agarose gel (method). Similarly the vector, pJLA503 The 
vector was digested at the unique Ndel site and the ends were made blunt. 
The blunt ended linear vector was then digested with EcoRl and the released 
polynucleotide, were removed by precipitating the digested vector with ethanol. 
The precipitated vector was finally resuspended in 1 X TE. For ligation, insert 
and vector DNA were mixed in 3:1 ratio and ligated using T4 DNA ligase 
[method]. 
5.3 The constructed vector was transformed into E. coli. 
The ligation mixtures were transformed into E. coil NM654 [method]. The 
transformation mixtures plated on L-amp plates and incubated overnight at 
30°C. Primarily the ampicillin resistant colonies were picked and then screened 
for the PfHPRT recombinants, by colony blot [method], using the purified 
PfHPRT cDNA as the probe. Figure 5.3 shows the blot. About one positive per 
12 ampicillin resistant colonies were obtained. 
5.4 The recombinant bacteria were checked for the expression. 
The two colonies thus obtained were checked for their ability to express 
the recombinant protein. The cells were induced for expression [section land 
then processed for SDS-PAGE [method]. To check the expression, protein 
profiles of cells from 300 i.tl culture of both the induced recombinant colonies 
were analysed on a 10% SOS-polyacrylamide gel (method) and compared with 
that of the uninduced recombinants, induced NM654 and pJLA503 transformed 
NM654. The result of this experiment shown in Figure 5.4, demonstrated that a 
protein of about 26.5 kD has expressed in both the induced recombinant 
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Figure 5.4 	Expression study with the pPfPRT2 transformant of NM654. The 
Figure shows the protein profiles of uninduced (lanes 4 and 6) and induced 
(lanes 5 and 70 transformants and uninduced (lane 2) and induced (lane 3) 
NM654/pJLA503. Lanes 1 and 8 show the protein molecular weight markers. 
The arrow shows the recombinant protein. 











from the cONA of the PfHPRT (26.392 kD). The protein is not present in the 
uninduced recombinants (Lanes 4 and 6), suggesting the protein is induced by 
the higher temperature. It is also not present in the induced host NM654 (lane 
1) or in the induced pJLA503 transformed NM654 (lane 2). These may suggest 
that the induced protein was expressed from the recombinant vector. It was 
concluded that the induced protein is P. falciparum HPRT. 
One, of the two colonies, was selected for further study and named SH2. 
To confirm the temperature inducibility of the gene, the selected recombinant 
SH2, was grown and induced for vector gene expression. The proteins of the 
induced SH2 were separated on a 12.5% SOS-polyacrylamide gel. The result in 
the Figure 5.5 shows the comparison of the induced SH2 protein profile (lane 
3), with that of the induced host NM654 (lane 1) and uninduced SH2 (lane 2). 
The result confirmed that the induced protein is of the recombinant vector 
origin and regulated by the temperature sensitive c1857 repressor. 
To check the structure of the recombinant vector, it was purified from the 
SH2 cells (method), and the position and the orientation of the vector was 
confirmed by restriction mapping (data not shown). And the vector was named, 
pPfPRT2. 
5.5 The expressed PfHPRT is recognised by the anti-PfHPRT 
antibody.  
The expressed protein was probe in a western blot with the preabsorbed 
polyclonal antiserum against the -gal:PfHPRT fusion protein. The proteins 
from the induced and uninduced SH2 were separated on a 12.5% 
SDS-polyacrylamide gel and western blotted. The blot was probed with the 
antiPfHPRT antibody (final dilution 1:100) previously absorbed with E. coil 
extract as described before (method). The result, shown in Figure 5.6, clearly 
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Figure 5.5 	Expression of PfHPRT in E. coil SH2 (NM654/pPfPRT2). Figure 
shows the protein profiles of induced NM654/pJLA503 (lane A), that of the 
uninduced SH2 (lane B) and induced SH2(lane C). A protein of size 26.5 kD is 
expressed in the induced SH2 which is similar to the predicted size of the 
PfHPRT (King and Melton, 1987). 
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Figure 5.6 	Recognition of the expressed recombinant protein in SH2 by 
the immune serum against the -gal:PfHPRT fusion protein (chapter 3). Lane A 
shows the recombinant protein in the induced SH2 cells is recognized by the 
antiserum. Lane B shows no such protein is recognized in uninduced SH2 cells. 







indicates that the expressed protein in induced SH2 (lane A) is recognised by 
the antibody, that it has atleast some epitopes of P. falciparum HPRT. No such 
protein is recognised in uninduced SH2 extract (lane B). 
5.6 The PfHPRT expressed in f..  coli is same size as the native 
protein. 
Following translation many eukaryotic proteins undergo post translational 
modification, like removal of any Leader(signal) peptides (Blobel & Dobberstein, 
1975), glycosylation (Astwell and Morell, 1974), phosphorylation (Rubin and 
Rosen, 1975) etc. Leader peptides direct the newly synthesizing protein into its 
target places, for example, to membrane bound vesicles, to plasma membranes 
for membrane bound proteins. Comparison of the amino acid sequence 
predicted from the PfHPRT cDNA, with that of the mammalian HPRT, revealed 
that PfHPRT contains an extra peptide of of 8 amino acids and an extension of 
3 amino acids at the C-terminal end. The biological significance of these extra 
amino acids are not clear at this moment. This raised the question whether 
this is targeting the protein to any particular part of the cell and removed from 
the protein afterwards. To answer the second question, the size of the protein 
synthesized in E. co/i NM654 and that of the native protein synthesized in vivo 
were compared in a western blot of the separated protein on a 12.5% 
SDS-polyacrylamide gel probed with the PfHPRT antiserum. The result of the 
experiment shown in figure 5.7, indicates that the size of the E. co/i expressed 
protein lane 2 is close or identical to that of the native protein (lane 3). 
Moreover, if the extra peptide is cleaved, a doublet protein band would be 
expected in the parasite protein profile. These may suggest that no part of the 
protein is remove after synthesis from spliced mRNA. This is interesting and 
the question of the significance of the extra amino acids is still remains. 
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Figure 5.7 	Size comparison of the recombinant protein in induced E. coil 
SH2 and native PfHPRT. Lane A shows the protein profile of the uninduced SH1 
as recognised by the antiPfHPRT antiserum. Lane B and C shows the same of 
the induced SH1 and whole P. falciparum Ki, cell extract respectively. The size 
of the recombinant protein and the native PfHPRT appears to be the same. 
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5.7 The PfHPRT expressed in E. cll is active. 
As we have seen in the case of the fusion protein that it may be 
enzymatically active or correctly folds into active form. If this is true the non 
fusion protein should fold into the active form even more efficiently. Which 
can be measured by assaying the activity in the induced SH2 extract. The 
extracts of the induced cell were prepared and the cell free extract was then 
assayed for the HPRT activity using hypoxanthine as substrate [method]. 
Specific activity of HPRT in induced SH2 extract was compared with that of the 
induced NM654 and uninduced SH2. The result is shown in Figure 5.8, 
suggests that the specific activity of HPRT is some 50 times more than that of 
the induced NM654. This result suggests that PfHPRT expressed in E. coil is 
active. However, since the bacterium has its won HPRT, the result is not 
conclusive. To confirm this conclusion, either the protein need to be purified 
or the enzyme should be expressed in a HPRT less bacterial strain. 
5.8 Discussion and conclusions. 
It has been mentioned before that because of unusual instability of the 
plasmodium enzyme the isolation of the P. fa/ciparum HPRT in sufficient 
quantities for biochemical use has been difficult (Queen et al., 1988) and 
although important, structural studies were prevented because of the limited 
supply of the highly purified material. This chapter demonstrated a new 
approach for recombinant production of this important enzyme. It should now 
be possible to isolate relatively large amount of pure P. falciparum HPRT, 
necessary for further biochemical and structural studies, from the SH2 
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Figure 5.8 	HPRT activities in recombinant strain SH2 and parent 
Data are expressed as percentages of the induced recombinant, SH2 
and bar 2 show the relative activities in induced NM664 and 
respectively. 
E. co/i NM654. 
(bar 3). Bar 1 
uninduced SH2 
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Plasmid pPfPRT1 was initially constructed as a fusion E. coil expression 
vector (chapter 3). This plasmid contained the complete open reading frame of 
the PfHPRT which is recoverable by double digestion with Hindill and EcoRl. 
This ORF is placed in the right context with the Translation initiation region of 
the atpE gene which was present in the vector. This put the gene under 
control of the Xpromoter PL  and  PR  and can be regulated by the temperature 
sensitive c1857 regulatory gene product. This newly constructed plasmid was 
called the pPfPRT2 and the transformed E. coil NM654 is called the SH2. 
Upon induction at 42°C, this bacterium produce high level of the PfHPRT 
protein which is of the similar size (26.4 kD) as predicted from the cDNA. 
Further confirmation about the authenticity was came from the western blot 
with the antiPfHPRT antibody prepared with the -gal:PfHPRT fusion protein and 
preabsorbed with E. coil protein. This antibody was previously shown to 
recognize PfHPRT in western blot experiments (chapter 4). Visual analysis of 
coomassie stained gel clearly suggested that PfHPRT is the major protein in the 
induced SH2 and the expression level is quite high. 
When the cell free extract of induced SH2 was extract was assayed for 
HPRT activity the bacteria showed significantly high activity compared to the 
uninduced SH2 and induced host NM654 cell extract. The activity in the 
induced SH2 extract is about 10 times higher than that of the uninduced SH2 
whereas the activity is some 50 times higher than the induced host NM654 
extract. It is concluded that the E. coil SH2 produced PfHPRT is enzymatically 
active. 
Comparison of the size of an in vitro translated protein from purified 
mRNA with that of the native is commonly used to study posttranslational 
cleavage of any signal peptide. Hart et al (1987) showed that invitro translation 
product of recognised by the monoclonal antibody against Trypanosomal 
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aldolase had the same size as the native protein. They concluded that the 
protein does not undergo any post translational cleavage. Because the PfHPRT 
had an extra 8 amino acid in the N-terminal which is hypothesized to have 
some possible role as signal peptide, I have compared the size of the E. coil 
produced PfHPRT (assuming E. coil does not have the specific signal peptidase 
to remove any Plasmodium signal peptide) and P. fa/ciparum produced native 
HPRT in an western blot analysis using the PfHPRT antibody as the probe. The 
identical size of both the proteins may suggest that The P. falc/parum HPRT 
does not undergo any detectable cleavage modification after synthesis. 
Moreover, If the protein undergoes such cleavage we would have expected a 
doublet in the western blot analysis. This result suggest that the extra peptide 
may not be a typical signal peptide. 
Now because the the E. coil expressed PfHPRT is enzymatically active it 
can be expected that the enzyme can complement a homologous gene in E. coil 
If this is possible the complemented strain could be an excellent source for 
the PfHPRT enzyme for further study. Furthermore, the strain will be a easy 




Biochemistry of the recombinant PfHPRT 
and 
Complementation of a bacterial mutation 
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The significantly high specific activity in induced SH2, in chapter 5 
suggested that the PfHPRT expressed in E. coil is enzymatically active. 
However, the possibility that the E. coil gene contributes to this activity can 
not be ruled out. An in vitro complementation of bacterial hpt mutation would 
enable us to study the enzymatic activity in a HPRT-less environment. 
Moreover, the determination of the biochemical properties of the expressed 
enzyme in such a system could give authentic information regarding the 
biochemical properties of the P. fa/ciparum HPRT. 
As mentioned in the introduction section that E. coil has as same basic de 
novo pathway for purine synthesis as other organisms and also similar salvage 
pathway to use preformed purines. E. coil has two 6-oxopurine phosphoribosyl 
transferases, HPRT and XGPRT, both use hypoxanthine and guanine as substrate 
although at different efficiencies (Hochstadt and Cashel, 1972). Furthermore, 
adenine and guanine nucleotide may interconvert through the common 
precursor, IMP. These features suggest that for complementation study with 
the recombinant PfHPRT, the suitable mutant must have blockage in the de 
novo biosynthesis of purine, in purine interconversion and also in HPRT and 
GPRT steps. 
The results described in the following sections are an attempt to 
complement a bacterial hpt mutation with the active recombinant enzyme. This 
will also study some biochemistry of the recombinant enzyme expressed in the 
bacterium. 
6.1 The S. typhimurium KP1684 was used for complimentation 
study. 
At the begining, E. coil was considered for the complementation study. 
But the hpt mutants available, were not suitable for this purpose. A mutant of 
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S. typhimurium, called KP1684 was described by Houlberg and Jensen (1983). 
This bacterium possesses all the required mutations for a suitable strain for the 
complementation study, and needs adenine and guanosine for its survival. 
Therefore, it was decided to use this strain for the complementation study. 
The genotype of the S. typhimurium strain KP1684 is purE deoD hpt gpt. 
Figure 6.1 shows the purine salvage pathway in S. typhimurium with the steps 
blocked in the strain KP1684. The gene purE, codes for the enzyme, 
phosphoribosylaminoimidazole carboxylase. Mutation in this gene, blocks the 
IMP biosynthesis, so de novo biosynthesis of purine can not occur in this 
bacterium. The mutation in the deoD, the purine nucleoside phosphorylase 
gene, blocks the interconversion of purines. So, the strain needs preformed 
both adenine and guanine nucleus. But mutation in both hpt and gpt do not let 
the strain to use guanine base rather it uses guanosine as the guanine source, 
which converts into GMP by guanosine kinase. Furthermore, the strain can not 
use hypoxanthine, due to the hpt mutation, as its sole source of purine, made 
the strain suitable for the complementation of this mutation with an exogenous 
HPRT. 
If the recombinant PfHPRT is enzymatically active and expressed in the 
Salmonella strain, It would be possible to compensate for the hpt mutation and 
the strain will then be able to use hypoxanthine as its sole source of purine. 
Before going to the complementation study, the growth phenotype as 
expected from the genotype, of the strain KP1684 was checked. The bacterium 
was grown in minimal plates with adenine, hypoxanthine, guanine and 
guanosine in different combinations. The result in Table 6.1 shows that the 
strain can not grow on minimal plates and hypoxanthine or guanine can not 
serve as the purine source, neither adenine by itself. The strain only grows 
when both adenine and guanosine are present in the medium. 
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Figure 6.1 	The blockages in the biosynthesis, salvage and interconversion 







A ++ - 
B ++ - 
C ++ - 
D ++ - 
E 
Table 6.1 	Growth phenotype of S. typhimurfum KP1684. A = minimal medium, B 
= A + 30jig/ml hypoxanthine, C = A + 30jig/ml adenine, D = A + 60 jig/ml guanosine 
and E = A + 30 jig/ml adenine + 60 jig/mI guanosine. - = no growth, ++ = small 
colony and +++ = big colony after overnight incubation at 37 °C. 
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This data fits with the prediction from the genotype of the strain. And 
seemed suitable for our purpose. 
6.2 pPfPRT2 was methylated for Salmonella modification 
pattern. 
One possible problem in the transformation of pPfPRT2 from E. coil SH2 
to Salmonella typhimurium KP1684, is restriction of the plasmid. To avoid such 
a problem, the plasmid was passaged through a (m strain of Salmonella to 
modify according to the Salmonella modification pattern. Strain S. typhimurium 
LB5000 (Bullas and Ryo, 1983) was used for this purpose. 
The purified plasmid from strain SH2 was transformed into the strain 
LB5000 [Methods], and the transformants were first selected by ampicillin 
resistant phenotype and later confirmed by colony hybridisation, using the 
original PfHPRT cONA as the probe. 100% of the ampicillin resistant colonies 
were positive in the hybridisation step. Further confirmation about the 
structure of the plasmid was obtained by purification from one of the 
transformants and restriction mapping. 
6.3 The modified pPfPRT2 was transformed into S. typhimurium 
KP1684. 
To express the recombinant protein in strain KP1684 the modified plasmid 
from LB5000, was transformed into the bacterium by standard transformation 
protocol. The ampiciltin resistant colonies were then picked and checked by 
colony hybridisation (Methods). The blot is shown in Figure 6.2. All of the 
ampicillin resistant bacteria were found to be positive when labelled HPRT 
cDNA was used as a probe. The plasmid was purified from one of the 
transformants and the structure of the plasmid was checked by restriction 
mapping. The transformant with the pPfPRT2 is called the S. typhimurium 
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Figure 6.2 	Colony hybridization with labelled Pfhprt cDNA for the 





6.4 The induced SH4 expressed PfHPRT protein. 
To check whether the recombinant PfHPRT does express in this 
Salmonella strain, the strain SH4 was grown and induced [Methods]. An 
uninduced culture was included as a control. Protein profiles of whole cell 
from both induced and uninduced SH4 were analysed by SDS-PAGE. Proteins 
were separated on a 12.5 % SDS-polyacrylamide gel and western blotted . The 
blot was then probed with PfHPRT antiserum (Chapter 4). 
The result ( Figure 6.3 ) showed that a protein of 26.5 kD is expressed in 
the induced SH4 (lane A ) and is recognised by the anti PfHPRT serum. This 
protein has the same size as the protein expressed in the E. coil as was shown 
in figure 5.5 . The protein is not expressed in the uninduced SH4 ( lane B ). 
This suggests that the Plasmodium protein is successfully expressing in the 
Salmonella strain SH4 as well as in the E. coil SH2. 
6.5 The complementation was not observed. 
The result in the previous section showed that the PfHPRT is expressed in 
the induced SH4. And since, the protein is active in E. coil, it can be expected 
that the protein will be active in Salmonella as well. If this is true, the 
mutation in the hpt gene in KP1684 should be compensated by this enzyme. 
To test this possibility, the strain SH4 were streaked on minimal plates 
containing ampicillin and 30 ig/ml hypoxanthine and incubated at 42 C. A 
similar plate was incubated at 30 C as a control. Two other plates without 
hypoxanthine were also included as the control and incubated at 30 C and 42 




Figure 6.3 	Expression of recombinant PfHPRT in S. typhimurium SH4 
(KP1684/pPfPRT2). Lane A, shows the expressed recombinant protein in 
induced SH4 is recognized by the antiserum against PfHPRT (arrow). Lane B 
shows no such protein is expressed in the uninduced SH4. 
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The immediate explanation could be that, the enzyme although active in 
the E. coli strain but may be inactive in the Salmonella typhimurium strain. 
6.6 The enzyme was active in in vitro assay. 
Assay of HPRT in cell free extract of the induced SH4 would enable us to 
confirm the activity of the recombinant PfHPRT expressed in the bacterium. 
This is possible because the host strain KP1684 does not have any detectable 
HPRT activity (Houlberg and Jensen, 1983). 
So to test the above explanation for the inability of the recombinant 
bacterium to grow on a Hypoxanthine plate, HPRT activity was measured in the 
extract of both induced and uninduced SH4. The uninduced and induced cell 
extract of the host strain KP1684 were included as the negative control. The 
result shown in Figure 6.4, conclusively proved that the recombinant enzyme is 
active in strain SH4. The figure shows that the enzyme activity increases with 
the addition of the cell free extract of the induced SH4. whereas there was no 
such detectable activity in uninduced SH4 extract and neither in the induced 
KP1684 extract. 
6.7 A modified medium supported the growth of 
S. typhimurium SH4. 
The result presented above argues against inactivity of the recombinant 
PfHPRT expressed in SH4. Then, why did the active enzyme not complement 
the hpt mutation in KP1684? 
One explanation is suggested by the fact, that addition of hypoxanthifle 
and other purine bases in vegetatively growing Salmonella cells causes severe 
depletion of the PRPP pool in the bacterium (Jensen, 1983). PRPP, the second 
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Figure 6.4 	HPRT activity in induced S. typh/mur/um SH4 and KP1684. Figure 
shows the incorporation of the Labelled hypoxanthine into IMP by cell free extracts of 
the bacteria, SH4 (c—o ) and KP1684  
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many other important metabolites. 	This includes histidine, tryptophan, 
pyrimidine bases, a total of 10 enzymes compete for PRPP as a substrate 
(Neuhard and Nygaard, 1987). Now if this is so, The overexpression of the 
active PfHPRT in the cell at 42 C and the abundant supply of the hypoxanthine 
in the medium may deplete the PRPP pool in the cell and as a result other 
important metabolites like histidine, tryptophan and pyrimidines can not be 
synthesized. To check whether this can be the reason, the minimal medium 
used in the previous experiment is now supplimented with each of 50 .ig/ml of 
histidine and tryptophan and 30 ig/ml of cytidine. The bacterium was streaked 
on the plates and incubated as in section 6.5. This time indeed, about 2mm 
diameter colonies of SH4 was observed after 72 hour incubation at 42 °C, in the 
plate supplimented with hypoxanthine. No growth was noted, either on the no 
hypoxanthine plate incubated at 42 °C or in hypoxanthine supplimented plate 
incubated at 30 °C. The result is shown in Table 6.2. Thus the impaired 
synthesis of other essential metabolites in the cells may be one of the reasons 
of the inability of the growth of the recombinant bacterium in the medium 
supplimented with only hypoxanthine. 
6.8 The growth rate was enhanced by adding other amino acids. 
The slow growth rate of the complemented mutant was not understood. 
Incubating the plates longer did not improve the colony size. One simple 
explanation could be that the overexpression of the active enzyme may have 
some effect on other important metabolic pathways. For example, during the 
overexpression of the PfHPRT, the cellular protein-synthesis--machiflary remains 
mostly involved in the synthesis of the induced protein, which may cause the 
less availability of the ribosomes and tRNAs (specially the rare tRNAs) for 
biosynthesis of other essential proteins. This speculation is strengthened by the 
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Table 6.2 	Complementation of the 
hpt mutation in S. typhimur/Um KP1684 with 
PfHPRT. Strain KP1684 and SH4 was streaked on solid medium A or B and growth was 
recorded after 72 hours. A = minimal medium + 30 jg/ml cytidine + 50j.ig/ml Histidifle 
+ 5Oig/ml Tryptophafl. B = A + 30 
pg/ml hypoxanthifle. - = no growth and ± 	small 
colony after 3 days. 
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observation that, during the overexpression of the fusion PfHPRT in E. coil 
other cellular protein content was decreased (Figure 5.5 lane C). This may also 
include the synthesis of other essential enzymes. 
Now if this is so, alleviation of the biosynthetic pressures from the cell, at 
least to a certain extent, should increase the growth rate of the complemented 
mutant. Bearing this in mind, the minimal medium was supplimented with 1% 
casamino acids and cytidine as above. Casamino acids (DIFCO) are the acid 
hydrolysate of the pure milk protein, casein and does not contain any nucleic 
acid precursor and used in the media where mixture of amino acids are 
essential. The addition of preformed amino acids should remove the pressures 
from the cells to synthesize these amino acids. 
When the experiment described in the previous section is repeated with 
the minimal medium supplimented with 1% casamino acids and cytidine a good 
growth was noted after 24 hrs incubation, only on the plates containing 
hypoxanthine and incubated at 42 °C as shown in the Figure 6.5, plate A. No 
growth was observed in plates, supplemented with l% casamino acid without 
hypoxanthine (plate C). Neither was growth observed in plates incubated at 
30 °C, with or without hypoxanthine (plates B and D). This result supported the 
explanation for the poor growth of the complemented mutant made earlier this 
section. But the involvement of the other mechanisms is also possible. 
Further study of bacterial metabolism and the effect of the recombinant protein 
expression on bacterial metabolism may help in designing of a better culture 
medium for the growth of the recombinant bacterium. 
6.9 The expressed enzyme can also use xanthine and guanine as 
substrates. 
P. fa/ciparum HPRT has been partially purified and biochemical studies on 
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Figure 6.5 	Complementation of the hpt mutation in S. typhimurium 
KP1684 by PfHPRT. Growth enhanced by improved medium. (A)growth of SH4 
in minimal medium supplemented with 30 .ig/ml cytidine and 1% casamino 
acids incubated at 42 °C, (B) same as A but medium contained no hypoxanthine, 
(C) same as A, plates incubated at 30 °C and (D) same as A except the medium 
contained no hypoxanthine and incubated at 30°C. 
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this enzyme had been reported (Queen et a/.1988). Their study showed that 
the P. fa/ciparum enzyme can also use both guanine and xanthine as its 
substrates. The property is unusual than that of the enzymes from other 
Plasmodia species. 
To study whether P. fa/ciparum really can use guanine and xanthine as its 
substrate or in other words whether the recombinant PfHPRT expressed in 
bacteria can fold the expressed polypeptide exactly into its native form, the 
induced SH4 extract was assayed for PRTase activity using guanine and 
xanthine as the substrates. The activities thus obtained were compared with 
that in the extracts of uninduced SH4 and induced KP1684. The results as 
shown in Figure 6.6, demonstrated that the extracts from induced KP1684 can 
indeed use the purines as its substrates. The extracts of the uninduced SH4 
and induced KP1684 did not activities with either of these substrates. This 
result may suggest that P. falciparum HPRT is able to use guanine and xanthine 
as its substrates and supports the report of Queen et al (1988). This result 
may also suggest that the polypeptide expressed in the bacterium can fold into 
native form as well as in the parasite. 
6.10 The recombinant enzyme uses hypoxanthine more 
efficiently than xanthine or guanine. 
It is not quite possible to measure the Km values of an enzyme for its 
substrates or Ki values for the inhibitors without purifying the enzyme to 
homogeneity at least to a certain extent. This is because the possible 
degradation of the product by other enzymes will make it difficult to measure 
the absolute amount of the product formed. However, in SH4 the enzyme 
expression rate is much higher than the other enzymes and the extract gave 
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Figure 6.6 	Utilization of guanine and xanthine as substrates by recombinant 
PfHPRT expressed induced SH4. The incorporation of the radiolabelled purines into 
corresponding nucleotides with respect to the volume of the induced SH4 extract 
added. 
lot, 
may be possible to measure the specific activity, allowing a degree of error. 
This could enable us to compare the affinity of these substrates to the enzyme. 
The specific activities were measured for the three substrates and expressed as 
the ng product formed per 10 minutes per mg of the total protein, the result is 
shown in Table 6.3. The table shows that the specific activity of the enzyme is 
about 11 times more with hypoxanthine than with xanthine as the substrate, 
whereas it is about 4 times higher than that with guanine. It may suggest that 
the efficiency of the enzyme to use hypoxanthine as substrate is highest and 
that is to xanthine is lowest putting guanine in between. 
6.11 The enzyme activities are inhibited by 6-thioguanine. 
As it is not possible to measure the Km values for Hypoxanthine, guanine 
and xanthine with unpurified enzyme, a different strategy was adopted to 
confirm that the enzyme has different affinity for these substrates. The specific 
activities of the enzyme was measured with the three substrates in presence of 
the competitive inhibitor, 6-thioguanine. 	The reason for choosing 
6-thioguanine is its higher Ki value to the enzyme (7 pM) 	than that for the 
hypoxanthine and guanine (0.46 .iM and 0.3 jiM respectively) and lower than 
that for xanthine (23 jiM). The idea was if the bacterially expressed protein 
shows any affinity difference the extent of inhibition of the activity by the 
competitive inhibitor would be different. The reaction mixture contained 100 
jiM purines high above the reported Kms and 1 mM 6-thioguanine. The 
reaction and measurement of product formation was carried out according to 
the method described for earlier experiments. The extent of inhibition was 
defined by the percent of the activity showed with the presence of 
6-thioguanine compared to that of without it. The result is shown in Table 6.3. 
It may be concluded from the result that the affinities of hypoxanthine and 
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estimated Z 	activity 
enzyme purine specific in presence 
source substrate activity of 1 mm 
nmole/10 mm/mg 6.-thioguanine 
KP1684 hypoxanthine ND - 
KP1684/ hypoxanthine ND - 
pJLA5O3 
hypoxanthine 60.8 	(± 4.6) 76 
SH4 xanthine 5.79 	(± 	1.2) 2.5 
guanine 15.8 	(± 	1.9) 75 
Table 6.3 Properties of P. falciparum HPRT expressed in S. typhimurium SH4. Under 
our conditions, the parent strain KP1684, has no detectable PRTase activities 
(methods). The table shows the estimated specific activities with hypoxanthine, 
xanthine and guanine. Specific activities shown are average of at least three 
determinations. Standard deviations appear in brackets. Inhibition of enzyme 
activities with 6-thioguanine was measured. by adding the analogue to appropriate 
reaction mixtures (final concentration 1 mM). 
•70 6 
guanine are higher than the inhibitor, so they win in the competition in binding 
to the enzyme active site, as a result the inhibitions of activities were not very 
efficient for these substrates, only about 25%. In contrast, the inhibition of the 
XPRT activity was immense, about 95%. This may indicate that the affinity of 
the enzyme to xanthine is very low. This result also indicates that the affinity 
of the enzyme to hypoxanthine and guanine is comparable. 
Such results also suggest that the Plasmodium enzyme is efficiently 
folded into the native form in the bacteria, as reflected by the fact by retaining 
activity for all three substrates with similar affinity difference pattern as 
described for the native enzyme (Queen et a/., 1988)). 
6.12 Strain SH4 can not use xanthine or guanine as its purine 
source. 
The obvious consequence of the above result which showed that the 
expressed protein can use xanthine and guanine as its substrates, is that the 
strain should use either of these bases as its purine source. So, to check 
whether xanthine and guanine could substitute for hypoxanthine in the 
complementation study, either 15 4g/ml of xanthine or guanine was replaced 
for hypoxanthine in the medium. The plates were inoculated with SH4 and 
incubated overnight at 30 °C and 42 °C as described in section 6.8. After 
incubation for 72 hours no growth was observed in any of the plates 
containing either xanthine or guanine. But good growth was observed with 
hypoxanthine. 
6.13 Discussion and conclusions. 
As it was established in chapter 5 that E. coil can synthesise active full 
length PfHPRT, obviously an E. coil mutant would be the first choice for the 
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complementation study. Instead, A Salmonella typhimur/um strain was used for 
this purpose. Search for a suitable E. coil mutant was fruitless. For example, 
an E. coil hpt mutant, strain S4606, although does not have any HPRT or GPRT 
activity and mutation in purR blocks the de novo purine synthesis, but it could 
use hypoxanthine through purine nucleoside phosphorylase (deoD) mediated 
salvage pathway (see introduction). Thus, it was not possible to use E. coil for 
the study. 
E. coil and Salmonella typhimurium are related organisms being in the 
same Enterobacteriaseae family. Along with several dissimilarities they share 
most of the common metabolic pathways (Neuhard & Nygaard, 1987). the 
purine metabolic pathway has been shown to be similar. And because a 
suitable strain KP1684 was available, it was used for the purpose. 
One potential problem of using S. typhimurium was the possible 
restriction of the E. coil grown plasmid in this bacterium. 
Restriction-modification system is species specific as well as organism specific. 
Evidence showed that modification system in Salmonella is different than that 
of E. coil. For instance, :z et al (1962 found that the frequency of 
transformation of an F. coil donated plasmid to S. typhimurium LT2 is as low 
as 10- . Possibility of such problem would make the transformation of the 
E. coil grown pPfPRT2 in S. typhimurium KP1684 difficult. Such possibility was 
overcome by passing the plasmid through a rm Salmonella strain LB5000, 
before any attempt was taken to transform it into KP1684. By doing so, a 
pPfPRT2 transformant of S. typhimurium KP1684 named SH4 was obtained, 
which expressed the parasite HPRT in high amount. The authenticity of the 
expressed protein was confirmed by probing the protein profile of the induced 
and uninduced SH4 in a western blot analysis. Such probing with the 
preabsorbed antiserum also recognised several other proteins in both induced 
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and uninduced cells. This may be due to insufficient preabsorption of the 
serum with E. co/i extract. A further absorption of the immune serum with 
Salmonella extract could remove some of the nonspecific bands. A minor band 
in the uninduced cell was possibly due to some leakage in the control of the 
gene regulation in the bacterium. 
As in the case of the E. coil expressed protein, the protein expressed in 
Salmonella was also active. Because the strain KP1684 does not have any HPRT 
and GPRT activity, the demonstration of such activity in this strain conclusively 
proved that the parasite enzyme is enzymatically active. In other words the 
recombinant polypeptide can fold into the active form as well as in the 
parasite. 
The activity was characterised by the increase in the incorporation of 
radioactive hypoxanthine into the IMP formed. However, the increase of the 
incorporation was observed upto a limit. At higher amount of cell extract the 
estimated product formation was low. Such lower observed lower product 
formation by higher amount of the bacterial extract may be due to the 
presence of the nucleosidase enzymes present in the cell. For example, 
adenylosuccinate synthetase (encoded by purA) and IMP dehydrogeflaSe 
(encoded by guaA) use IMP, the product of HPRT as substrate and produces 
succinyl-AMP and XMP respectively. Both these enzymes are active in KP1684. 
Moreover, it has been shown that purA expression is induced in E. coil when 
hypoxanthine is added in the medium (Neuhard and Nygaard, 1987). This may 
suggest that at higher amount of the extract the hypoxanthines are used up by 
the overexpressed HPRT and the product, IMP is removed by the above 
enzymes. 
The 	enzymatic 	activity led to 	test the ability 	of the 	protein 	in the 
compensation 	of the hpt, gpt mutation of the 	strain. However, the first 
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Attempt, where the minimal medium was supplemented with Hypoxanthine was 
failed. This was thought be due to the unavailability of the important 
metabolite PRPP, the second substrate of HPRT, for other biosynthetic purpose. 
Such hypothesis was tested by supplementing the medium with Histidine, 
tryptophan and cytidine. Biosynthesis these metabolites depend on the 
availability of PRPP. Such modification of the medium supported the growth of 
SH4 only if the medium contained hypoxanthine and the PfHPRT gene in the 
vector was allowed to express. Addition of casamino acids, which can lower 
the biosynthetic pressure from the organism to synthesize amino acids, 
increased the growth rate significantly. Further increase of the growth rate 
may be possible by understanding the metabolism of the bacterium and 
modifying the medium according to that. For example, biosynthesis of vitamin 
nicotinamide adenine dinucleotide (NAD) also need PRPP, so addition of NAD 
may improve the quality of the medium. 
Queen et al (1988) reported that P. falciparum HPRT can use xanthine and 
guanine in addition to hypoxanthine. However, the enzyme from other 
Plasmodium species studied so far do not have this ability. For instance, 
P. chabaudi (Walter & Konigk, 1974) and P. Iophurae (Schimandle et al, 1987) 
HPRT can use only hypoxanthine and guanine. The strain SH4 provided an 
excellent system to study such properties because, the bacterium does not 
have any HPRT ,GPRT or XPRT activity (hpt gpt phenotype). Assay of the 
induced SH4 extract for PRTase activities with xanthine and guanine showed 
that the enzyme indeed can use these two purines as its substrates. 
However, the enzyme showed difference in efficiency for the utilisation of 
different purines. It was found that hypoxanthine is the most favoured 
substrate and xanthine is the least, and guanine is in between. This conclusion 
was came from the the result that the induced SH4 cell extracts showed 10 
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times higher specific activity with hypoxanthine than that with xanthine and 
about 4 times higher than that with guanine. 
Such differences in efficiency could have two different causes. Firstly, the 
enzyme may have higher affinity to hypoxanthine than the other two, so it 
binds to the enzyme more efficiently. This possibility also suggested by Queen 
et a/(1988). They measured the Km values of all these three substrates using 
partially purified enzyme preparation and reported the Km value of 
hypoxanthine is 0.46 tiM and that of the xanthine is 29 1IM. The value of 
guanine was 0.30 iiM. Their result suggests that guanine is somewhat more 
favourable substrate than hypoxanthine. These differences in result may be 
due to the use of unpurified enzyme of recombinant bacterium in this work. 
Further studies using purified recombinant enzyme may give us the true values. 
The difference of the affinity to these substrates was also o an inhibition study. 
The competitive inhibitor, 6-thioguanine inhibited the utilisation of xanthine to 
about 98% whereas the utilisation of the hypoxanthine or guanine were 
inhibited to only about 25%, suggesting that the enzyme has more affinity to 
6-thioguanine than xanthine but less than to hypoxanthine or guanine. 
Secondly, it is possible that the turnover number of the enzyme for 
hypoxanthine is higher, in other words, the transfer of the phosphoribosyl 
group from PRPP to the enzyme-bound hypoxanthine is faster than to other 
substrates. At the saturation concentration of the substrate, like in our 
experimental concentration (100 j.iM), the difference in affinity does not play 
any crucial role in the reaction rate if the turnover number is the same. So, 
the result in this study may also suggest that the enzyme has different 
turnover numbers for different substrates. It is possible that both of these 
factors contribute to the different specificities observed. 
Why should PfHPRT be able to use xanthine ? The role of purine 
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metabolism in the mosquito may bear upon this question. In man, Plasmodium, 
like other parasite, predominantly uses the most available purine, hypoxanthine 
(see introduction). By contrast, mosquitoes, like other terrestrial insects use 
purine metabolism in the excretion of nitrogen (Gilmour, 196). This insects 
produce large amount purine ribotides from ammonia, the end product of 
amino acid metabolism (introduction). This are metabolized to xanthine which 
is later converted into uric acid by xanthine oxidase. This may result in high 
concentration of xanthine in the haemocoel. In the mosquito the parasite 
multiplies extensively (Pringle, 1966), needing much more purine than in man. 
Perhaps the parasite has evolved an HPRT able to exploit the available xanthine 
in the insect. 
The ability of the enzyme to use xanthine and guanine suggests that the 
PfHPRT should also complement the gpt phenotype. This means the bacteria 
should use xanthine or guanine as its purine sources. However, replacement of 
the hypoxanthine from the medium with guanine or xanthine did not allow 
growth. 
This result was surprising at the first instance. But study of the metabolic 
phenotype purE deoD double mutants of S. typhimurium may bear upon the 
reason. Neuhard and Nygaard (1987) described that a purE deoD double 
mutant can only grow on guanosine if the requirement of the adenosine 
nucleotides is satisfied by adenine. Although, guanosine can convert into GMP 
by guanosine kinase which subsequently can convert into IMP by GMP 
reductase, the basis of this phenomenon was not clear. He also demonstrated 
that, this lack of growth in guanosine is partially suppressed by a mutation in 
gsk gene which code for a altered guanosine kinase and complete suppression 
is achieved by a further mutation in genes of the de novo purine synthesis 
pathway before purE. These observations may suggest that the 
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complementation of the gpt-mutation could be achieved by the PfHPRT, if the 





Cellular studies on native PfHPRT. 
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Hypoxanthine phosphoribosyl transferase is a metabolic enzyme. Since 
the parasite does not contain the de novo biosynthetic pathway for purine 
nucleotide synthesis, the enzyme plays a key role in parasite's life . The 
biosynthesis of DNA does not occur continuously through the parasite life 
cycle. However, RNA synthesis seems to occur in all stages. This suggests 
the necessity of the enzyme HPRT to be present in all the stages of parasite's 
life. The apparent presence of only one copy of the HPRT gene in the genome 
and the varied requirement for the enzyme in different stages (Pringle, 1966), 
where large amount of DNA synthesis takes place, raises the question; is the 
gene expression is under a certain type of regulation ? The difficulty in the 
purification of parasites from different stages is probably one of the major 
obstacles in the way of answering such a question. 
Another important question to answer is about the location of the enzyme 
in the parasite. In other words, whether the enzyme is a soluble, cytosolic 
protein like the mammalian enzyme, or a membrane associated protein. The 
eukaryotic cell has localized many of its metabolic processes into specific 
membrane-bound compartments. For example, the Kreb's cycle enzymes of 
carbohydrate metabolism reside in mitochondria (Lehninger, 1982). In this case, 
acetyl coA, the end product of the Embden-Mayerhoff pathway enters into this 
organelle and subsequently degrades into CO2 and H20. Similarly, the enzymes 
of photosynthesis and lysosomal proteases are present in chloroplast and 
lysosome respectively. Several microbodies present in the cell cytoplasm also 
contain different metabolic enzymes, for instance peroxysomes, glyoxysomes 
and glycosomes. 
An indication that the PfHPRT may be associated with some membrane 
bound system comes from the work of Reyes et al (1982). They found that 
addition of the membrane fraction of the parasite sonicated Iysate into the 
218 
reaction mixture, largely increased the conversion of hypoxanthine to AMP and 
GMP and suggested that maybe some of the purine salvage enzymes are 
associated with membranes. However, they found high activity of the HPRT in 
the soluble supernatant fraction of the lysate and also considered the enzyme 
as a cytosolic protein. 
In contrast, the enzyme is a membrane-bound 'glvcosomal' protein in 
several other intracellular parsites, Such as, Trypanosoma brucel (Hammond at 
al., 198), T. cruzi (Gutteridge and Davies 1982), Leishmarlia spp. (Hassan et al., 
1985). These parasites obtain their purine nucleotides through the salvage 
pathway like Plasmodia. 
Moreover, Queen et a/(1988) reported very low yield of the enzyme while 
purifying from the soluble fraction of the sonicated parasite lysate. Moreover, 
western blot of the parasite proteins with antiserum against PfHPRT suggested 
that the enzyme is quite abundant in the parasites. This information together 
suggests that the protein may be compartmentalised in some membrane bound 
organelle or a membrane associated one. However, Queen and co-author's low 
yield may be due to the loss of enzymatic activity during the purification 
process. 
Finally, comparison of the predicted amino acid sequence of the protein 
with that of the mouse (King & Melton, 1987)) reveal that the P. falciparum 
protein contains an extra stretch of 8 amino acids in the N-terminal region and 
3 amino acids in the C-terminal region, which are not present in mouse where 
the protein is cytosolic. This may also indicate the possible targeting of the 
protein into some membrane bound compartment. In this chapter, I will be 
presenting results of in vivo probing of the PfHPRT with the antiserum prepared 
in chapter 4 and will discuss the findings. 
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7.1 The anti-PfHPRT antiserum does not recognize human HPRT 
One possible problem of using the P. fa/ciparum anti-HPRT antibody for 
probing the location of the enzyme in vivo, may be the possible cross-
reactivity with the homologous human enzyme. Red blood cells are rich in 
HPRT and amino acid sequence homology between P. falciparum and mouse 
HPRT showed that although the overall homology is low (48%) but patches of 
high sequence homologies are present between two enzymes. Such homology 
is particularly noticeable in the postulated active site (75%) (King & Melton, 
1987). 
To resolve this question, proteins from 20il of uninfected human blood 
(0+) were analysed by western blotting using the anti-PfHPRT antiserum as a 
probe. Induced 5H2 protein (from section 5.5) and the parasite protein were 
included in the experiment for comparison. The blot was then probed with 
preabsorbed anti-PfHPRT antiserum as described in section 5.5 . The result 
shown in Figure 7.1, indicates that none of the human red blood cell proteins 
(lane B) were recognised by the anti-PfHPRT anti serum. However the protein is 
recognised both in parasite (lane 0) and bacterial lysate (lane B). A similar 
result was obtained with a higher amount of RBC proteins. This result clearly 
suggest that the antiserum is specific to the parasite protein and does not 
cross-react with the host enzyme. 
One possible explanation of these results may be that, since the 
antibodies were raised in a rabbit, common epitopes between human and the 




Figure 7.1 	Western blot of human red blood cell proteins with the PfHPRT 
antiserum. Figure shows the protein profiles as recognized by the antiserum. 
(lane A), uninduced SH2 cell extract, (lane B), induced SH2 cell extract, (lane C), 
whole red blood cell extract and (lane 0) Whole P. falc/parum strain Ki extract. 
A B C 0 	kD 
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7.2 Evidence that the homologous region in the parasite and 
mouse enzyme did not elicited immune response in rabbit. 
As mentioned before the highest homology (75%) between mammalian 
HPRT (mouse) and plasmodium HPRT is at the predicted active site of the 
enzyme (Argos et a/., 1983). To check whether this region elicited any immune 
response in the rabbit, the inhibition of the enzyme activity was measured in 
presence of the anti PfHPRT antiserum. The antiserum used for this study was 
incubated at 55 C for 1 hour. The serum did not have any detectable HPRT 
activity. Twenty Ills of the cell free extract of the induced SH4 were mixed 
with 100 jils of the serum and incubated at room temperature for 10 minutes. 
The PRTase activities of the incubated extract were measured using 10 ills of 
the incubation mixture [method]. In a control experiment the antiserum was 
replaced by BSA (10 mg/ml). The result is shown in Figure 7.2 and indicates 
that the enzyme activities with all three substrates (panel 1,2,3) are not 
inhibited by the antibody at all, and appear if anything to be stimulated. This 
indicates that the antiserum does not contain any antibody against the active 
site of the protein, otherwise the bound antibody would restrict the access of 
the substrate to the active site. 
An increase in activity was observed for all the substrates in presence of 
the antiserum. This may be due to the binding of other antibodies, at sites 
other than the active sites which may have increased the affinity of the enzyme 
to its substrates by changing the structure of the enzyme. 
7.3 Confirmation of the specificity of the antiserum. 
It was discussed in section 7.1 that none of the proteins in red blood cell 
were recognised by the polyclonal serum. To confirm this result and to get 
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Figure 7.2 	Enhancement of PRT activities with xanthirie, hypoxanthine and 
guanine of the recombinant PfHPRT by antibodies raised in rabbit. Data is expressed 
as the percentage of the activities without any antiserum added (bar B). Bar C, shows 
the activities in presence of the antiserum (see text). bar A, shows the PRTase 
activities present in the antiserum. Panels 1, 2 and 3 show the activity measurements 
with xanthine, hypoxanthine and guanine respectively. 
some direct evidence that the antiserum is parasite-specific, indirect 
immunofluorescence assay (IFA) was carried out using the antiserum 
preabsorbed with bacterial extract at a final dilution of 1:50 and 1:100 [method]. 
The result is shown in Figure 7.3. 
It is clear from the result that only parasitized cells ( pigmented in the 
phase contrast, frame A/C), gave fluorescence with the antiserum (frame B/D). 
Whereas the uninfected red blood cells remained completely unstained. This 
result confirmed that the anti-PFHPRT antiserum prepared in rabbits using the 
recombinant protein is parasite specific and does not recognize the human 
HPRT. 
7.4 IFA pattern of P. falciparum infected red blood cells probed 
with anti-PfHPRT antiserum. 
Indirect immunofluorescence (IFA) has been used successfully to study the 
distribution of antigens in malaria parasites (Mcbride, et a/.,1982, Hall et al., 
1983 ) . These studies demonstrated that IFA with several antibodies against 
different antigens showed characteristic patterns, which correlated with the 
location of the antigens. For instance, antibody against p190, a .merozoite 
surface antigen gives a "raspberry" pattern with the mature schizont stage (Hall 
et al., 1983), whereas antibody against lactate dehydrogenase, which is a 
cytoplasmic protein gives a spherical dot pattern for the same stage of the 
parasite (Simmons et al., 1985 ). 
However, although the result in the last section confirmed that the 
polyclonal serum against PfHPRT is specific to the parasite protein and does 
not cross-react with the host HPRT, it did not indicate clearly the location of 
the protein in the parasite or in the infected red blood cells. In other words, 
the IFA on infected red blood cells with antiPfHPRT antibodies did not show any 
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Figure 7.3 	Confirmation of the specificity of the AntiPfHPRT serum. (B) 
and (0) show the specific binding of the PfHPRT antibodies to parasitized red 
blood cells only ( pigmented in the phase contrast field, A and C). 
w 
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characteristic fluorescence pattern for individual parasites, rather a more or 
less homogeneous staining of the whole infected RBC was seen. Such a 
pattern can be explained in two ways. Firstly, perhaps at the schizont stage, 
growing parasites fill the intra erythrocyte space completely and the enzyme is 
a cytoplasmic one like its mammalian counterpart. This may result in the 
homogeneous staining of the infected schizont stage of the infected RBC. 
Alternatively, the enzyme could secrete into the extra-parasitic spaces in the 
RBC. Thus, antibodies binding to extraparasitic spaces, may mask the individual 
parasite's profile resulting in the homogeneous staining. IFA on unfixed slides 
did not show antibody binding to the infected RBC membrane(result not 
shown), suggesting that the protein is not exported to the surface of the RBC. 
Both the above possible interpretations could apply to the schizont IFA 
pattern fig 7.3. However, earlier stages of the intraerythrocytic growth cycle 
also gave interesting patterns. The early trophozoite stage (Figure 7.4), shows 
a pattern suggesting that at the early stage of the parasite's life, the protein is 
found in a particular membrane-bound vesicular region in the infected RBC. 
This vesicle could be the parasitophorous vacuole or the growing parasite 
itself. Since, there is no evidence in favour of either of these possibilities, it is 
difficult to make any definite conclusion about the nature of the vesicles at this 
moment. 
However, it is clear from the pattern that within the vesicles the 
fluorescence is homogeneous- there is no sign of differential staining inside it. 
This may suggest that if the vesicle is the growing parasite itself, the protein is 
cytoplasmic. On the other hand, if the vesicle is the parasitophorous vacuole, 
perhaps the protein secretes into the vacuolar space, and is seen in the IFA as 
a stained sack-like space, filled with the protein. In this case, the pattern also 
may suggest that the protein does not pass through the parasitophorous 
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Figure 7.4 	IFA pattern of infected red blood cells at a early stage of 
infection by the PfHPRT antiserum. The uninfected cells did not show any 
fluorescence. 
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vacuol membrane (PPVM). 
Confirmation of the specific IFA pattern of earlier stages of the 
intraerythrocytic stages can be obtained from Figure 7.5, which shows that the 
size of the vesicle is related to the stages of the parasite. If the vesicle is the 
parasitophorous vacuole, then the result may suggest that the vacuole grows 
bigger as the parasite passes through the stages and that the PfHPRT releases 
into the parasitophorous vacuolar space. on the other hand it could be the 
parasite growing inside the RBC. Since there is no other supporting evidence 
for either of the explanations, these suggestions are not conclusive. 
7.5 Immunogold electron microscopy reveals that PfHPRT is 
localized in electron dense granules. 
Because of the poor resolution of indirect immunofluorescence assay, the 
two different explanations of IFA pattern can not be resolved. In such a case 
immunogold electron microscopy on thin sections of purified merozoites and 
infected RBCs could throw some light on the problem. The preabsorbed 
antiserum was sent to professor M. Aikawa in Cleveland, USA and the 
immunogold micrographs obtained with the antibody on thin sections of 
purified merozoites are shown in Figure 7.6. Figure 7.7 shows that of an 
infected RBC probed with same antibody. Both the figures suggest that the 
protein is associated with electron dense granules (Toni et al., 1989) in the 
cytoplasm. Very little labelling in the cytosol indicates the absence of the 
protein in this space. Control experiments with preimmune serum and a 
antiserum against a nonrelevant fusion protein also gave negative results, 
emphasizing the specificity of the immunogold pattern with the antibodies 
against PfHPRT. 
Such location is expected for a secretory protein. In eukaryotes, secretory 
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Figure 7.5 	IFA pattern of infected red blood cells by the PfHPRT antiserum 
at different growth stages of the intraerythrocytic parasite. 
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Figure 7.6 	Immunogold electron micrograph of mature merozoite sections 
with the PfHPRT antiserum. Overall enlargement is 41000x. The parasite 
enzyme appears to be present in some vesicular structure. (Note: This 
experiment was kindly done by Professor M. Aikawa. cleaviand, USA.). 
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Figure 7.7 	Immunogold electron micrograph of parasitized red blood cell 
with the PfHPRT antiserum. No labelling with the PfHPRT antibodies was 
observed in red cell cytoplasm. Overall enlargement is 41000X. (NOTE: This 





proteins are synthesised by membrane bound ribosomes and the newly 
synthesized protein translocates into the RER matrix. After any essential 
modification the protein transports into the Golgi apparatus which subsequently 
gives rise to electron dense secretory granules. These granules then migrate 
to the plasma membrane and fused with it by a mechanism called reverse 
pinocytosis. Examples of such proteins include insulin and peptide hormones. 
If PfHPRT is a secretory protein, similar events might prevent the 
identification of the protein in the cytosol but would permit their recognition in 
the electron dense granules. This mechanism needs the protein to be secreted 
out of the parasite cell, i.e. into the parasitophorous vacuole membrane. IFA 
- pattern with the antibodies suggests the presence of the protein in the PPV, 
but surprisingly, electron micrograph of infected RBC section (Figure 7.7) did 
not show any specific labelling in the parasitophorous vacuole spaces. 
However, we have not analysed enough infected RBC micrographs to be able to 
suggest confidently that no protein is present in the PPV. Moreover, it should 
be remembered at this point, that immunogold electron microscopy is not as 
sensitive as the indirect immunofluorescence microscopy. Perhaps only the 
vesicular proteins are recognised in the electron micrographs because of the 
high concentration of the protein in these vesicles. The proteins in the PPV 
may not be concentrated enough to be detected by the latter technique. On the 
other hand, IFA being more sensitive may recognise the protein in the PPV. 
The other explanation of the IFA pattern which stated that the whole 
parasite is recognised, requires PfHPRT to be a ctosolic protein. Well perhaps 
it is, and for some reason the protein tends to concentrate in intracellular 
vesicles. This may cause a higher concentration of the protein in these 
vesicles compared to the cytosol and so immunogold microscopy would only 
recognise the protein in these vesicles where the proteins are concentrated 
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enough for their detection. The cytosolic proteins would not be recognised 
due to their lower concentration. 
What is the significance of vesicle bound cvtosolic HPRT ? In mammalia, 
HPRT is a soluble cytosolic protein (Melton, 1987). However, the enzyme in 
some other parasites like, Trypanosoma (Hammond et al., 1985; Gutteridge and 
Davies, 1982), and Leishmania (Hassan et al., 1985) was found to be associated 
with the glycosome, a membrane bound organelle only reported in these 
parasites (Opperdoes, 1987) and thought to be of the same origin as the 
peroxysome or glyoxysome of higher eukaryotes . The matrix of these 
microbodies is electron dense and their major function is reported to be 
anaerobic glycolysis in these organisms the first nine enzymes of the glycolytic 
pathway are found to be concentrated in these microbodies of the parasites 
(Opperdoes, 1988). Glycosomes are found to be very abundant in the blood 
stream stage of Trypanosoma brucei about 240 per cell. Another important 
feature of glycosomes is their rapid turnover; a turnover time of less than 2 
hours has been reported. The fate of these rapidly degenerating vesicles is not 
known. This lack of information is partly due to the lack of any probe to 
identify this microbody in vivo. Glycosomes have not been seen in Plasmodium 
If the electron-dense vesicles seen in the electron micrograph are the 
glycosome-like microbodies, this work is reporting for the first time the 
presence of these in Plasmodia. And if so, the antibody against PfHPRT could 
be a probe to identify the microbodies of the parasite in vivo or in vitro. 
Hart et a! (1987) showed that the mRNA5 of glycosomal proteins translate 
on free polysomes and reported the sequence of events involved in the 
synthesis of glycosomal enzymes in the cytosol and their subsequent 
translocation into the organelle. Studies with glyceraldehyde phosphate 
dehydrogenase, aldolase and glycerol-3-phosphate dehydrogenase of T. brucei. 
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These authors also showed that the enzymes are first detected in the cytosole 
and after a few minutes, appeared in glycosome enriched fractions. If this is 
the case for PfHPRT, it may explain the reason for the lower concentration of 
the protein in the cytosole. 
7.6 Scoring PfHPRT as a glycosomal and secretory protein. 
The secretory proteins known to date contain a leader peptide at the N-
terminal of the protein which directs the synthesizing polysome to the rough 
endoplasmic reticulum Although there is evidence of particular consensus 
sequences for prokaryotic secretory proteins, sequences in eukaryotic secretory 
proteins seem more heterogeneous. Comparison of the predicted primary 
structure of PfHPRT protein with that of the mammalian protein reveal that 
there is an extension of 8 amino acids present in the parasite protein. 
However, the amino acid sequence of this leader peptide does not match with 
any known sequence of signal peptides. 
The signal peptides in both prokaryotes and eukaryotes are most 
commonly cleaved off after the translocation of the protein across the targeted 
membrane. Comparison of the recombinant protein and native parasite protein 
did not suggest any obvious cleavage modification in the native protein 
(section 5.6). 
One consensus feature of the glycosomal proteins is that they are not 
processed . The sizes of in vitro translated glycosomal glyceraldehyde 
phosphate dehydrogenase (GAPDH) and glycerol phosphate dehydrogenase 
(GPDH) and those of the native proteins was found to be same (Hart et 8/., 
1987). This feature fits with that of the PfHPRT. 
One more feature in which the glycosomal proteins differ, is that they all 
have a relative molecular mass larger (between 1 - 5 kO) than their cytosolic 
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homologues (Opperdoes, 1988). Sequence homology analysis showed that all 
these proteins contain insertions and extensions in their amino acid sequences. 
For example, comparison of the twelve GAPDH sequences showed 5 unique 
insertions in the glycosomal enzymes (Misset et al., 1987), and also analysis of 
the phosphoglucokinase (P0K) sequence revealed a 20 amino acid extension at 
the c- terminus of the protein (Osinga et al., 1985). No such generalization can 
be made for secretory proteins. Comparison of the PfHPRT with mouse HPRT 
showed that the parasite enzyme has 231 amino acids whereas the mammalian 
enzyme has only 218 amino acids. Moreover, bestfit alignment of the two 
sequences suggested that there is an insertion of three amino acids and a 
three amino acid extension at the C-terminus of the parasite protein. These 
may suggest the glycosomal protein property of PfHPRT. In addition to these, 
studies with aldolase, triose phosphate isomerase (TIM) and GAPDH sequences 
led to the suggestion that these proteins have a significantly higher (as much 
as +13) overall charge than the cytoplasmic proteins (-1) (Wierenga et a/., 
1987). The overall charge of PfHPRT protein is +1, whereas mouse and human 
HPRT are -1 and -2 respectively. Figure 7.8 shows the substitution of the 
neutral amino acids in mouse sequence into charged amino acids in PfHPRT. It 
is also noticeable that two positively charged amino acids are present in the 
inserted tripeptide and are among the three extra amino acids present in the 
C-terminus ( one is a hydrophobic, Leucine and the other two are serine and 
threonine, both hydroxyl-containing amino acids). These features may be of 
importance, because Swinkels et a! (1988) found that the C-terminal extension 
region of Crithidial phosphoglucokinase (PGK), a glycosomal enzyme, is 
positively charged and is rich in hydrophobic and hydroxyl containing amino 
acids and suggested that the C-terminal extension is responsible for the 
different topogenesis compared to the cytoplasmic enzyme. 
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Figure 7.8 	Comparison of mouse, human and P. falciparum HPRT 
protein sequences. In mouse and human sequences only the amino 
acids which are different from the parasite sequence are shown. 
Dots show the position of deletions or insertions of amino acids 
in the corresponding sequence. Substitution of the neutral and 
acidic amino acids in mouse and human proteins to basic amino acids 
in the parasite protein are boxed. Such substitutions may 
contribute to the overall positive charge of the parasite protein. 
In contrast, the evidence against the PfHPRT being a membrane bound 
protein is that in sonicated lysate of P. fa/ciparum, the protein is found in the 
supernatant fraction, indicating the protein is present in the cytoplasm, as is 
the mammalian protein. But, Toni et a! (1989) recently, reported that the 
content of the dense granules are released into the parasitophorous vacuol 
during the invasion process. 
Finally, analysis of the electron micrographs showed that the size of the 
PfHPRT containing vesicle are approximately 0.20 pm, a comparable size with 
the Trypanosomal glycosomes ( 0.25 pm) (Opperdoes, 1987)). 
7.7 Is PfHPRT transported into the RBC cytoplasm? 
There is evidence that some proteins which are transported to the 
infected RBC membrane, first release into the parasitophorous vacuol and then 
traffic through the RBC cytoplasm to RBC membrane as membrane-bound 
vesicles (e.g. the so-called 5.1 antigen, Simmons et al., 1987). Vesicle bound 
cellular components may release by budding out. In such cases, small 
vesicular bodies are seen in the infected RBC cytoplasm when probed with 
antibodies against those antigens. Detail of such proteins have been discussed 
by Howard (1988). In this article he proposed two different mechanisms for 
trafficing particular proteins from parasite to RBC membrane. If PfHPRT 
releases into the PPV, it should be present is such vesicles. 
Cellular proteins which are targeted to particular membrane bound 
structures may also bud out to form particular vesicles. For example, the 
proteins in rough endoplasmic reticulum (RER) when transported into the Golgi 
complex lumen or during formation of secretory vesicles, the lumen buds out 
from the RER or golgi complex respectively. So if PfHPRT is present in a 
membrane bound vesicle, the question arises, whether similar events occur in 
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the case of PfHPRT. 
To study such possibilities, the IFA slides were reexamined. The 
observations are presented in Figure 7.9. It is seen in the IFA slides that that 
antibody also recognised small structures in the infected RBC cytoplasm. Such 
structures are not seen in uninfected cells. Reexamination of some of the 
previously taken photographs also showed these structures. These 
observations may indicate that the protein does transport into the RBC 
cytoplasm enclosed by some membrane. The number of such structures is 
variable. In some cases it was about 4-5 per cell, whereas in others no 
structure was seen at all. The higher number of such structure did not 
correlate with the later stages of the intraerythrocytic development. Another 
observation of interest is that such structures are normally seen near the host 
cell membrane. 
7.8 In P. falciparum HPRT is present in all developmental stages. 
To study whether HPRT expression is regulated in different stages of 
parasite development, the protein from various stages was probed with the 
antiPfHPRT antibody. Acetone-fixed slides of gametocytes and gametes were 
made with in vitro cultured P. fa/ciparum strain 3137 or HB3. Sporozoite slides 
were made using pooled salivary glands of infected mosquitoes and fixed with 
acetone. IFA was carried out by the same method as described in method 
section using preabsorbed antibody. Figure 7.10 shows the characteristic IFA 
patterns as seen with the PfHPRT antibody on each stage of parasite used. The 
general observation is that the protein is present in all the stages of parasite. 
And no clear indication of quantitative difference was observed. However, 
sporozoite stage showed most intense pattern. This may simply be because 
the sporozoites are an extracellular stage of the parasite and so, the antibodies 
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Figure 7.9 	IFA pattern of infected red blood cell cytoplasm. Possible 
evidence of presence 0fPfHPRT in the RBC cytoplasm. 
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Figure 7.10 	IFA pattern of the parasite with the PfHPRT antiserum at 
different stages of the parasitic growth. (A) and (B) Gametocytes, (C) and (D) 
gametes and (F) sporozoite stages. (E)shows the same frame as (F) but stained 
with DAPI for nucleus. 
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are more accessible to the proteins in this stage than in the intracellular 
stages. However, the possibility of higher enzyme production can not be ruled 
out. 
The pattern of IFA in these stages are also remarkable. In contrast to the 
pattern seen for earlier asexual blood stages, in the gametocyte stages 
although the whole parasitized cell was recognised, two distinct zones of 
different intensities were observed. The most intense was the crescent part of 
the gametocyte and a lighter zone was observed at the middle was observed 
of the crescent. 
There was a large number was observed of granular bodies present in the 
surrounding area of some gametocytes and gametes in acetone fixed slides. 
Initially, these granules were thought to be an experimental artefact. However, 
the reproducibility of this feature suggested that these unknown granular 
bodies may be of parasite origin and recognised by the antiHPRT antibodies. 
Similar granular patterns have also been observed with antibody against other 
parasite proteins (Richard Carter, personal communication). 
7.9 Antibodies against PfHPRT are not present in immune 
human sera. 
The result in section 7.7 indicated that in the cytoplasm of P. falciparum 
-infected RBC, the enzyme HPRT may be present in vesicular structures. The 
significance of this is not clear. It was suggested that after invasion, some 
parasite antigens are transported into the host cell membrane e.g.. Knob 
associated Histidine Rich Protein (HRP) (Howard, 1988). But the IFA pattern with 
the PfHPRT antibody did not label the protein on the host cell membrane and 
so the latter theory is unlikely. Another possibility is that the protein is 
secreted into the host serum along with other possible secretory proteins. 
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To study such a possibility, an attempt was made to detect antibodies 
against PfHPRT in immune human sera. The idea was, if the protein secretes 
into the serum, it must elicit immune response in the human body. Pooled 
sera of four immune individuals from Nigeria was used as the primary antibody 
in western blot analysis. These sera were previously shown to have antibodies 
against P. falciparum antigen p190 and 5.1 . The induced SH2 whole cell protein 
was separated on a 12% SOS-polyacrylamide gel and western blotted. Pooled 
human sera was used as the primary antibody with a final dilution of 1 in 50 
The result is shown in Figure 7.11 indicates that although the serum recognised 
other E. coli proteins, the serum did not contain any antibodies against PfHPRT. 
This result may indicate that the protein is not secreted into the serum or 
indeed it may not be a secretory protein at all. 
7.10 In the sporozoite, the enzyme may secrete into the 
intrapellicular spaces. 
In the IFA studies with different stages of the parasite (fig. 7.10), the 
sporozoite was the most intensely stained stage. However, the interesting 
observation was that most of the fluorescence was seen in the peripheral 
region of the parasite (Figure 7.12 and 7.10), although the protein was not 
found to be membrane associated as shown by the immunogold electron 
micrograph. So, what is the explanation of such a pattern ? 
The following feature may bear upon the answer. In section 7.5 it was 
discussed that the enzyme or some degradative part of it may secrete into the 
parasitophorous vacuole. The sporozoite is not an intracellular stage of the 
parasite, rather it is a free living organism in the mosquito salivary gland 
Ultrastructural examination has revealed that the sporozoites pellicle is 
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Figure 7.12 	IFA pattern of the sporozoite stage of the parasite from 
mosquito salivary gland with the PfHPRT antiserum. Frame (A) shows a detail 
and close look of the pattern seen in figure 7.10. (8) shows the same frame 
with DAPI stain. 
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outermembrane and two inner membranes (Aikawa, 1980). It can be postulated 
that perhaps the protein is secreted through the inner membranes of the 
parasite pellicle, but is unable to pass through the outer membrane. This may 
result in the accumulation of the enzyme in the intra pellicular spaces which 
may give rise to the typical IFA pattern. Another interesting observation which 
may support this postulation is that along with live sporozoites, characterised 
by the presence of a nucleus with DAPI-staining, there are also some faintly 
fluorescing sporozoite ghost lacking a nucleus (Figure 7.13). These are perhaps 
the shedded coat or outer membranes of the sporozoites, which may still 
contain some of the residual proteins. This shedding is a common 
characteristic of plasmodium sporozoites. The faint fluorescence may also 
suggest that the protein was not bound to the membrane of the parasite. 
Figure 7.14 illustrates the above explanation of the sporozoite IFA pattern. 
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Figure 7.13 	Unusual IFA pattern of sporozoite stage of the parasite with 
PfHPRT antiserum. (A) and (C) show the DAPI staining of the same frame as 
shown in IFA frames (B) and (D). Note the absence of nucleus and faint 
fluorescence compared to the normal nucleus containing parasites (Fig. 7.12). 
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Figure 7.14 	Cartoon explaining the sporozoite IFA pattern with PfHPRT antiserum 




Concluding remarks and future directives. 
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Largely because of the complexity of the problem of vaccine development 
against malaria, chemotherapy seems to be the only hope in hand at least in 
the immediate future. A considerable amount of work on the parasite 
biochemistry and elucidation of the mechanisms of action for several drugs 
have revealed that the parasites metabolic pathways, specially those are 
different from the host could be the target for successful antimalarial drugs. 
Study of the mechanism of drug resistance also emphasized this fact. 
Purine metabolism in Plasmodia is one such target, because unlike its 
host the parasite cannot synthesize purine nucleotides, but rather scavanges 
preformed purine from its host by the salvage pathway. Hypoxanthine was 
found to be the most favourable form of purine for the parasite and the 
enzyme, hypoxanthine phosphoribosyltranferase which utilizes the purine, is the 
key enzyme of the pathway and is important for the parasite's life. Hence, the 
enzyme is a promising target for drug design against malaria. 
Difficulty in the large scale culture of the parasite in vitro and 
extraordinary lability of the enzyme during purification steps, are major 
obstacles in the way of the study of the enzyme at the molecular level. 
To overcome the afore-mentioned problems, this work has described the 
successful use of molecular biological and genetic engineering approaches to 
the study of the enzyme. Initially, expression of PfHPRT in E. co/i as a 
-galactosidase fusion protein facilitated the rapid purification of protein for 
making antibody against the parasite enzyme. This antibodies were powerful 
tool in the study of the cellular biology of the enzyme. Probing the enzyme in 
vivo with these antibodies revealed that 
The enzyme is expressed in the parasite at all the stages of the 
parasite's life, without any noticeable difference in the expression level. 
The enzyme is concentrated in some vesicular bodies, whose identity is 
yet to be revealed. 
3. in the sporozoite stage, the enzyme is possibly released into the 
intrapellicular spaces. 
However, much remains to be done in this area. The significance of the 
intracellular localization must be elucidated and whether this is an exploitable 
feature must be studied. Moreover, the regulation of the gene expression has 
to understood clearly in order to find the exact time at which the parasite is 
most vulnerable to the drug attack. 
The enzyme was subsequently expressed directly in E. co/i. The 
expressed full length enzyme was active and provides a new method of 
obtaining large amounts of parasite enzyme without growing the parasite. 
Thanks to molecular biology, it will now be possible to obtain large amounts of 
PfHPRT for molecular study, in order to understand the structure-activity 
relationship of the enzyme which may provide an insight into the design of an 
effective drug against the parasite. It must be pointed out at this stage that 
this is the first Plasmodial enzyme expressed in E. co/i in an active form. The 
future work in this area may involve the purification of large amounts of the 
enzyme, for crystal preparation for X-ray crystallography. The antibodies 
against the enzyme, prepared at the initial stage of the work, may facilitate the 
purification stage greatly. Moreover it is now possible to use site-directed 
mutagenesis to map the active site of the enzyme. A combination of active 
site mapping and 3-D structure from x-ray crystallographic data will reveal the 
architechture of the substrate binding site of the enzyme. This will help in the 
designing of an inhibitor of the enzyme. 
The activity of the E. coil-expressed enzyme enabled the compensation of 
a bacterial hpt mutant. The compensated strain of S. typhimurium can only 
grow on hypoxanthine plates if the recombinant PfHPRT is active. This strain 
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SH4 can now be used to screen large number of putative antimalarial drug 
which might act against the parasite HPRT . This can be done in a simple and 
inexpensive way. 
Since the S. typhimurium hpt mutant strain did not have any endogenous 
HPRT activity, the estimation of the HPRT activity in the induced bacterium 
elucidated several interesting properties of the parasite enzyme. For instance, 
it was possible to confirm the finding that unlike any other Plasmodia studied 
so far, P. falciparum HPRT can use xanthine as its purine source. Furthermore, 
specific activity measurements and competitive inhibition studies revealed that 
hypoxanthine is the most favourable purine. Further studies in this field may 
reveal the affinity of the enzyme to different purine analogues which, I believe 
will help to design an effective antimalarial drug, which the whole world is 
looking forward to. 
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